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1. Introduction
At the heart of multicellular life are the complex interactions between genes, proteins and 
metabolites. These interactions give rise to the function and behavior of biological systems. 
To  study  and  understand  such  systems  as  a  whole  abstractions  are  needed  such  as  the 
concept of networks, in which molecules are represented as nodes and interactions or causal 
influences  are  represented  by  edges.  The  reconstruction  of  biomolecular  networks  from 
experimental  data  and  subsequent  network  analysis  is  a  challenging  and  active  field  of 
research. The major focus of the present dissertation is on the inference of gene regulatory 
networks (GRNs).
1.1. Gene regulatory network modeling
Gene expression is mainly regulated at the level of DNA transcription by proteins called 
transcription factors (TFs). These TFs specifically bind short DNA sequence motifs at the 
regulatory region of their target genes. In doing so, they control the recruitment of RNA 
polymerase, which reads the DNA and transcribes it into RNA. However, gene regulation is 
a far more complex multi-layered process. Any step of gene expression may be modulated, 
from the RNA synthesis to the post-translational modification of proteins. Many genes are 
(directly oder indirectly) involved in these gene regulatory mechanisms, and therefore it is 
reasonable to regard genes as nodes in a network of mutual regulatory interactions.
The  introduction  of  DNA  microarrays  in  the  mid-1990s  offered  the  possibility  to 
simultaneously measure the levels of thousands of RNA transcripts in a single sample of 
cells  or  tissues.  Since then,  researchers  utilized  the  growing amount  of  large-scale  gene 
expression  data  as  input  for  algorithms  to  infer,  or  "reverse-engineer",  the  regulatory 
interaction  structure  of  genes  [1-3].  When  inferring  models  of  transcriptional  regulation 
solely  from  gene  expression  data,  one  typically  seeks  for  influences  between  RNA 
transcripts. In this case, the expression levels of each gene are explained by the expression 
levels of other genes. By construction, such GRN models do not generally describe physical 
interactions as transcripts rather exert their regulatory effects indirectly through the action of 
proteins, metabolites and effects on the cell environment (figure 1). Therefore, these models 
can be difficult to interpret in terms of real physical interactions, and the implicit description 
of hidden regulatory factors may limit the reliability of the inference results.
To overcome these issues and support the network reconstruction it is necessary to integrate 
additional  biological  information.  Diverse types  of data (e.g.  protein-protein and protein-
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DNA  interaction  data)  and  prior  knowledge  (e.g.  from experts,  scientific  literature  and 
biological  databases)  can  be  analyzed  in  combination  with  gene  expression  data.  This 
actually  means  that  known or  putative  network  links  are  preferred  to  be  in  the  model. 
Furthermore,  biological plausible assumptions about the network topology (e.g. structural 
sparseness)  should  be  considered  by  including  specific  modeling  constraints.  Evidently, 
these  advancements  allow  for  GRN  models  that  more  accurately  describe  (physical) 
interactions  between  genes.  The  integration  of  heterogeneous  data  and  use  of  prior 
knowledge  is  a  current  focus  in  the  field  of  GRN  inference  in  particular,  and  in 
computational biology in general.
Figure 1. Gene regulation is carried out by interactions of RNA molecules, proteins and 
metabolites.  (A)  Simplified  illustration  of  an  example  GRN  where  gene  "3"  encodes  a 
membrane-bound metabolite transporter protein (green shape). The metabolite (blue triangle) 
that is imported by this protein binds a TF (orange shape). The activated TF binds the DNA 
and together with RNA polymerase (RNAP) initiates the transcription of gene "2". Hence, 
the expression of gene "2" is influenced by the other two gene transcripts (red lines). (B) A 
graph model of the network in (A). Because the model is inferred from measurements of 
RNA transcripts only,  it implicitly captures the regulatory mechanisms at the protein and 
metabolite level that are not measured. The inferred GRN is a projection of the true network 
where  transcripts  influence  the  level  of  each  other,  even though  they do not  physically 
interact.
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Various modeling approaches have been proposed to reconstruct GRNs from experimental 
data.  They  rely  on  different  mathematical  concepts  and  learning  strategies,  and  distinct 
degrees  of  abstraction.  The  most  commonly  used  modeling  formalisms  are  Boolean 
networks, Bayesian networks, association networks and systems of equations. Their main 
ideas as well as their pros and cons are described in more detail in manuscript I. This review 
addresses  two  major  aspects:  dynamic  network  models,  i.e.  models  that  have  a  time-
component, and GRN inference methods that employ different types of information. Here it 
is sufficient to say that Bayesian networks and systems of linear equations (linear models) 
have  been most  studied  for  an  integrative  modeling.  Linear  models  constitute  the  basic 
modeling framework used in this work (manuscript II and IV). They are therefore described 
briefly in the following.
Linear models assume that the regulatory relationship between genes is approximately linear. 
In principle, one can distinguish a static and a dynamic type of model:
–   static model:
–   dynamic model:
where xi is the expression of gene i (at time t), N is the number of genes in the network, wi j 
denotes an edge weight, i.e. the regulatory effect of gene  j on gene  i, and  bi represents a 
(possible) external influence on gene i. As each experimental observation will contain some 
error, a "disturbance term" εi is introduced adding noise to the linear influence function. The 
dynamic  form (a system of  linear  difference  equations)  is  preferred  if  appropriate  time-
course gene expression data are available, and if not only the network structure but also the 
dynamics  are  considered important,  e.g.  for simulation  purposes.  In comparison to  static 
models,  dynamic  models  also  allow  for  self-interactions  that  express  the  sum  of  RNA 
degradation and self-regulation.
When  inferring  a  static  or  dynamic  linear  GRN model  as  outlined  above  one  needs  to 
estimate the model parameters wi j and bi from the data. However, despite the simplicity of 
these models,  their  inference is always challenging.  This is because of the combinatorial 
nature  of  the  problem,  the  incomplete  knowledge  of  the  molecules  involved  in  specific 
conditions,  and because  experimental  data  are  typically  limited  and noisy.  Amount  and 
quality  of  the  gene  expression  data  have  a  strong  impact  on  the  reliability  of  a  GRN 
reconstruction. Moreover, in case of an integrative modeling, the model accuracy depends on 
x i  = ∑
j=1, j≠i
N
wi j x jbii
x i [ t +1]− x i[ t ]  =  ∑
j=1
N
w i j x j [ t ]bii[ t ]
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the quality of the additional biological information to be utilized and the capability of the 
inference algorithm to incorporate such (possibly uncertain) information (see also section 
"data requirements" in manuscript I).
Once derived, the structure of the network can be analyzed in more detail. Characteristic for 
GRNs is the presence of hubs (key genes regulating multiple genes) and specific network 
motifs  (frequently recurring  interaction  patterns)  as  well  as  a  modular  network  structure 
(where sets of genes are highly interconnected and share a given property) [4]. Beyond that, 
the  study  of  gene  interactions  could  provide  insights  into  control  principles  such  as 
redundancy  and  feedback,  and  uncover  intertwined  gene  regulatory  cascades.  Dynamic 
models  allow to evaluate  the network's  dynamical  stability.  They can also be applied  to 
predict the time behavior of a system for different parameter settings. As a result, an inferred 
GRN model often provides a bunch of new hypotheses and generates assumptions for further 
research  activities.  Therefore,  network  modeling  can  be  useful  in  many applications.  In 
computational  medicine,  an important  issue is  to  unveil  and examine the architecture  of 
GRNs  under  normal  and  pathological  conditions.  Here,  the  inference  of  regulatory 
interactions  between  genes  can  play  a  pivotal  role  in  understanding  the  mechanisms, 
diagnosis and treatment of complex diseases such as human autoimmune diseases [5].
1.2. Autoimmune diseases
Autoimmune  diseases  are  disorders  characterized  by  an  inappropriate  immune  response 
against constituents normally present in the human body. More exactly, the immune system 
produces T cells and antibodies that attack cells, tissues and organs of the body as if they 
were  foreign,  thereby  leading  to  inflammation  and  damage.  The  causes  of  autoimmune 
conditions  are  largely  unknown,  but  it  appears  that  there  is  an  inherited  genetic 
predisposition  in  many  cases  [6].  Autoimmune  diseases  are  typically  multifactorial 
polygenic  diseases  and  affect  approximately  3% of  the  world  population  [7].  To  better 
understand such complex disorders it is crucial to unravel the structure and dynamics of the 
molecular networks that play a role in the aberrant immune response. Network analyses may 
not only support the investigation of autoimmune diseases, but also the optimization of their 
treatment. Two common diseases with an autoimmune basis are rheumatoid arthritis (RA) 
and multiple sclerosis (MS) (table 1).
RA is a chronic inflammatory disorder primarily afflicting the synovial joints. Blood-derived 
cells migrate into the joints and together with activated synovial cells produce cytokines and 
degradative enzymes that progressively lead to the destruction of cartilage and bone. The 
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disease  is  systemic  and  over  the  years  more  and  more  joints  are  affected.  Significant 
disability and a reduced quality of life are result of chronic disease activity [8].
MS is a central nervous system disease. It is the most common progressive and disabling 
neurologic disease of young adults. In people with MS, lesions accumulate in the brain and 
Table 1. Comparative overview of RA and MS disease attributes.
Abbreviations:  ACPA  =  anti-citrullinated  protein/peptide  antibody,  ACR  =  American 
College of Rheumatology, CSF = cerebrospinal fluid, DAS = disease activity score, EDSS = 
expanded disability status scale, MHC = major histocompatibility complex, MRI = magnetic 
resonance imaging, RF = rheumatoid factor.
1 The human leukocyte antigen (HLA) complex is involved in antigen presentation, a process 
crucial to the initiation of an adaptive immune response.






















Prevalence (European population) 0.06 - 0.2 % 0.5 - 1.0 %
Concordance: first-degree relatives 2 - 5 % 2 - 3 %
Concordance: monozygotic twins 20 - 35 % 15 - 30 %
Female : male ratio 1.6 - 2.0 : 1 2 - 3 : 1












Diagnosis McDonald criteria, CSF analysis ACR criteria, ACPA tests
Prognosis
Measures of disease severity EDSS, number of relapses, MRI DAS, radiology
Treatment
Treatment goals Control symptoms, prevent progression
Central nervous system (brain and
spinal cord)
Synovial joints and other
tissues / organs
Chronic, inflammatory, T cell mediated, 
autoimmune
Chronic, inflammatory, systemic, 
autoimmune
Progressive, often fluctuating disease 
activity
Immune cells cross the blood-brain 
barrier and induce neurodegeneration 
(axonal and myelin loss)
Inflammation of synovial membrane leads 
to cartilage destruction and anky-losis of 
joints (polyarthritis); immune 
dysregulation affects the whole body
Genetic: MHC locus
(e.g. HLA-DRB1*1501 allele1)













disability, muscle weakness, deficits in 
sensation and of movement, visual and 
speech problems
Joint swelling and pain, significant 
disability, loss of mobility, morning 
stiffness, low-grade fever, malaise, 
fatigue, loss of appetite
Less common in people living near
the equator or in countries with lower 
socioeconomic level
Consistent throughout the world with 
some exceptions
Depends on disease subtype, sex,
age and initial symptoms
Depends on initial symptoms (early








Control symptoms, prevent progression, 
relief of pain
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spinal cord, particularly in the white matter, and damage the myelin covering of nerve fibres. 
Inflammation and the loss of myelin cause disruption to nerve transmission and thus affect 
many functions of the body [9,10].
In the pathogenesis of both, RA and MS, genetic susceptibility, environmental exposure and 
immune  dysregulation  play  significant  roles.  However,  it  is  less  clear  how  the  chronic 
inflammation is set up and maintained exactly. It is assumed that the onset of these diseases 
in  predisposed  individuals  may  also  reflect  random  processes  during  immune  cell 
development such as immunoglobulin or T cell receptor gene recombination and mutation 
[11]. Common genes are likely to be involved in both diseases, as the chromosomal regions 
that  contain susceptibility  genes coincide  [12].  Nevertheless,  MS patients  do not  have a 
higher risk to develop RA and vice versa. In fact, a reduced comorbidity of RA and MS has 
been observed [13]. Both diseases follow an unpredictable course with variable severity. Our 
incomplete understanding of autoreactive inflammatory processes, the clinical heterogeneity 
of the diseases, and their complex pathogeneses are among the factors that render a specific 
treatment very challenging.
It is presently not possible to cure RA, MS or any other autoimmune disorder. Nevertheless, 
the course of RA and MS can be relatively well controlled in many patients by disease-
modifying therapies. Current medications aim to alleviate symptoms, minimize organ and 
tissue damage, prevent functional loss, and slow the advance of the disease, generally by 
decreasing  the  immune  response.  Existing  MS therapies  are  primarily  designed  to  limit 
lesion formation and brain atrophy, reduce the rate and severity of relapses (acute periods of 
worsening) and slow progression to disability [14]. The goal of RA management is to relief 
pain and to prevent further joint damage [15].
The use of immunomodulatory "biologic" agents has significantly improved the treatment of 
these diseases. Biologics, in contrast to drugs that are chemically synthesized, are derived 
from living sources. They are often complex proteins targeting the disease in a more specific 
manner than traditional therapies. Several biologic drugs for RA and MS try to intervene in 
the immune system by altering the levels of cytokines. Cytokine proteins play a critical role 
as mediators of immune regulation. The tumor necrosis factor-alpha (TNF-α) cytokine is a 
master regulator of inflammation, and has been widely implicated in the pathophysiology of 
both diseases [16,17]. Clinical trials have shown that blocking the action of TNF-α reduces 
disease  activity  in  RA  patients  [18,19],  but  not  in  MS  patients  [20].  Biologic  TNF-α 
antagonists  are  usually  prescribed  to  patients  with  RA  when  other  disease-modifying 
antirheumatic  drugs  (DMARDs)  have  failed  to  work,  or  have  produced  intolerable  side 
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effects. For controlling the exacerbations in relapsing-remitting MS, interferon-beta (IFN-β) 
administration is currently the most established treatment and several studies have confirmed 
its clinical benefit [21,22]. IFN-β is, like TNF-α, a natural human pleiotropic cytokine. Its 
antiproliferative  activities  are  believed  to  be  responsible  for  the  beneficial  effect  of 
IFN-β-based drugs.  In  addition,  IFN-β improves  the  integrity  of  the  blood-brain  barrier, 
which generally breaks down in MS patients [23].
However, these (and other) biologics are only modestly effective and fail to control disease 
progression in a subset of patients. Approximately one-third of MS patients suffers from a 
higher or identical annual relapse rate while on IFN-β treatment than before (so-called non-
responders) [24]. Similarly, only 60% percent of RA patients receiving a TNF-α blocking 
agent for at least 6 months achieve a 20% improvement in the ACR criteria [25]. Adverse 
effects  and  the  occurrence  of  drug-neutralizing  antibodies  in  some  patients  are  further 
problems  related  to  these  therapies  and  also  demonstrate  the  patients'  heterogeneity  in 
therapeutic response.
To improve the clinical  success of RA and MS therapies,  more  individualized treatment 
approaches are needed. For this purpose,  it  is essential  to early identify the patients  that 
benefit most from particular therapies. This would protect the patients against unnecessary 
drug exposure, loss of time and side effects, improve compliance and probably reduce health 
care  expenditures.  However,  currently  no  clinically  established  laboratory  (molecular) 
markers  are  available  that  allow  to  predict  either  favorable  or  detrimental  therapeutic 
outcomes  with  sufficient  reliability.  Therefore,  it  is  important  to  better  understand  the 
pharmacogenomic and -dynamic effects of these drugs.
Although IFN-β and anti-TNF-α agents have been marketed for more than a decade, we are 
still learning how they work. While the intracellular signaling pathways triggered by TNF-α 
and  IFN-β are  known  in  great  detail  [15,26],  their  effects  on  gene  expression  in  the 
individual are relatively poorly understood. Eventually, they influence many immune system 
processes  -  directly  or  indirectly  as  a  consequence  of  the  activity  of  induced  proteins. 
Ongoing  research  continues  to  explore  the  precise  molecular  mechanisms  that  are 
instrumental for the drugs' therapeutic efficacy and the side effects associated with them. 
Network  models  can  disclose  useful  information  about  the  various  complex  processes 
involved.  Therefore,  GRN inference  techniques  are  suited  to  investigate  the  therapeutic 
effects  on transcriptional  regulation,  and may help  to  explain  why some patients  do not 
achieve adequate clinical responses.
Introduction 8
1.3. Objectives and experimental approach
Etanercept (Enbrel, Wyeth) is an example of a protein-based drug directed against TNF-α. It 
is a soluble TNF-α receptor fusion protein used to treat moderate to severe RA and other 
inflammatory disorders. Betaferon (IFN-β-1b subcutaneous,  Bayer  Schering) and Avonex 
(IFN-β-1a intramuscular, Biogen Idec) are two similar but different IFN-β medications for 
patients with relapsing-remitting form of MS. The aim of this work was to characterize the 
transcriptional  effects  induced  by  these  immunomodulatory  therapies.  Gene  network 
analyses  were  applied  for  elucidating  the  interactions  between  genes  responsive  to  the 
different drugs (manuscript II-IV).
For each therapy, genome-wide expression profiles of a group of patients were measured 
using Affymetrix DNA microarrays. The general experimental workflow used to obtain the 
data is depicted in figure 2. As shown, gene expression levels were determined in peripheral 
blood mononuclear cells (PBMC) immediately before therapy initiation and at different time 
points during treatment. The PBMC population (lymphocytes and monocytes) is the main 
cellular source of inflammatory cytokines and thus plays a major role in the immune system. 
Blood  here  serves  as  a  surrogate  tissue,  i.e.  as  a  sensor  of  autoimmune  diseases  which 
actually affect other, less accessible tissues.
As a first step to the analysis, genes significantly up- or down-regulated after start of drug 
administration had to be identified. Next, by screening the regulatory regions of the genes for 
known TF binding sites (TFBS), one can reveal TFs that are putatively responsible for the 
transcriptional  changes  observed  in  the  data.  The  aim  was  then  to  reverse-engineer 
regulatory interactions between the genes based on gene expression data, TFBS information 
and/or  text-mining  knowledge  (that  is  knowledge  gathered  from biological  literature  by 
computational means). As a result, novel hypotheses about the drugs' mode of action were 
expected from the reconstructed GRN models.
In the Betaferon study (manuscript III), molecular interactions obtained by text-mining were 
used to build network structures. For unraveling the regulatory effects between genes up- or 
down-regulated in response to Etanercept and Avonex therapy, an integrative GRN inference 
algorithm, called TILAR, was developed and applied to the data (manuscript II and IV). The 
algorithm realizes a new modeling constraint to derive a model from the expression data 
while directly incorporating TFBS information. As it employs a linear modeling approach, 
the method can draw on well established statistical techniques to efficiently fit the model 
parameters.
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Figure 2. Study design to investigate transcriptional regulation in response to three different 
therapies. Peripheral venous blood was taken from a group of patients immediately before 
first (green arrow) and selected subsequent drug injections. The blood samples were then 
processed in different steps to perform an Affymetrix microarray analysis. First, whole RNA 
was extracted from isolated PBMC. Second, through reverse transcription,  the RNA was 
converted into double-stranded complementary DNA (cDNA), which in turn served as a 
template to generate biotinylated cRNA. Next, this labeled cRNA was randomly fragmented 
and added to the microarrays. After hybridization of the cRNA fragments to complementary 
oligonucleotide  probes  on  the  chip,  the  arrays  were  washed,  stained  with  fluorescent 
molecules that stick to Biotin and scanned with a laser. The detected fluorescence intensities 
disclose what genes were expressed and at what approximate level. Finally,  the obtained 
expression profiles can be analyzed bioinformatically. Given clinical data of the patients one 
can seek for genes whose expression before or early in therapy is predictive for long-term 
benefit of the respective treatments. The focus of the presented works was to characterize 
blood gene expression changes during therapy and to apply GRN inference to improve the 
understanding about the drugs' mechanisms of action.
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Analysis of network topology was then performed to uncover sub-networks of co-regulated 
and functionally related  genes as well  as network motifs,  e.g.  feedback and feedforward 
loops. Such network properties provide useful insights into the complex regulatory processes 
underlying  the  drugs'  therapeutic  effects.  Finally,  the  inferred  GRN  structures  were 
correlated to clinical data (e.g. treatment response and drug-related side effects) to identify 
gene sets that could serve an individual prognosis of therapeutic outcomes. A further task 
was to evaluate the performance of the TILAR modeling algorithm to investigate how far 
integrating different types of biological data can improve the inference results.
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2. Overview of manuscripts
MANUSCRIPT I (PUBLISHED)
Gene regulatory network inference: data integration in
dynamic models - a review
Hecker M, Lambeck S, Töpfer S, van Someren E, Guthke R
Biosystems 2009, 96(1):86-103.
Summary
This  is  a  review  on  the  reconstruction  of  GRNs  from  experimental  data  through 
computational  methods.  It  focuses  on  dynamic  network  modeling  approaches  and  the 
integration  of  prior  biological  knowledge  and  heterogeneous  types  of  data.  First,  some 
background on the nature of large-scale gene expression experiments together with short 
descriptions of methods for analyzing such data is given. Basic modeling frameworks are 
then  specified  and the  mathematical  principles  which  both  define  and limit  them.  After 
addressing  their  pros  and  cons,  algorithms  for  GRN  inference  under  those  models  are 
described.  General  difficulties  of  GRN reconstruction  are  discussed  as  well  as  ways  to 
counter  them.  Key  modeling  properties,  like  low  average  connectivity,  and  integrative 
modeling  strategies  that  aid  in  understanding  and  inference  of  GRNs  are  presented. 
Moreover, the review covers the validation of inferred models and the evaluation of network 
reconstruction methods, and outlines future perspectives in GRN modeling.
Authors' contributions
All authors compiled the literature, drafted parts of the manuscript and prepared the tables 
and figures. MH was particularly involved in writing chapter 2 and 6. Chapter 5 was mainly 
written  by  ST,  and  RG  wrote  the  summary  in  chapter  8.  RG  and  MH  completed  and 
improved the whole manuscript.
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MANUSCRIPT II (PUBLISHED)
Integrative modeling of transcriptional regulation in response to
antirheumatic therapy
Hecker M, Goertsches RH, Engelmann R, Thiesen HJ, Guthke R.
BMC Bioinformatics 2009, 10:262.
Summary
The  purpose  of  this  study  was  to  characterize  the  transcriptional  effects  induced  by 
Etanercept  therapy  in  patients  with  RA.  The  analysis  is  based  on  an  Affymetrix  DNA 
microarray dataset  providing genome-wide PBMC expression profiles  of 19 RA patients 
within the first week of treatment. Significant transcriptional changes were observed for 83 
genes. The so-called TILAR algorithm was introduced for the first time in this work and 
applied on the data to model the regulatory interactions between these genes. First of all, 
overrepresented  predicted TFBS were identified  in the genes'  regulatory regions.  TILAR 
then allowed to integrate the gene expression data and TFBS information to infer a model of 
the underlying GRN. A hybrid of the least angle regression and the ordinary least squares 
regression  was  used  to  find  the  model  structure  and  estimate  the  parameters.  The 
reconstructed GRN exhibits a scale-free and self-regulating organization, and indicates the 
pleiotropic immunological role of the therapeutic target TNF-α. A benchmarking analysis 
demonstrates that TILAR is able to reconstruct GRNs more reliably than other established 
methods,  in  particular  if  additional  prior  knowledge  on  the  regulators  of  TF activity  is 
available and incorporated during inference (adaptive TILAR).
Authors' contributions
RG and HJT directed the study. MH conceived and implemented the algorithms, carried out 
the analyses on the data, wrote the paper and prepared all tables and figures. RG, RHG and 
RE assisted in interpretation of the results and corrected and improved the paper.
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MANUSCRIPT III (PUBLISHED)
Long-term genome-wide blood RNA expression profiles yield
novel molecular response candidates for IFN-beta-1b treatment in
relapsing remitting MS
Goertsches RH, Hecker M, Koczan D, Serrano-Fernández P, Möller S, Thiesen HJ, Zettl UK
Pharmacogenomics 2010, 11(2):147-161.
Summary
In this work, long-term transcriptional profiles were obtained for 25 patients with relapsing-
remitting MS. Using Affymetrix microarrays, PBMC expression levels were measured for 
each patient before (baseline), as well as two days, one month, one year and two years after 
start  of  Betaferon  therapy.  The  data  were  analyzed  with  the  aim  to  investigate  the 
pharmacodynamic  effects  of  sustained drug administration.  The strongest  changes  to  the 
transcriptome  were  observed  at  one  month  into  treatment:  A  total  of  175  genes  were 
significantly  up-  or  down-regulated  in  comparison  to  baseline.  Nineteen  genes  were 
consistently found modulated over the two years observation period which suggests that the 
medication continually influences the patients' immune system. The lists of filtered genes 
were finally examined for overrepresented gene functional annotations, and literature text-
mining  was used to  explore  molecular  interactions  between  the  genes.  Two major  gene 
networks were identified: the first consists of several known IFN-β-induced genes, whereas 
the second mainly contains down-regulated genes that to date have not been associated with 
IFN-β  activity.  The  study  thus  provides  novel  marker  genes  for  biological  response  to 
Betaferon and information on the molecular networks it affects.
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Summary
The  aim of  this  study was  to  investigate  the  transcriptional  effects  induced  by Avonex 
therapy  in  patients  with  relapsing-remitting  MS.  For  24  MS  patients,  Affymetrix  DNA 
microarrays were employed to determine the gene expression levels of PBMC within the 
first four weeks of IFN-β administration. Overall, 121 genes were found significantly up- or 
down-regulated during therapy,  including known IFN-β-modulated genes. Analysis  of the 
regulatory regions of these genes revealed 11 overrepresented TFBS. As in the RA study 
(manuscript II), the new TILAR algorithm was then applied for deriving a GRN model from 
the gene expression data and TFBS predictions.  The inferred network shows a scale-free 
topology and specifies  a  number  of  feedback loops.  An NF-κB-centered  sub-network of 
genes was found higher expressed in patients with IFN-β-related side effects. The inferred 
GRN thus provides novel insights into functional mechanisms of Avonex therapy in MS, and 
exposes molecular differences between the patients. A benchmarking analysis confirmed that 
the integrative modeling strategy realized by TILAR performs much better than algorithms 
using gene expression data or TFBS information alone.
Authors' contributions
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documentation.  DK  participated  in  performing  the  microarray  and  real-time  PCR 
experiments. MH conducted the analysis and interpretation of the data, wrote the paper and 
prepared all tables and figures. RG, RHG and HJT assisted in interpretation of the results 
and contributed to the writing of the paper.
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a b s t r a c t
Systems biology aims to develop mathematical models of biological systems by integrating experimen-
tal and theoretical techniques. During the last decade, many systems biological approaches that base
on genome-wide data have been developed to unravel the complexity of gene regulation. This review
deals with the reconstruction of gene regulatory networks (GRNs) from experimental data through com-
putational methods. Standard GRN inference methods primarily use gene expression data derived from
microarrays. However, the incorporation of additional information from heterogeneous data sources, e.g.
genome sequence and protein–DNA interaction data, clearly supports the network inference process.
This review focuses on promising modelling approaches that use such diverse types of molecular bio-
logical information. In particular, approaches are discussed that enable the modelling of the dynamics of
gene regulatory systems. The review provides an overview of common modelling schemes and learning
algorithms and outlines current challenges in GRN modelling.
© 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
In ‘systems biology’, one aims to model the physiology of living
systems as a whole rather than as a collection of single biologi-
cal entities. Such an approach has the practical benefit of offering
insight into how to control or optimise parts of the system while
taking into account the effect it has on the whole system. There-
fore, taking a ‘systems-wide’ view may lead to alternative solutions
in application areas such as biotechnology and medicine. The abil-
ity to take a systems-wide approach is only possible due to recent
developments in high-throughput technologies that enable scien-
tists to carry out global analyses on the DNA and RNA level and
large-scale analyses on the protein and metabolite level. To gain
a better understanding of the observed complex global behaviour
and the underlying biological processes, it is necessary to model the
interactions between a large number of components that make up
such a biological system. To be able to learn respective large-scale
models, the use of novel computational methods that can make an
integrative analysis of such different sources of data is essential and
challenging at the same time.
Uncovering the dynamic and intertwined nature of gene regula-
tion is a focal point in systems biology. The activity of a gene’s func-
∗ Corresponding author. Tel.: +49 3641 532 1083; fax: +49 3641 532 0803.
E-mail address: reinhard.guthke@hki-jena.de (R. Guthke).
tional product is influenced not only by transcription factors (TFs)
and co-factors that influence transcription, but also by the degra-
dation of proteins and transcripts as well as the post-translational
modification of proteins. A gene regulatory network (GRN) aims to
capture the dependencies between these molecular entities and
is often modelled as a network composed of nodes (represent-
ing genes, proteins and/or metabolites) and edges (representing
molecular interactions such as protein–DNA and protein–protein
interactions or rather indirect relationships between genes). Many
GRN inference approaches solely consider transcript levels and aim
to identify regulatory influences between RNA transcripts. Such
approaches employ an ‘influential’ GRN, i.e. a GRN where the nodes
consist of genes and edges represent direct as well as indirect
relationships between genes (Fig. 1). This approximation leads to
‘influence’ network models that are intended to implicitly capture
regulatory events at the proteomic and metabolomic level which
sometimes makes them difficult to interpret in physical terms. The
modelling (reconstruction) of a GRN based on experimental data
is also called reverse engineering or network inference. Reverse
engineering GRNs is a challenging task as the problem itself is of
a combinatorial nature (find the right combination of regulators)
and available data are often few and inaccurate.
Therefore, it is beneficial to integrate system-wide genomic,
transcriptomic, proteomic and metabolomic measurements as well
as prior biological knowledge (e.g. from the scientific literature)
into a single modelling process. Using computational support to
0303-2647/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.biosystems.2008.12.004
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Fig. 1. Schematic view of a simple gene regulatory network. Gene A regulates its own expression and those of gene B. Thereby, gene A might exert its regulatory influence
directly (if it encodes a TF) or indirectly (if it controls the activity of another TF possibly via a signalling cascade). When reconstructing the GRN, one often aims to infer an
‘influence’ network model as shown at the bottom.
adequately manage, structure and employ heterogeneous types of
information in order to obtain a more detailed insight into bio-
logical network mechanisms represents a major challenge in GRN
inference today.
Outstanding review articles covering the field of data-driven
inference of GRNs are from De Jong (2002), van Someren et al.
(2002a), Gardner and Faith (2005), Filkov (2005), Van Riel (2006),
Bansal et al. (2007), Goutsias and Lee (2007), Cho et al. (2007) as
well as Markowetz and Spang (2007). Well-structured overviews
of the general idea behind GRN inference and diverse common
mathematical modelling schemes can be found in De Jong (2002)
and Filkov (2005). van Someren et al. (2002a) arranged reverse
engineering techniques according to the characteristics of their
underlying model and learning strategies; moreover, the pros and
cons of distinct approaches are discussed. Gardner and Faith (2005)
clearly outlined between two general reverse engineering strate-
gies: (1) physical models that describe real physical interactions
such as TF–DNA interactions and (2) influence models that allow
any type of influence to be modelled, but do not necessarily provide
a physical explanation of an effect. Markowetz and Spang (2007)
focused on probabilistic models, such as Bayesian networks.
In this review we want to emphasize two major aspects:
dynamic network models, i.e. approaches that aim to capture
the complex phenomena of biological systems by modelling the
time-course behaviour of gene expression, and integration of prior
biological knowledge and heterogeneous sources of data. We chose
the following text structure according to the main steps taken dur-
ing the modelling of GRNs (Fig. 2): first, experimental aspects and
biological databases relevant to the study of GRNs are addressed,
and main issues of data-driven modelling discussed. Next, Section 3
provides a survey of typical GRN modelling architectures. Section 4
Fig. 2. The systems biology cycle. In this cycle, knowledge leads to new hypotheses,
which leads to new experiments, which leads to new models, which leads to new
knowledge, etc. Numbers refer to the corresponding sections.
deals with data- and knowledge-driven feature selection and map-
ping methods which aim at reducing the number of variables in the
model to lower model complexity. Fundamental learning strategies
for inferring GRNs are described in Section 5. In Section 6 we focus
on inference methods that employ other types of data in addition to
gene expression measurements. Section 7 addresses the validation
of inferred mathematical models and the assessment of network
inference methods. Section 8 draws conclusions and outlines per-
spectives for future research on GRN inference.
2. Biological Data
The reconstruction of GRNs is largely promoted by advances
in high-throughput technologies, which enable to measure the
global response of a biological system to specific interventions.
For instance, large-scale gene expression monitoring using DNA
microarrays is a popular technique for measuring the abundance
of mRNAs. However, by integrating different types of ‘omics’ data
(e.g. genomic, transcriptomic and proteomic data) the quality of
network reconstruction could be drastically improved. In the fol-
lowing we outline the main characteristics of diverse ‘omics’ data,
itemize distinct types of molecular interactions and briefly refer to
relevant databases as well as measurement techniques.
2.1. Omics Data and Related Technologies
Genome sequence data are supportive to the reconstruction of
GRNs since transcription is regarded as the main control mecha-
nism of gene expression. The analysis of sequence data includes
the investigation of TF binding sites (TFBS). Thereby, the aim is
to detect potential links between sequence motifs and tissue-
specific gene expression. In the past, a vast amount of in silico
approaches has been developed to identify TF binding sequence
elements (Wasserman and Sandelin, 2004). However, as compu-
tational approaches provide only a simplified representation of
DNA-binding events, usually a large number of potential binding
sites (candidates) are predicted, of which many are not functional
(false positives). More detailed data on TFs and their binding sites
are accessible via databases such as JASPAR and TRANSFAC.
Experimentally, the ChIP-on-chip technique (chromatin
immunoprecipitation combined with microarray technology)
allows to characterise protein–DNA interactions at high-
throughput. By identifying the regions of a genome that are
bound by a particular TF in vivo, potential gene regulatory effects
can be derived (Ren et al., 2000). As more and more ChIP-on-chip
data (also called location data) are generated, the large number of
in silico predicted TFBSs gets more and more paralleled by a large
number of experimentally observed TFBSs.
The amounts of transcripts, proteins and metabolites available
at a specific point in time reflect the current state (of activity) of
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Table 1
Categories of interaction databases presented in Pathguide as of 10/2008. In the column ‘#Resources’ the number of databases belonging to each category is shown.
Category Content #Resources Examples
Protein–protein interactions Mainly pairwise interactions between
proteins
105 DIP, BIND, STRING, HPRD
Metabolic pathways Biochemical reactions in metabolic
pathways
60 KEGG, Reactome, ENZYME
Signaling pathways Molecular interactions and chemical
modifications in regulatory pathways
50 STKE, Reactome, TRANSPATH
Transcription factors/Gene regulatory networks Transcription factors and the genes
they regulate
42 JASPAR, TRANSFAC, RegulonDB
Pathway diagrams Hyperlinked pathway images 30 KEGG, HPRD, SPAD
Protein–compound interactions Interactions between proteins and
compounds
24 ResNet, CLiBE
Protein sequence focused Diverse pathway information in
relation with sequence data
16 REBASE
Genetic interaction networks Genetic interactions, such as epistasis 6 BIND, BioGRID
the biological system. Transcriptome data measured by genome-
wide DNA microarrays are traditionally used for GRN modelling
as RNA molecules are easily accessible in comparison to proteins
and metabolites. In general, two types of DNA microarrays can be
distinguished: single and two-channel microarrays. Thereby, the
abundance of mRNAs is typically quantified on the basis of short
DNA oligonucleotides and cDNA molecules, respectively (Kawasaki,
2006). A huge amount of gene expression microarray data is pub-
licly available via repositories such as ArrayExpress and Gene
Expression Omnibus. However, one has to be aware that DNA
microarray data are characterised by a high degree of variability
(noise). One way to overcome this problem is to apply real-time
quantitative PCR assays (RTQ-PCR) to get more precise measures of
transcript levels for a selected set of genes.
Similar to the transcriptome, the term proteome describes the
ensemble of proteins produced in a cell or organism. Protein lev-
els are decisively influenced by the amount of mRNA transcripts.
Remarkably, the total number of human proteins is much higher
than the number of protein-encoding human genes, because alter-
native mRNA splicing and post-translational processing increase
the proteome diversity. Moreover, proteins often form complexes
with other proteins or RNA molecules to achieve specific function
and activity. The structural variety of proteins and their functional
interactions cause a high degree of complexity and therefore large-
scale proteomic studies are usually difficult (Pandey and Mann,
2000).
Proteins (enzymes) can catalyse enzymatic reactions and thus
are also the basis of all metabolic events. Metabolites also modulate
GRNs, however, similarly as within proteomics, technical difficul-
ties hamper a global analysis of the metabolome (Goodacre et al.,
2004). Therefore, connecting metabolic and gene regulatory net-
works is out of the scope of this review and remains a challenge
for the future. However, it should be noted that the area of systems
biological modelling originates from the modelling of metabolic
networks (Heinrich and Schuster, 1996).
A complementary approach to the systematic measurement of
molecular and cellular states is the characterization of molecular
interactions. The complex network of intermolecular interac-
tions that wires together the vast amount of genes, proteins
and small molecules is also called the interactome. Here, high-
throughput methods enable researchers to systematically screen
for protein–protein and protein–DNA interactions (e.g. ChIP-on-
chip for the latter as mentioned above). Interactome information
can also be found in many different databases containing known
and predicted interactions. Some of these databases provide
detailed information on regulatory proteins and their associated
regulated genes (e.g. RegulonDB for Escherichia coli), others con-
tain known metabolic networks (e.g. KEGG), still others catalogue
protein–protein interaction (PPI) information (e.g. DIP). More than
260 web-accessible biological pathway and network databases are
linked in the meta-database Pathguide (Table 1). Note that the infor-
mation in these databases is by far not complete.
However, besides the wealth of information stored in biological
databases, a large amount of information is found in the scientific
literature. Therefore, text mining tools have been developed to auto-
matically extract interrelations between genes and proteins from
literature with sufficient reliability (e.g. PathwayStudio). Clearly,
such text mining methods also provide useful information for GRN
modelling.
A further type of data relevant to study genes and their regula-
tory interactions are gene functional annotations. Several projects
such as the Gene Ontology (GO) provide a controlled vocabu-
lary to describe gene and gene product attributes. The functional
annotations in the GO database (GO terms) are organized in a hierar-
chical way defining subsets of genes that share common biological
functions. This type of information alleviates the functional inter-
pretation of genes participating in a GRN.
Clearly, this section does not provide a complete and detailed
description of the diverse types of biological data that are available.
However, it illustrates the potential benefit as well as the challenge
of utilizing such diverse and complementary types of biological
information to reliably infer GRNs.
2.2. Experimental Design
As a gene expression experiment is often the basis for a GRN
reconstruction, some aspects concerning the design of such exper-
iments will be covered here. Specifying the experimental design is
an important issue in the investigation of GRNs, since the choice of
a modelling approach and its learning strategy is often related to
the type and amount of data generated. At least two aspects are cru-
cial in this context: perturbation (i.e. the choice of intervention or
experimental condition) and observation (sampling, measurement)
of the biological system.
2.2.1. Perturbation
In general, systems identification is based on the analysis of
input–output signal data that describe the system’s response to
perturbations (Ljung, 1999). Similarly, in order to understand a
dynamic biological system, i.e. its behaviour and functioning, we
need to perturb it systematically. Perturbation experiments can
be designed in different ways depending on the available tech-
niques and the system of interest, and include manipulations of
environmental factors as well as interventions on the genetic, tran-
scriptomic, proteomic or metabolic level.
Environmental perturbations comprise, e.g. heat shock, chem-
ical stresses or compound-treatments up to the administration
of therapeutic agents in medical care. In comparison, genetic
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perturbations, e.g. gene deletion (knock-out) and over-expression
studies, may exclusively affect those genes in the network, which
lay downstream of the perturbed gene and are therefore a valuable
method to specifically detect regulatory dependencies. However,
genetic perturbation experiments are not easy to establish in most
organisms. The realisation of such studies is therefore restricted to
in vitro experiments or to lower organisms such as the eukaryotic
model organism Saccharomyces cerevisiae (yeast).
In addition, experiments including perturbations on the tran-
scriptome level can be performed and used for GRN inference
(Markowetz et al., 2005; Rice et al., 2005). One possibility is to
use a natural mechanism called RNA interference, which is an
RNA-guided regulation of gene expression (so-called knock-down
experiment) (Fire et al., 1998; Mello and Conte, 2004).
Having techniques available that can directly intervene on the
molecular level, researchers are in the position to selectively affect
gene expression. The ability to systematically influence the expres-
sion of genes in a network as well as to subsequently measure
altered gene expression levels also allows for alternating arrange-
ments of experimental design and model construction. Ideker et
al. (2000), for example, proposed a network inference approach
in which genes with the most uncertain connections in the net-
work model are perturbed in order to incrementally determine a
Boolean network (see Section 3.2) using only a few experiments.
The underlying concept of iterated and systematic perturbations
was also used by Tegner et al. (2003). Although a promising strat-
egy, the applicability of this approach to real data remains to be
proven, since both authors used artificial data in their work.
2.2.2. Sampling
Effects of interventions can be observed by static (steady
state) or time-course measurements, where the latter reflects the
dynamic behaviour of the system over time. Therefore, the choice
between a static and a dynamic GRN model largely depends on the
experimental setup. The setup, in turn, should depend on the type
of knowledge one aims to achieve, i.e. the importance of capturing
the effect that changes in initial conditions have on the final states
(static) versus capturing the sequence of intermediate processes
that leads to the final state (dynamic).
While generating static data (at well-defined experimental con-
ditions), the observation is accomplished at the presumed steady
state of the biological system. For instance, samples taken from
knock-out organisms are supposed to provide gene expression lev-
els at steady-state in the absence of a specific gene product. Network
inference based on data derived from knock-out experiments is very
efficient (Bansal et al., 2007). However, to infer all interactions from
such data, each node in the network has to be perturbed separately.
Moreover, the steady-state design may miss dynamic events that
are critical for reliably inferring the structure of a GRN.
On the other hand, time-series experiments (when samples are
taken in a series of time-points after perturbation) might reveal
dynamics, but the data may contain redundant information lead-
ing to inefficient use of experimental resources. It should be noted
that an appropriate design of time-series experiments is difficult
on its own. For instance, one has to find a compromise between
observation duration and the interval between two subsequent
measurements, as the number of time-points also determines the
amount of experimental efforts. Note that the number and alloca-
tion of time-points for sampling affects the performance of the GRN
inference as was studied using synthetic data (Yeung et al., 2002;
Geier et al., 2007).
2.3. Data Requirements
While generating experimental data, researches have to face a
trade-off. On the one hand, they aim to minimise experimental
efforts and costs, hence try to minimise the number of experiments.
On the other hand, a reliable GRN reconstruction cannot be done
without a considerable quantity of accurate data.
The general opinion is that the amount of data required for GRN
modelling (e.g. DNA microarrays) increases approximately logarith-
mically with the number of network nodes (e.g. genes) (Akutsu et
al., 1999; Yeung et al., 2002; Filkov, 2005). However, it is difficult to
specify the experimental data requirements more precisely as many
further factors influence the network inference performance.
One, the quality of an inferred model depends on the qual-
ity of the given data. Large variations in the biological outcome,
high measurement noise and inappropriate experimental designs
might lead to less informative data and thus hamper a reliable
GRN reconstruction. Two, the aim of the modelling can range from
estimating gene regulatory interactions with high confidence up
to reconstructing even highly speculative regulatory dependen-
cies. Precise estimates of parameters are not always needed to
understand certain qualitative features of a GRN. Three, different
modelling formalisms exhibit different data requirements. More
complex models consist of many model parameters and therefore
their learning is more data demanding. Four, different network
inference algorithms infer gene regulatory effects from a given
amount of data with different efficacy. Searching for the best model
parameter setting is typically computationally intractable even
for simple models. Hence, heuristics have to be applied (see Sec-
tion 5), which may perform suboptimally. Moreover, the applied
inference technique might exploit modelling constraints such as
sparseness of the inferred network (see below and Section 6.1) or
assess the accuracy of the edges in the network by internal vali-
dation (see Section 7.2) to increase the inference reliability. Five,
the inference strategy might use external prior knowledge from
databases and literature (see Section 6). In this case, the neces-
sary amount of experimental data depends on the amount, type
and quality of such additional information and the capability of the
inference algorithm to adequately integrate this information during
modelling.
To summarize, there is a tight relationship between model com-
plexity, the amount/type of data required for inference and the
quality of the results. Due to this, the inference of more accurate (i.e.
complex, dynamic, large-scale) GRN models is impeded. The main
problem is that a more accurate modelling makes the correct model
much harder to find, because the size of the search space increases
exponentially with the number of unknown model parameters (the
so-called problem of dimensionality). In consequence, the modeller
has to counter the dimensionality problem in network inference, for
example by:
(i) increasing the amount of data by increasing the number of
measurements M;
(ii) reducing the number of network nodes N;
(iii) restricting the number of model parameters, e.g. by use of sim-
ple models and network connectivity constraints;
(iv) integrating specific prior knowledge about the network struc-
ture.
(i), the number of measurements M can be increased by addi-
tional experiments or by merging own gene expression data with
complementary data from external repositories, e.g. as in Faith et al.
(2007). Alternatively, D’haeseleer et al. (1999) proposed for time-
series data to simply interpolate additional time-points between
the actual measured time-points. This is justified by the fact that
gene expression levels change rather smoothly over time. However,
it was shown that interpolation did little to solve the dimensionality
problem (Wessels et al., 2001).
(ii), the number of network nodes N can be reduced by focus-
ing on features (genes, proteins, . . .) of special interest employing
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Fig. 3. Exemplary overview of the four main GRN modelling architectures. Here, the aim is to infer the regulatory interactions of three genes (the GRN graph on the top-right)
based on the expression data of these three genes for a handful of experiments (the gene expression matrix on the top-left). For modelling we may utilize (pre-processed)
gene expression data as well as other available biological information. The four modelling architectures reflect the same GRN in different ways. Each of the model architectures
shown here is illustrated by a single typical example of a possible realization of its model formalism category. Note that there exist a lot more approaches for each of the
model architectures than what is reflected by the given examples.
methods for feature selection and/or feature mapping (see Section
4).
(iii), by using less complex network models and biologically
motivated modelling constraints, the dimensionality of the model
search space can be reduced. The most widely used modelling con-
straint is the sparseness constraint, which minimises the number
of edges in the network thereby reducing the number of (unknown)
model parameters (see Section 6.1).
(iv), the integration of different types of biological data may aug-
ment the modelling and thus facilitates inference results of higher
quality (see Section 6.2).
2.4. Data Pre-processing
Data pre-processing is a critical step in GRN reconstruction as
it affects the performance of the inference algorithms and thus the
inference results, i.e. the generated hypotheses. Methods for data
pre-processing have to be applied specifically to different data types
and experimental designs.
The analysis of large-scale data is a challenging task, not so much
because the amount of data is large, but because large-scale mea-
surement technologies possess high inherent variability. The two
sources of this variability are systematic errors (bias) and stochastic
effects (noise). Systematic effects affect all measurements in a simi-
lar manner and thus can be nearly eliminated by data normalisation
(Quackenbush, 2002). Stochastic effects cannot be corrected by pre-
processing, but can be quantified, in particular by the application
of repeated measurements (replicates).
Depending on the modelling approach further data manipula-
tions may be necessary. Several network inference methods require
a very specific pre-processing of the data. For instance, interpolation
of time-series data is a frequently applied method. Furthermore,
many learning algorithms for the inference of differential equation
systems (see Section 3.3) require the estimation of time derivatives
for each measurement point of the time-series, which can also be
done by interpolation (Chen et al., 1999; Yeung et al., 2002). Besides,
some network formalisms require discrete gene expression values.
For instance, to infer Boolean networks, the measured expression
levels have to be converted into binary numbers. Note that such
a data discretization is often non-trivial and has to be done with
adequate care.
3. Network Model Architecture
Before inferring a GRN, the appropriate type of network model
architecture has to be chosen. The model architecture is a parame-
terised mathematical function that describes the general behaviour
of a target component based on the activity of regulatory compo-
nents. Once the model architecture has been defined, the network
structure (i.e. the interactions between the components) and the
model parameters (e.g. type/strengths of these interactions) need
to be learned from the data (see Section 5). Over the last years,
a number of different model architectures for reverse engineering
GRNs from gene expression data have been proposed. They cover
varying degrees of simplification and reflect distinct assumptions
of the underlying molecular mechanisms (Fig. 3).
In general, the network nodes represent compounds of inter-
est, e.g. genes, proteins or even modules (sets of compounds). As
described by van Someren et al. (2002a), model architectures can
be distinguished by (1) the representation of the activity level of the
network components. The concentration or activity of a compound
can be represented by Boolean (‘on’, ‘off’) or other logic values (e.g.
‘present’, ‘absent’, ‘marginal’), discrete (e.g. cluster labels), fuzzy
(e.g. ‘low’, ‘medium’, ‘high’) or continuous (real) values. Further-
more, network model architectures can be distinguished by (2)
the type of model (stochastic or deterministic, static or dynamic)
and (3) the type of relationships between the variables (directed
or undirected; linear or non-linear function or relation table).
Although many undirected network representations exist, the focus
of this review is on directed networks.
3.1. Information Theory Models
One of the simplest network architectures is the correlation
network (Stuart et al., 2003), which can be represented by an
undirected graph with edges that are weighted by correlation
coefficients. Thereby, two genes are predicted to interact if the
correlation coefficient of their expression levels is above some set
threshold. The higher the threshold is set, the sparser is the inferred
GRN.
Besides correlation coefficients, also Euclidean distances and
information theoretic scores, such as the mutual information,
were applied to detect gene regulatory dependencies (Steuer et
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al., 2002). The network inference algorithms RELNET (RELevance
NETworks; Butte and Kohane, 2000), ARACNE (Algorithm for the
Reverse engineering of Accurate Cellular NEtworks; Margolin et al.,
2006; Basso et al., 2005) and CLR (Context Likelihood of Related-
ness; Faith et al., 2007) apply network schemes in which edges
are weighted by statistic scores derived from the mutual infor-
mation. Rao et al. (2007) proposed an asymmetric version of the
mutual information measure to obtain directed networks. Like-
wise, graphical Gaussian models (GGMs) using partial correlations
to detect conditionally dependent genes also allow to distin-
guish direct from indirect associations (Opgen-Rhein and Strimmer,
2007).
Simplicity and low computational costs are the major advan-
tages of information theory models. Because of their low data
requirements, they are suitable to infer even large-scale networks.
Thus, they can be used to study global properties of large-scale reg-
ulatory systems. In comparison to other formalisms, a drawback
of such models is that they do not take into account that multiple
genes can participate in the regulation. A further disadvantage is
that they are static.
3.2. Boolean Networks
Boolean networks are discrete dynamical networks. They were
first proposed by Kauffman (1969) and since then have been inten-
sively investigated for modelling gene regulation (Thomas, 1973;
Bornholdt, 2008). They use binary variables xi ∈ {0, 1} that define
the state of a gene i represented by a network node as ‘off’ or ‘on’
(inactive or active). Hence, before inferring a Boolean network, con-
tinuous gene expression signals have to be transformed to binary
data. The discretization can be performed, for instance, by cluster-
ing and thresholding using support vector regression (Martin et al.,
2007). Boolean networks can be represented as a directed graph,
where the edges are represented by Boolean functions made up of
simple Boolean operations, e.g. AND ∧, OR ( ), NOT ( ). The chal-
lenge of reverse engineering a Boolean network is to find a Boolean
function for each gene in the network such that the observed (dis-
cretised) data are explained by the model. Various algorithms exist
for the inference of Boolean networks, e.g. REVEAL (REVerse Engi-
neering ALgorithm; Liang et al., 1998). REVEAL was later extended
to allow for multiple discrete states as well as to let the current state
depend not only on the prior state but also on a window of previous
states.
Boolean networks are limited by definition as gene expression
cannot be described adequately by only two states. Nevertheless,
Boolean networks are easy to interpret and as they are dynamic,
they can be used to simulate gene regulatory events. In naïve
Boolean network models there are no kinetic constants and other
continuous variables.
3.3. Differential and Difference Equations
Differential equations describe gene expression changes as a
function of the expression of other genes and environmental fac-
tors. Thus, they are adequate to model the dynamic behaviour of
GRNs in a more quantitative manner. Their flexibility allows to
describe even complex relations among components. A modelling




= f (x, p, u, t) (1)
where x(t) = (x1(t), . . ., xn(t)) is the gene expression vector of the
genes 1, . . ., n at time t, f is the function that describes the rate
of change of the state variables xi in dependence on the model
parameter set p, and the externally given perturbation signals u.
Here, network inference means the identification of function f and
parameters p from measured signals x, u and t.
In general, without constraints, there are multiple solutions, i.e.
the ODE system is not uniquely identifiable from data at hand.
Thus, the identification of model structure and model parameters
requires specifications of the function f and constraints repre-
senting prior knowledge, simplifications or approximations. For
instance, the function f can be linear or non-linear. Evidently, regu-
latory processes are characterised by complex non-linear dynamics.
However, many GRN inference approaches based on differential
equations consider linear models or are limited to very specific
types of non-linear functions (Voit, 2000; De Jong, 2002; see Section
3.3.2).
There are further, more complex variants of differential equation
models, such as stochastic differential equations that are thought to
take into account the stochasticity of gene expression, which might
occur especially when the number of TF molecules is low (Kaern et
al., 2005; Climescu-Haulica and Quirk, 2007).







wi,j · xj + bi · u, i = 1, . . . , N (2)
can be applied to describe the gene expression kinetics xi(t) of N
genes by N × (N + 1) parameters for (a) the N2 components wi,j of the
interaction matrix W and (b) N parameters bi quantifying, for exam-
ple, the impact of the perturbation u on gene expression. In general,
the simplification obtained by linearization is still not sufficient to
identify large-scale GRNs from gene expression data unequivocally.
Several approaches have been proposed to cope with this problem,
e.g. methods for inferring sparse interaction matrices by reducing
the number of non-zero weights wi,j (see Section 5.2).
Differential equations can be approximated by difference equa-
tions (discrete-time models). Thereby, the linear differential Eq. (2)
becomes the linear difference Eq. (3):





wi,j · xj[t] + bi · u, i = 1, ..., N (3)
In this way one obtains a linear algebraic equation system that
can be solved by well-established methods of linear algebra. Sin-
gular value decomposition (SVD) (Holter et al., 2001; Yeung et al.,
2002) and regularised least squares regression are the most promi-
nent ones that solve the linear equation system with the constraint
of sparseness of the interaction matrix. For instance, the LASSO
(Least Absolute Shrinkage and Selection Operator) provides a robust
estimation of a network with limited connectivity and low model
prediction error (van Someren et al., 2002b; see Section 5). Further
inference algorithms based on linear difference equation models
are NIR (Network Identification by multiple Regression; Gardner
et al., 2003), MNI (Microarray Network Identification; di Bernardo
et al., 2005) and TSNI (Time-Series Network Identification; Bansal
et al., 2006). Under the steady-state assumption, NIR and MNI use
series of steady-state RNA expression measurements, whereas TSNI
uses time-series measurements to identify gene regulatory interac-
tions (see also Bansal et al., 2007).
3.3.2. Non-linear Differential Equations
Complex dynamic behaviours such as the emergence of multi-
ple steady states (e.g. healthy or disease states) or stable oscillatory
states (e.g. calcium oscillations and circadian rhythms) cannot be
explained by simple linear systems. Instead, systems of cellular
regulation are non-linear (Savageau, 1970, Heinrich and Schuster,
1996). The identification of non-linear models is not only limited
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by mathematical difficulties and computational efforts for numer-
ical ODE solution and parameter identification, but also mainly by
the fact that the sample size M is usually too small for the reli-
able identification of non-linear interactions. Thus, the search space
for non-linear model structure identification has to be stringently
restricted. For that reason, inference of non-linear systems employ
predefined functions that reflect available knowledge. Sakamoto
and Iba (2001) used genetic programming to identify small-scale
networks (up to three genes) by fitting polynomial functions f of
differential Eq. (1). Spieth et al. (2006) applied different search
strategies, such as evolutionary algorithms, for the inference of
small-size networks (2, 5 and 10 genes). They studied different
types of non-linear models: generalized linear network models
(Weaver et al., 1999), S-systems (Savageau, 1970; Kimura et al.,
2005) and models composed of a linear interaction matrix and an
additional non-linear term (called ‘H-systems’).
Exemplarily, S-systems model the gene expression rate by exci-










Here, ˛i and ˇi are positive rate constants and gi,j and hi,j are
kinetic exponents. Non-linear models such as S-systems consist of
many parameters demanding a large number of experiments to fit
them to the data (Vilela et al., 2008; Voit, 2008). Therefore, the
problem of data insufficiency still limits the practical relevance of
non-linear models.
3.4. Bayesian Networks
Bayesian networks (BNs) reflect the stochastic nature of gene
regulation and make use of the Bayes’ rule. Here, the assumption is
that gene expression values can be described by random variables,
which follow probability distributions. As they represent regulatory
relations by probability, BNs are thought to model randomness and
noise as inherent features of gene regulatory processes (Friedman et
al., 2000). Most importantly, BNs provide a very flexible framework
for combining different types of data and prior knowledge in the
process of GRN inference to derive a suitable network structure
(Werhli and Husmeier, 2007; see also Section 6.2). Besides, BNs
have a number of features that make them attractive candidates for
GRN modelling, such as their ability to avoid over-fitting a model to
training data and to handle incomplete noisy data as well as hidden
variables (e.g. TF activities). Methods for learning BNs are covered
in detail in Heckerman (1996) and Needham et al. (2007). In short,
there are three essential parts for learning a BN:
• Model selection. Define a directed acyclic graph (DAG) as candidate
graph of relationships.
• Parameter fitting. Given a graph and experimental data find the
best conditional probabilities (CP) for each node.
• Fitness rating. Score each candidate model. The higher the score,
the better the network model (the DAG and the learned CP dis-
tribution) fits to the data. The model with the highest score
represents the GRN inference result.
Thereby, the critical step is ‘model selection’. The naïve approach
is to simply enumerate all possible DAGs for the given number of
nodes (so-called brute-force search). Unfortunately, the number of
DAGs on N nodes, grows super-exponentially. Therefore, as for other
model types, heuristics are needed to efficiently learn a BN (see
Section 5).
BNs can be learned based on discrete (often Boolean) and contin-
uous expression levels. Thereby, the underlying probabilistic model
might be, e.g. a multinomial distribution or a Gaussian distribution.
Fig. 4. Difference between static BNs (left panel) and dynamic BNs (right panel). A
feedback loop from gene A to gene B to gene C and back to gene A is not allowed in
static BNs. However, this feedback loop can be represented in a dynamic BN.
BNs of continuous nodes are typically harder to infer from experi-
mental data, because of their additional computational complexity.
However, their inference does not require discretisation of the data.
Moreover, static and time-series data can be used to reconstruct
static and dynamic Bayesian networks (DBNs), respectively. As the
former have the structure of a DAG, they cannot capture feedback
loops. In contrast, DBNs separate input nodes from output nodes,
i.e. each molecular entity is represented by a regulator node (rep-
resenting the expression level at time t) as well as by a target node
(representing the expression level at time t + t) (Van Berlo et al.,
2003; Perrin et al., 2003). This way, DBNs are able to describe regula-
tory feedback mechanisms, because a feedback loop will not create
a cycle in the graph (Fig. 4).
BNs are widely used for GRN reconstruction (see also Section 6).
As an example, Rangel et al. (2004) inferred a 39-gene linear state-
space model – a subclass of DBNs – of T-cell activation from gene
expression time-series data. Noteworthy, BANJO is a ready-to-use
software application for BN and DBN inference (Hartemink et al.,
2001).
3.5. Further Network Model Architectures
Not all GRN modelling techniques can be assigned to one of
the four categories described above. To complete this section,
three of these approaches are mentioned here exemplarily: Segal
et al. (2003) identified regulatory modules in S. ceresivisiae and
used them for modelling the regulation program by regression
trees. Thereby, each decision node in the tree corresponds to a
regulating gene. The so-called Dynamic Regulatory Events Miner
(DREM) algorithm introduced by Ernst et al. (2007) uses hidden
Markov models for identification and annotation (by TF names)
of so-called bifurcation points in gene expression profiles. As a
third example, Mordelet and Vert (2008) decomposed the GRN
inference into a large number of local binary classification prob-
lems, which focus on separating target genes from non-targets for
each TF.
4. Feature Selection and Feature Mapping
To reliably identify the structure and parameters of a model, the
model size/complexity must suit the experimental data at hand. In
essence, both feature selection as well as feature mapping reduce
the complexity of the model by selecting only relevant features
for network reconstruction. While analysing gene expression data,
genes that are non-responsive or not well measured in the data are
typically removed during feature selection. With feature mapping
molecular entities can be combined into functional entities that
represent the common behaviour of its constituents or that reflect
a particular biological function. Thus, a functional entity might be
for instance a cluster of co-expressed genes or a group of proteins
with the same function. Feature mapping is an excellent way
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to remove redundant information. However, the modeller has
to carefully choose which dimensionality reduction approach is
appropriate to (a) obtain a sufficiently large network to investigate
the biological phenomena under study while (b) still being able
to obtain a reliable inference of the underlying network. Filtering
differentially expressed genes and clustering co-expressed genes
are widely applied techniques to reduce the number of model vari-
ables. Advanced feature selection/mapping approaches combine
data- and knowledge-driven methods.
4.1. Data-driven Feature Selection
Network reconstruction approaches often consider only genes
that show significant changes in expression under the experimen-
tal conditions studied. For instance, Wang et al. (2006) narrowed
down the list of relevant genes of S. cerevisiae to 140 genes based
on 2-fold change up or down in at least 20% of the expression lev-
els across all data sets. Guthke et al. (2005) selected 1336 cDNA
features (out of 18,432 cDNAs representing 7619 unique genes)
by requiring a 8-fold up- or downregulation after perturbation
by infection. van Someren et al. (2006) studied 101 murine genes
(out of 9596) that showed significant changes in expression with
respect to the initial state under their experimental conditions.
Martin et al. (2007) selected murine genes represented by 5085
probesets (out of 45,119 probesets representing ∼34,000 unique
genes) that exhibited differences in expression between control
cells and IL-2-stimulated cells using the following inclusion cri-
teria: (1) change call other than ‘no change’, (2) same trend of
change call (‘increase’, ‘decrease’), (3) ‘present call’ and ‘signal
intensity > 100’ and (4) at least a 1.5-fold difference in expres-
sion between the two compared conditions. As a remark, the
significance of expression change, often used for filtering can-
didate genes, can be assessed using t-statistics or its variations
(Pan, 2002).
4.2. Data-driven Feature Mapping
Another way to reduce the number of network components is
the identification of clusters of co-expressed and/or co-regulated
genes or proteins. Methods for cluster analysis have been widely
applied to find functional groups under the assumption that genes
which show similar expression patterns are co-regulated or part
of the same regulatory pathway. Afterwards, cluster-representative
genes or the mean expression level of all genes in a cluster might be
used for GRN inference (D’haeseleer et al., 2000; Wahde and Hertz,
2000; Mjolsness et al., 2000; van Someren et al., 2000; Guthke et
al., 2005, 2007; Bonneau et al., 2006).
Clustering does not guarantee that genes within a cluster share
the same biological function. Nevertheless, a common subsequent
analysis step is to annotate each cluster with a functional cat-
egory that is representative for that cluster (Gibbons and Roth,
2002). From a statistical learning perspective, clustering methods
can be subdivided into (a) combinatorial algorithms, (b) mixture
modelling, and (c) mode seeking (Hastie et al., 2001). Hierarchi-
cal algorithms are still frequently employed, although they have
been criticized (Morgan and Roy, 1995; Radke and Möller, 2004)
and more reliable methods are available. For instance, k-means
and fuzzy c-means (Granzow et al., 2001; Dougherty et al., 2002)
were used in conjunction with GRN inference (Guthke et al., 2005).
Apart from that, Mjolsness et al. (2000) applied an expectation-
maximization algorithm for clustering by mixture modelling and
used the mean time-courses of ‘aggregated genes’ for inferring a
dynamic network model.
A complete description of clustering algorithms is beyond the
scope of this review, and the reader is referred to the literature for
more on this subject (Shannon et al., 2003).
4.3. Knowledge-driven Feature Selection/Mapping
As feature selection/mapping is a crucial step in GRN inference,
one might not only exploit the limited set of gene expression data
but also employ alternative sources of biological information. One
way to do this is to use knowledge about which genes code for
transcription factors. For instance, one can start to select (known or
putative) TFs, which are differentially expressed or just belong to a
certain process of interest. Then, further genes can be additionally
selected on the basis of their (known or putative) regulation by one
or more of these TFs, e.g. as done by Bernard and Hartemink (2005).
This selection can be based on protein–DNA binding data or based
on results from searching for regulatory motifs in sequence infor-
mation. However, a drawback of this feature selection approach is
that the activity of TFs not necessarily correlates with their changes
in transcript abundance.
Alternatively, one can focus on modelling particular pathways
or biological processes. Here, annotation databases (see Section
2.1; Table 1) provide functional classifications that can be used to
directly select genes of a specific pathway, process or cellular com-
ponent (see for an example: Hartemink et al., 2002). In analogy, one
can select genes that are associated with the same biological con-
text based on text mining (e.g. Tamada et al., 2003). A drawback of
these solely knowledge-based approaches is that gene expression
levels are not taken into account, and thus relevant features, which
are not yet correctly annotated might be missed, while features that
do not play a role under the particular conditions might be falsely
included.
A more sophisticated way to reduce the number of features is to
analyse the expression of specific groups of genes instead of individ-
ual genes. Using annotation terms in conjunction with expression
levels allows to find functional modules, which play a key role in the
particular system. Current methods that deduce a biological mean-
ing, i.e. an association to functions and processes, from large-scale
gene expression data, consist of two steps. At first, a group of genes
is defined (e.g. by data-driven feature selection/mapping). Then,
the enrichment of biologically relevant terms (derived from anno-
tation databases) in these genes can be determined. For example
using Gene Ontology one can test whether particular functions or
processes are specifically related to the group of genes. A lot of freely
available tools are based on this approach (Khatri and Draghici,
2005). These and other annotation enrichment methods uncover
functional modules of genes. This allows the modeller to concen-
trate on modelling the interactions between just those modules or
the involved genes.
5. Learning Algorithms for Network Inference
In general, network reconstruction is performed by applying a
learning algorithm that fits the output of the mathematical model
to the provided experimental data. The choice of an appropri-
ate learning algorithm is mainly influenced by the selected model
architecture (see Section 3) as well as by the quality and the quantity
of the available data. Furthermore, if prior knowledge about gene
regulatory interactions is available, the learning algorithm should
be able to incorporate this knowledge into the final model (Section
6).
In network inference, two tasks can be distinguished: (1) the
estimation of the model structure and (2) the estimation of the
model parameters. Structure optimization corresponds to the prob-
lem of finding the network connectivity or topology that best
explains the observed data and that simultaneously fulfils con-
straints representing the available knowledge, e.g. that takes the
network-sparseness requirement into account (van Someren et
al., 2001; Filkov, 2005). Parameter estimation concerns the prob-
lem of identifying the corresponding model parameters once a
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Fig. 5. Overview of structure optimization methods that can be applied in particular for the learning of linear differential/difference equation models.
model structure is given (Section 5.1). To capture the network
sparseness, most network inference approaches try to reduce the
in-degree for each node. In many of these approaches the struc-
ture is optimized explicitly and parameter optimization becomes
an embedded task of structure optimization (see Section 5.2.1).
Alternatively, there exist several approaches where the structure
is implicitly determined during parameter estimation (Section
5.2.2).
The estimation of other systems biology models, i.e. metabolic
networks and signal transduction networks, is characterised
by a mainly knowledge-driven determination of the model
structure. Here, the focus lies on parameter estimation meth-
ods that surmount inherent ill-conditioning and multi-modality
(Rodriguez-Fernandez et al., 2006; Moles et al., 2003). In contrast,
in GRN inference a single node function has usually few parame-
ters and nonlinearity is taken into account only in rare cases (e.g. in
S-system models). Therefore, the decisive problem is the solution
of the structure optimization problem. Note that the main focus of
this section is on learning algorithms for differential and difference
equation systems.
5.1. Parameter Optimization
The optimization of the parameters of a model is connected with
the chosen model architecture and the scoring function that has to
be optimized. The scoring function always contains a term quanti-
fying the fit of the predicted model outputs to the gene expression
data, also referred to as data-fit. Dependent on the assumed noise
distribution, measures for this criterion are, e.g. the sum of squared
errors (e.g. Mjolsness et al., 2000; Yeung et al., 2002; van Someren
et al., 2006) or the maximum likelihood function. For each type of
model architecture a large number of standard parameter optimiza-
tion techniques are available, e.g. as presented Polisetty et al. (2006)
for Generalized Mass Action models and by Vilela et al. (2008) for
S-systems.
5.2. Structure Optimization
Deriving the model structure or the connectivity between the
nodes is a challenging combinatorial optimization problem. For
each node function the most likely combination of regulators has to
be found. The total number of possible combinations for each node
function is 2N − 1, where N is the number of nodes in the network.
For a relatively small network with N = 20 nodes the total number of
possible regulatory combinations is about 1,000,000 for each node.
Consequently, even for small networks it is an impractical task to
test all possible network structures. However, the number can be
significantly decreased by the assumption of limited connectivity
between the genes. If, e.g. the number of regulators is restricted to
four and N = 20, then only 6195 regulatory combinations are possi-
ble. In this case, one might test all combinations by an exhaustive
(brute-force) search.
A general rule in network reconstruction is that as the connec-
tivity of the network increases, the model will better fit the data.
However, several difficulties are concerned with higher-connected
networks. First of all, genes are assumed to be regulated by a limited
number of regulators (Arnone and Davidson, 1997; see Section 6.1).
Secondly, the reliability of the parameter estimation deteriorates
when the number of parameters increases. Due to the dimension-
ality problem (i.e. many parameters and few data), many network
structures of sufficiently high connectivity can describe the same
data equally well (Krishnan et al., 2007). Consequently, it is diffi-
cult to reliably determine which of these network structures is the
best, making the inference results not robust. Therefore, a compro-
mise between model quality and model complexity has to be found,
which is known as the bias-variance trade-off. A general overview of
structure optimization methods applied in experimental modelling
is given in Nelles (2001).
As a remark, some network inference methods are characterised
by the decomposition of the overall structure optimization problem
into separate optimization steps. Then, in each step, the most likely
regulators of a single gene have to be found.
5.2.1. Explicit Structure Optimization
Explicit structure optimization methods examine GRN mod-
els with different topology and compare them by means of their
scoring function (from Section 5.1). The scoring function is often
augmented with a model complexity term aimed to prevent data
over-fitting and ensure network sparseness. Such scoring functions
were introduced for different network modelling formalisms, for
instance BNs. Here, approximations such as the Bayesian Informa-
tion Criterion (BIC) score are commonly used to assess the degree to
which the resulting structure explains the data, while at the same
time avoiding overtraining by penalizing the complexity (number
of parameters) of the model.
Following a given strategy, interactions are added and removed
trying to obtain a structure with a better score. Since testing all pos-
sible combinations of interactions can only be performed for very
small networks, different structure optimization strategies exist
that systematically search in the space of possible solutions (i.e. net-
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work structures). As shown in Fig. 5, explicit structure optimization
strategies comprise the simple testing of all possible combinations,
heuristic search methods, evolutionary algorithms and simulated
annealing (van Someren et al., 2001). Finally, given the modelling
architecture and a network structure optimization strategy, a model
can be estimated from the given data. The estimation might be
supported by prior knowledge and additional types of data, e.g. by
adapting the scoring function (see Section 6).
In case of very small networks or strong restrictions, e.g. limiting
the number of regulators per gene, all possible combinations can
be tested. For instance, Chen et al. (1999) suggested to simply test
all combinatorial choices that have at most k regulators for a lin-
ear differential equation system. This brute-force strategy is often
applied for inferring Boolean networks, too (e.g. Akutsu et al., 1999;
Martin et al., 2007).
Heuristic search algorithms apply rules-of-thumb or guesses to
guide the search in direction towards plausible solutions (most
likely solutions first). Well known heuristic search techniques are,
e.g. best first search, beam search and hill-climbing. In GRN infer-
ence, search algorithms might start from an initial topology and
either add or remove interactions or reverse the direction of causal-
ity. Three types of main search strategies can be distinguished:
forward selection (growing), backward elimination (pruning) and
stepwise selection. Forward selection methods start with a sim-
ple model (e.g. without interactions) and add the most significant
interactions until a stopping criterion is met. Alternatively, back-
ward elimination methods start with a fully connected model and
remove the least significant interactions until a stopping-criterion
is met. Stepwise selection methods combine forward selection and
backward elimination.
Note that similar heuristic structure learning algorithms are
used for the inference of different model architectures, e.g. in BN
inference to identify the most probable structure of a GRN learned
from data (Heckerman, 1996; Needham et al., 2007). For the infer-
ence of BN models the REVEAL algorithm introduced by Liang et al.
(1998) applies a forward selection algorithm, where subsequently
all input pair combinations with k = 1, 2, 3. . . regulators are exam-
ined. In Weaver et al. (1999) an advanced backward elimination
strategy was suggested that removes recursively the interactions
with the smallest parameter values, whereas the parameters are
re-estimated in each iteration. Chen et al. (2001) proposed an infer-
ence method for an information theoretical model where first,
putative pair-wise interactions are derived by correlating peaks in
the time-series data and afterwards, less important interactions
are eliminated. The NetGenerator algorithm (Toepfer et al., 2007;
Guthke et al., 2005) combines forward selection and backward
elimination to fit a system of linear or non-linear differential equa-
tions. Thereby, in order to avoid over-fitting (and to obtain a sparse
network model), the inclusion or removal of interactions was tied
to specific conditions, e.g. (i) an increase in model complexity must
lead to a considerably improved model fit and (ii) the number of
model interactions must not exceed a predefined limit.
The Inferelator inference method proposed by Bonneau et al.
(2006) is based on a more complex differential equation system. In
contrast to other approaches, the combination of regulators is not
restricted to simple weighted sums. A special encoding of TF inter-
actions allows to accommodate combinatorial logic (AND, OR, XOR)
into the model. Here, this encoding was restricted to pair-wise inter-
actions. Then, to fit a model for each gene, a combination of explicit
and implicit structure optimization is performed: explicit structure
optimization is utilised to get a selection of potential single TFs and
pair-wise interactions. Implicit structure optimization selects the
best combination for the final model using LASSO (see Section 3.3).
Different heuristic search strategies and genetic algorithms for
the inference of GRNs using artificial data were compared by van
Someren et al. (2001).
5.2.2. Implicit Structure Optimization
Implicit structure optimization is reached by optimising the
model parameters using an extended scoring function. In addition
to a model fitting term this extended scoring function includes a
model complexity term which directly penalises the number of
network interactions. This is also known as a form of regularisa-
tion. Regularisation reduces the effective number of parameters
for each node function while the nominal number of optimized
parameters corresponds to the total number of possible regu-
lators. During parameter optimization the model is adopted to
the measured data, while parameters not required for fitting are
driven to zero. In consequence, a sparsely connected network
results. Different implicit structure optimization methods can be
distinguished with respect to the applied regularisation technique.
Mjolsness et al. (2000) used a weight decay term that penalises
the sum of the squared interactions weights within a non-linear
differential equation system. A similar approach is proposed by
van Someren et al. (2006). Their LARNA method (Least Absolute
Regression Network Algorithm) minimises the sum of the abso-
lute weights of a linear difference equation model. In Yeung et al.
(2002) a two step procedure is applied to infer linear differential
equations systems including SVD and subsequent robust regres-
sion.
6. Integration of Diverse Biological Information
As mentioned throughout this review, the inference of a large-
scale GRN is complicated due to the combinatorial nature of the task
and the limitations of the available data. Therefore, the use of prior
knowledge and biologically plausible assumptions with respect to
the model structure is essential to support the reverse engineering
process. In addition, information from alternative experiments, var-
ious databases as well as from the scientific literature itself should
be incorporated.
6.1. General Network Properties and Modelling Constraints
Several general properties of GRNs can be used for network
reconstruction, including sparseness, scale-freeness, enriched net-
work motifs and modularity. The most common and important
design rule for modelling gene networks is that their topology
should be sparse. Sparseness reflects the fact that genes are reg-
ulated only by a limited number of genes (Arnone and Davidson,
1997). Note that the term ‘sparse’ stands for limited regulatory
inputs per gene, thus a low in-degree is desired. However, some
so-called master genes may control a large part of the entire net-
work, thus the out-degree is unrestricted. Enforcing the sparseness
property during network identification has the benefit that it sig-
nificantly reduces the number of model parameters to be estimated
and consequently improves the quality of network inference. Tech-
niques to constrain the number of regulators per gene are covered
in Section 5.2. For instance, when scoring candidate models during
structure optimization one might use scores that have a measure
of how well the model fits the data, and a penalty term to penalise
model complexity. Note that a drawback of limiting the number of
edges in the network is that one may miss redundant paths in the
network such as feed-forward loops.
Several studies have shown that the distribution of node degrees
in biological networks often tends to have the form of a power law
(Jeong et al., 2000; Bork et al., 2004), i.e. the fraction P(k) of nodes
in the network having k connections goes as P(k) ∼ k− , where 
is a constant. In these, so-called scale-free networks, most of the
genes are sparsely connected, while a few are very high connected.
Scale-freeness ensures the performance and robustness of net-
works with respect to random topological changes and is therefore
an organising principle of biological structures (Jeong et al., 2000).
Manuscript I 26
96 M. Hecker et al. / BioSystems 96 (2009) 86–103
Not surprisingly, large-scale GRN models (information theory mod-
els) inferred from human gene expression data also demonstrate
scale-free structures (Jordan et al., 2004; Basso et al., 2005). As
scale-freeness is a stronger assumption than sparseness, it seems
reasonable to utilize this property as a modelling constraint. Scale-
freeness has been implemented by Chen et al. (2008) for a method
that infers undirected edges based on a thresholded ranking of
the most correlating genes by specifying whether a node is a core
node or a periphery node. It came to our attention that at least
one group considers scale-freeness during inference of dynamic
GRNs (Westra, 2008). They first introduce a measure that compares
how well the degree-distribution of a difference equation network
model fits a perfect scale-free network. Then, they iteratively esti-
mate the model parameters while maximizing this measure and
optimizing  until a convergence criterion is met. Alternatively, the
concept of scale-freeness can be taken into account indirectly by
limiting the number of candidate regulators in the network. Pre-
defining known (and putative) TFs as regulators is a widely used
approach to limit the model search space (e.g. Chen et al., 2001;
Segal et al., 2003; Bonneau et al., 2006). However, one should be
aware that the expression level of a TF does not necessarily reflect
its activity.
Another property of natural regulatory networks is that they
are highly structured. The low-dimensional connection structures
in these networks follow regular hierarchies. This facilitates the
decomposition of biological networks into basic recurring modu-
lar components that consist of only a few genes, so-called network
motifs (Shen-Orr et al., 2002; Lee et al., 2002). Consequently,
regulatory network motifs open the way to structured model iden-
tification. However, the use of such structural motifs is still under
discussion. For instance, the handling of feedback loops is diverse
and depends on the biological problem. Some authors recon-
struct networks that are restricted to a hierarchical structure, e.g.
Hartemink et al. (2002) using a BN formalism, whereas others forbid
short loops. For example, ARACNE aims to remove indirect interac-
tions from the inferred network. Thereby, if triplets of genes are fully
connected, the edge with the weakest statistical relevance will be
eliminated (Margolin et al., 2006). Apart from this, many reverse
engineering algorithms are completely unrestricted to allow even
short positive or negative feedback loops within the system (e.g.
Liang et al., 1998; van Someren et al., 2002b).
Modularity is also an important property of GRNs. It is evi-
dent that genes share functionality and often act together, thus
appearing to have a decentralised, redundant organisation. This
property is well supported by the common occurrence of clusters
of strongly co-expressed genes and correspondingly strong func-
tional enrichment. The concept of modularity is important for the
reconstruction of GRNs as it allows to tackle the data insufficiency
problem. Therefore, a widely used approach is to group genes based
on functional similarities or similar expression patterns (see Sec-
tion 4.2) and then to model the regulatory interactions between
those modules to get a higher-level view of gene regulatory mech-
anisms (e.g. Segal et al., 2003; Bar-Joseph et al., 2003; Guthke et al.,
2005).
6.2. Integration of Heterogeneous Data
Many techniques have been proposed to identify GRNs from
transcriptome data (e.g. obtained by DNA microarray experiments).
Some authors derived dynamic network models from time-course
gene expression data, e.g. D’haeseleer et al. (1999), van Someren
et al. (2002b), Guthke et al. (2005). Others have utilized static
expression data for network inference. For instance, in the study
of Rung et al. (2002) an information theoretical model of the GRN
of yeast was reconstructed from expression data of 274 different
single gene deletion mutants. Further groups used both steady-
state and temporal measurements to compute hypothetical GRNs,
e.g. of Halobacterium (Bonneau et al., 2006) and E. coli (Faith et al.,
2007).
Although, DNA microarray data are widely used in the field of
network inference, the reconstruction of GRNs using microarray
data alone is inherently bounded as the information content of
such data is limited by technical and biological factors. Therefore,
more sophisticated methods have been developed to reconstruct
the structure and dynamics of GRNs more reliably by incorporat-
ing other kinds of biological information. For instance, information
on molecular interactions is accessible in many ways (see Section
2.1; Table 1) and thus can augment GRN modelling. Prior knowl-
edge and additional large-scale experimental data also facilitate
the reconstruction of more mechanistic models. Note that the prior
knowledge utilized must suit the given data and the scientific ques-
tion of the study.
An integrative learning strategy often consists of two steps. First,
a template of the network is built using various levels of additional
information, e.g. from databases and the literature. This template
represents a supposition of the real underlying network topology.
Second, an inference strategy is applied that fits the model to the
data while taking the template into account. The template infor-
mation can be incorporated into the network inference process,
e.g. in Bayesian frameworks by appropriately setting prior proba-
bilities of the network structure. A more general approach is to let
the template adapt the cost function or to simply use the template
to constrain explicit search methods.
A BN is a good representation of the combination of prior knowl-
edge and data because it reflects both causal and probabilistic
semantics. More exactly, the integration of biological knowledge
can be realised by inferring the model in a maximum a posteriori
sense. Formally, the probability distribution for a model  given data
D and background knowledge  is according to the Bayes’ theorem:
p(|D, ) = p(|)p(D|, )/p(D|).
The probability distributions p(|) and p(|D, ) are commonly
referred to as the prior and posterior for , respectively. p(D|, ) is
the likelihood of the “data given model”, i.e. describes the fitness of
a model to the data, and we assume here that D and  are indepen-
dent. If prior knowledge is available, the prior defines a function
that measures the agreement between a given network and the
biological prior knowledge (template) that we have at our disposal.
There are many types of priors that may be used, and there is much
debate about the respective choice. Heckerman (1996), Needham
et al. (2007) as well as Werhli and Husmeier (2007) are excellent
tutorials on learning with BNs using prior knowledge. Commonly
used heuristics to learn BNs (i.e. to identify the most probable GRN
structure) are covered in Section 5.
As shown for BNs inferred from synthetic data, the integration
of prior knowledge about the network topology increases the net-
work reconstruction accuracy (Le et al., 2004; Geier et al., 2007). As
a concrete example, Imoto et al. (2003) derive GRNs from microar-
ray gene expression data, and use biological knowledge (regulatory
interactions from the Yeast Proteome Database) to effectively favour
biologically relevant network structures. Thereby, according to the
BN framework explained before, the fitness of each model to the
data was first measured and subsequently biological knowledge
was input in the form of a prior probability for structures (in this
case expressed in terms of an energy function). Then, the posterior
probability for the proposed GRN was the product of the fitness and
the prior probability of the structure. With this in mind, TF–DNA
binding data was applied complementary to DNA microarray data.
In the work of Hartemink et al. (2002), TF–DNA interactions found
by ChIP analysis were incorporated into the modelling of a network
of 32 selected yeast genes. Thereby, BN models that failed to include
an edge where the location data suggested one were eliminated
from consideration a priori (by setting p(|) = 0). In a later work
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by Bernard and Hartemink (2005), these constraints were relaxed.
Here, edges for which location data indicates TF–DNA interactions
were more likely though not forcibly included in the model, consid-
ering that the prior knowledge is not infallible. Similarly, TF–DNA
interactions predicted by analysing promoter DNA sequences for
TFBS were used in combination with gene expression data (Tamada
et al., 2003; Jensen et al., 2007). Information on protein–protein
interactions have also been used to refine GRNs estimated from
expression data (Nariai et al., 2004). Here, the biological impli-
cations of protein–protein interactions were incorporated in the
learning scheme by adding nodes representing protein complexes
when the resulting BN structure is better suited to reflect the
data.
The application of BNs for knowledge supported network infer-
ence is an active field of research. However, analogously, the
incorporation of prior knowledge can be realised within differ-
ent inference architectures by appropriately setting a model fitness
scoring function (e.g. as a weighted sum of data-fit and template-
fit). Variants of this approach have been proposed for Boolean
networks (Birkmeier, 2006), linear difference equation models
(Yong-A-Poi, 2008; Koczan et al., 2008) and non-linear differential
equation models (Spieth et al., 2005). For instance, a linear differ-
ence equation model can be inferred using prior knowledge by an
adaptation of the LASSO method. The LASSO fits the model to the
data in a least-squares sense subject to
∑
j|ˇj| ≤ s, s > 0. Because
of the nature of this constraint it tends to produce some coefficients
ˇj (model parameters) that are exactly zero and hence gives sparse,
interpretable models (the lower s, the sparser the resulting model).
Now, a template (i.e. prior knowledge) can be used by assigning dif-
ferent weights to the coefficients:
∑
jw̃j|ˇj| ≤ s, s > 0. Thereby, a
relatively low weight w̃j provokes that the edge corresponding to
ˇj is preferred to be in the final model. This concept was applied
to integrate human microarray data with gene regulatory interac-
tions obtained by text mining by Yong-A-Poi (2008) and Koczan et
al. (2008), in which w̃j was defined as a constant and as function of
ˇj, respectively.
However, whenever heterogeneous data and additional infor-
mation from the literature are incorporated into the inference
process, one has to keep in mind that the quality of the inferred
models always depends on the quality and completeness of this
additional/prior knowledge. Today, S. cerevisiae is one of the best-
studied model organisms. It is hence not surprising that a lot of
GRN modelling studies focused on this organism (Hartemink et
al., 2002; Rung et al., 2002; Bar-Joseph et al., 2003; Segal et al.,
2003; Imoto et al., 2003; Tamada et al., 2003; Nariai et al., 2004;
Bernard and Hartemink, 2005; Jensen et al., 2007; Larsen et al.,
2007). As more and more specific information becomes available,
the inference of (dynamic) network models supported by diverse
sources of biological knowledge will be more frequently carried
out for other organisms as well. A so far underexplored topic is
the trade-off between data-fit and confidence in the prior knowl-
edge, i.e. the difficulty to conveniently set the confidence associated
with the prior knowledge relative to the expected noise in the
data.
7. Network Validation and Assessment of the Network
Inference Methods
Network validation consists of assessing the quality of an
inferred model with available knowledge. For quantitative vali-
dation of an inferred GRN, it is necessary to employ a scoring
methodology that evaluates the model with respect to (a) informa-
tion already used to generate the model (internal validation) and (b)
information independent from the information used to reconstruct
the network (external validation).
7.1. Scoring Methodology
In general, the quality of a GRN model can be evaluated by the
answer to one or both of the two questions:
(a) Does the model correctly predict the behaviours of the GRN?
(b) Does the model represent the true structure of the system?
Answering the first question, one compares the simulated
behaviour of the model system with the measured or observed
behaviour of the real system. This can be quantified by cost func-
tions that are also used for model optimization as discussed in
Section 5. Answering the second question, one needs at least partial
knowledge about the true interactions, which is generally incom-
plete, uncertain or difficult to obtain (especially when modelling
a network of gene modules) in practice. For the assessment of
network inference methods one might overcome this problem by
employing synthetic data generated from artificial networks (see
Section 7.4). Supposing that a representation of the true structure of
the network is known or can be obtained (e.g. by direct experimen-
tal verification or database search), the predicted network structure
can be compared to this ‘true network’ based on a variety of perfor-
mance measures. To this end, the number of truly (T) and falsely (F)
predicted regulatory edges is counted, and the presence or absence
of interactions between nodes is referred to as positive (P) or neg-
ative (N) respectively. Now, the following numbers can be defined:
• TP = the number of true positives, i.e. the number of correctly
inferred edges;
• FP = the number of false positives, i.e. the number of inferred
edges that are incorrect;
• TN = the number of true negatives, i.e. the number of missing
edges in the inferred network that are also missing in the true
network;
• FN = the number of false negatives, i.e. the number of missing
edges in the inferred network that are an edge in the true network.
Note that this nomenclature is based on a binary classification of
edges, i.e. does an edge occur in the network or not. This approach
is sufficient in most cases as it can be applied on both directed and
undirected networks. However, to distinguish between inhibiting
and activating effects, similar counts could be defined for the three
classes of ‘activation’, ‘inhibition’ or ‘no effect’. For instance, the
situation of having “inferred an activation” while an inhibition was
expected might be counted as a false positive prediction. In rare
cases, one might even want to assess how close the strength of
interactions was inferred (e.g. using the Euclidean metric on the
expected and inferred continuous model parameters).
Based on the previously defined binary counts, performance
scores can be computed. The ‘recall’ or ‘sensitivity’ is defined by
TP/(TP + FN) and denotes the fraction of correctly identified interac-
tions in relation to the number of expected interactions. ‘Precision’
is determined by TP/(TP + FP) and denotes the fraction of correctly
identified interactions out of all predicted interactions. ‘Specificity’
computed by TN/(TN + FP) measures the proportion of non-existing
edges (number of potential edges – number of inferred edges)
which are correctly identified. Further commonly used scores are
the false positive rate (=FPR = 1 − specificity) and the false discovery
rate (=FDR = 1 − precision). Note that each of these scores is calcu-
lated only from two numbers out of {FN, FP, TP, TN}, i.e. each score is
hardly informative when used alone. For instance, an inferred fully-
connected network will result in a recall equal to 1, but is obviously
not biologically meaningful.
Typically, when inferring a GRN one (a) has a ranking on the
edges reflecting the reliability of the predictions (e.g. an ordering
on pair-wise computed correlation coefficients of an information
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theory model) or (b) can adjust the parameters of the infer-
ence learning scheme to obtain networks of low, moderate and
high connectivity. Then, the performance of the network infer-
ence algorithm can be visualised as a precision-versus-recall curve
(PRC-curve). The curve results from increasing the number of
edges predicted following (a) or (b). Alternatively, a similar curve
results when visualising recall versus FPR (receiver operating char-
acteristic or simply ROC-curve). Both, PRC-curve and ROC-curve
have advantages and disadvantages, thus they are usually used
together to evaluate the performance of different inference tech-
niques (Soranzo et al., 2007; Stolovitzky et al., 2007). In general,
the ROC analysis is only valid for the binary classification problem
indicated above, but allows to directly compare the inference qual-
ity against a random prediction by calculating the area under the
curve (AUC), which is often used as a single metric in benchmark
tests. An AUC(ROC) close to 0.5 corresponds to a random forecast,
AUC(ROC) < 0.7 is considered poor, AUC(ROC) > 0.8 good (Soranzo et
al., 2007). However, since GRNs are sparse, FP might far exceed TP.
Thus, specificity (1 − FPR) which is used in ROC analysis, is inappro-
priate as even small deviations from a value of 1 will result in large
FP numbers. For this reason, the PRC-curve can be a more useful
component for GRN performance evaluation.
7.2. Internal Validation
In statistics, there are different resampling techniques to eval-
uate the generalization performance or robustness of a model, e.g.
subsampling, bootstrapping and perturbation. Subsampling, e.g.
cross-validation, and bootstrapping are based on splitting the avail-
able data into training and test data sets. In k-fold cross-validation,
the data set is partitioned into k subsamples. A single subsample is
retained as the test data set, and the remaining k − 1 subsamples
are used for training. Subsampling and bootstrapping are not well
suited for time series data (since splitting such data makes little
sense). Instead, the effect of measurement noise on the inferred
model might be assessed by repeated network inference on ran-
domly perturbed data (D’haeseleer et al., 2000; Guthke et al., 2005).
Thereby, the noise added to the measured data should be of the
order of magnitude of the measurement noise or biological vari-
ability (Moeller and Radke, 2006).
7.3. External Validation: Knowledge- and Experiment-based
Validation
The internal model validation may be insufficient because the
presumptions that underlie the chosen modelling architecture (Sec-
tion 3) and modelled components (Section 4) may oversimplify the
true complexity in GRNs. In addition, the available data is mostly
inadequate with respect to the data requirements for large-scale
models (Section 2.3). Often, the inference result is not unique,
i.e. some model elements cannot be identified. Therefore, model
predictions should be checked by data, information and obser-
vations that where not used for modelling. Subjects for external
validation are knowledge available from literature or databases,
and data from experiments possibly initiated in response to the
modelling. By using such additional information, an assessment of
the network reconstruction is possible by the scores explained in
Section 7.1. Exemplarily, in the work of van Someren et al. (2006)
knowledge-based validation employing text mining information
was used to assess and compare diverse network inference meth-
ods. Recently, the elegant concept to integrate half of available
prior knowledge into the network inference and subsequently val-
idate the model on the remaining knowledge was addressed by
Yong-A-Poi (2008). However, knowledge-based model validation
is unsuited to validate novel insights of the GRN model. To set
an example, Perkins et al. (2006) compared the behaviour of five
models inferred from data and two models found in the literature
describing early Drosophila melanogaster development. Interest-
ingly, some inferred relationships were found to be inconsistent
with standard textbook models, thus experimental validation is
inevitable.
7.4. Assessment of The Network Inference Methods
The assessment of GRN inference algorithms requires bench-
mark data sets for which the underlying network is known.
However, experimental (gold standard) data sets with the corre-
sponding ‘complete’ knowledge of the network structure are hardly
available, even if there is ongoing work. Hence, there is a need to
generate synthetic data that allow for thorough testing of learn-
ing algorithms in a reproducible manner. The inherent weakness
of such approach is that the performance of an inference strategy
would strongly rely on the model used to construct the artificial
data. Zak et al. (2001), Mendes et al. (2003) and others proposed
models and tools for generation of synthetic data that include rates
of transcription and mRNA degradation. Using synthetic data from
models introduced by Zak et al. (2001) in a slightly modified form
and by analyzing ROC-curves, Husmeier (2003) demonstrated how
the performance of network inference by employing DBNs depends
on the reliability of prior assumptions, the size of the training set
and the number of sampling points. Synthetic gene expression data
from in silico ‘experiments’ simulated by models similar to the
model from Mendes et al. (2003) were used by Yeung et al. (2002) to
introduce a novel algorithm that combines SVD with robust regres-
sion. They concluded from their analyses that the number of sample
points needed to recover a sparsely connected network scales log-
arithmically with the size of the network. Synthetic data were also
applied by Geier et al. (2007) to compare the performance of DBNs
and linear regression with variable selection based on F-statistics.
They used synthetic data simulated by a non-linear model accord-
ing to Mendes et al. (2003) representing 10 TFs and 20 other genes to
study specific perturbations of the GRN in the form of TF knock-outs
and the use of prior knowledge.
Faith et al. (2007) applied the CLR algorithm (see Section 3.1) and
compared its performance with other popular inference strategies
(ARACNE, RELNET, linear regression networks) on a compendium
of 445 DNA microarray experiments for E. coli. When evaluated
against known regulatory interactions from RegulonDB, both CLR
and RELevance NETworks reach high precisions, but CLR attains
almost twice the sensitivity of RELNET at some levels of precision.
The algorithms NIR, MNI and TSNI (see Section 3.3.1) were bench-
marked by Bansal et al. (2006) on a synthetic data set. They showed
that the reverse engineering tools MNI and TSNI are not well suited
for inferring large-scale networks, but rather for identification of
the targets of a perturbation. In a later work Bansal et al. (2007)
evaluated public software tools (ARACNE, BANJO and NIR—see Sec-
tion 3) using both synthetic and experimental microarray data with
the following conclusions: ARACNE performed well for steady-state
data, but was not suited for the analysis of short time-series data.
NIR worked very well for steady-state data, but required knowledge
on the genes that have been perturbed directly. BANJO required a
large number of data points, but when this condition was met, it
performed comparably to the other methods.
Noteworthy, the Dialogue on Reverse Engineering Assessment
Methods (DREAM) is fostering a concerted effort by computa-
tional and experimental biologists to understand the limitations
and strengths of techniques for inferring networks from high-
throughput data through network inference challenges. Thereby,
they aim to create what seems to be a suitable set of gold stan-
dards for network inference assessment by providing curated data
sets to the community and defining common evaluation metrics
(Stolovitzky et al., 2007). A recent example of the DREAM initiative
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is the five-gene network challenge. In this challenge, they provide
expression data obtained from a synthetic 5-gene network in yeast,
i.e. a network by human design that was transfected into an in vivo
model organism. This allows the inference of a GRN for which the
true network structure is known.
8. Conclusions
Discovering structures and dynamics of GRNs based on large-
scale data represents a major challenge in systems biology. There
is a vast variety of data and network types, inference methods as
well as evaluation metrics for network inference. Even if the differ-
ent model architectures rely on completely different mathematical
formalisms, all models can be interpreted as networks of inter-
acting nodes. Nodes represent molecular entities such as genes
and proteins, or functional modules, whereas edges correspond to
regulatory interactions and other relations between those nodes.
Due to limitations in the amount and quality of available data and
the corresponding computational efforts, network inference meth-
ods require simplifications such as linearization, discretization or
aggregation of compounds to modules. The usefulness of a GRN
inference method mainly depends on both the intended application
of identified networks and the data at hand.
Table 2 provides an overview of the characteristics of differ-
ent reverse engineering studies, covering the used data, feature
selection methods, inference techniques, constraints and validation
methods.
8.1. The Purpose
Mathematical models can be used in two different ways (see also
Gardner and Faith, 2005): first, the use of ‘mechanistic’ network
models aims to identify true molecular interactions. These include
protein–DNA interactions, in particular the interactions of TFs with
binding sites of their target genes, as well as protein–protein and
protein–ligand interactions forming signalling pathways. Due to the
vast amount of molecules in cells, it is necessary to mention that
such reverse engineering approaches do not claim to recover the
totality of connections in a biological network but rather reveal
interactions that are highly significant under defined (experimen-
tal) conditions.
Second, so-called ‘influence’ network models generally reflect
global properties of a system’s behaviour. Influence networks relate
the expression of one gene or a group of genes (module) to
the expression of another gene or module. Using the influence
approach, true molecular interactions are described rather implic-
itly. Therefore, influence models can be difficult to interpret and
also difficult to integrate or extend using further information. Solely
analysing gene expression data allows to infer influence networks of
gene-to-gene interactions. Though, the integration of prior knowl-
edge as well as the use of additional experimental data can lead to
network models whose edges might be interpreted more mecha-
nistically in terms of molecular interactions.
8.2. The Data
Data obtained from DNA microarray monitoring of gene expres-
sion are the most common type of data used to reverse engineer
GRNs. Other less mature high-throughput techniques are emerg-
ing and improving at a rapid pace. However, with respect to data
quality and quantity, no single measurement technique is capable
of providing all necessary data for an error-free network inference.
Deeper biological insight will be gained combining different types
of information including measurements of transcript levels, pro-
teins and small molecules, as well as interactome measurements.
Considering network edges that are supported by more than one of
these data sets will further increase the chance to actually identify
biologically relevant interrelations.
The identifiability of model structure and parameters depends
on the chosen model architecture and the modelled features (see
Section 4) as well as on the experimental design (e.g. the kind of
intervention; see Sections 2.2 and 2.3). Perturbation experiments
by environmental changes such as heat shock or starvation alter
the behaviour of the system in a non-specific way, often initiat-
ing extensive changes in the cellular behaviour. Experiments that
apply specific techniques of intervention, such as gene knock-out or
RNA interference, are able to generate highly informative data for
network inference. This has been impressively demonstrated for
simple microorganisms, e.g. Halobacterium (Bonneau et al., 2006),
E. coli (Faith et al., 2007) and S. cerevisiae (Lee et al., 2002).
The quantity and quality of data available today is in general
insufficient to infer mechanistic networks on a genome-wide scale.
Only a small portion of the actually existing interactions can be
identified by current approaches. The higher the number of inter-
acting compounds (genes, proteins, etc.) the higher the complexity
of a corresponding network model and thus, a larger number of
both state variables and model parameters is required.
8.3. The Integration of Diverse Biological Information
The dimensionality (data insufficiency) problem strongly
impedes the modelling of GRNs. Hence, in order to obtain reliable
inference results, it is important to carry out feature selection, to
incorporate biologically motivated constraints (such as sparseness)
and to combine diverse types of data (e.g. gene expression data and
sequence information). While network sparseness is commonly
postulated during inference and implemented by limiting the
number of regulators per gene or in general penalising model
complexity, the properties of scale-freeness and modular design of
regulatory networks have just been recognised as additional mod-
elling constraints. As shown, various data and information from
scientific literature and biological databases can be used in combi-
nation with gene expression levels, e.g. genome sequence data (TF
binding motifs), gene functional annotations, text-mining infor-
mation, ChIP-on-chip data and protein–protein interaction data.
We reviewed promising studies that integrate such diverse types of
data during the reconstruction of (dynamic) GRN models. The incor-
poration of heterogeneous data and prior biological knowledge
has been presented in particular for Bayesian networks and linear
difference equation models. Facing limited amounts of experimen-
tal data, such a combined analyses of different types of biological
information supports the inference process and thus allows to
infer more exact and more interpretable models. The integration
of multiple sources of heterogeneous data and prior biological
knowledge will be one of the major focuses in future GRN research.
8.4. The Assessment of Network Inference Methods
Current efforts aim to understand individual strengths and
weaknesses of various GRN inference methods by applying them
to equal data sets. Such comparisons require an appropriate eval-
uation scheme to assess the success and correctness of network
reconstruction. Generally, researchers apply so-called ‘synthetic
networks’. Here, designed networks are thought to produce artifi-
cial data approximating real gene expression values. Data produced
by synthetic networks may be used to address questions like: Which
experiments and data types are best suited for a specific net-
work inference method? For individual methods, which algorithm
configuration works best? Obviously, models used to generate syn-
thetic data cannot reflect the complexity of a real biological system.
However, standards are still missing to evaluate different inference
methods using real biological data.
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Systems biological models are intended to assist biologists in
generating assumptions for further research activities. Hypotheses
generated by modelling can and should be experimentally tested.
Faith et al. (2007), for instance, tested and confirmed predicted
interactions using ChIP. The predictive power of a GRN model
inferred by Bonneau et al. (2006) was successfully verified using
DNA microarray data which were not included in the data set used
for network inference. The validation and interpretation of GRN
models ideally goes in line with new knowledge and experimental
data available for modelling, and thus a reiterative cycle between
model construction and experimental validation can be formed. It
is exciting to see, how the modelling of GRNs can be improved by
advances in biotechnology and bioinformatics in the future.
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Abstract
Background: The investigation of gene regulatory networks is an important issue in molecular
systems biology and significant progress has been made by combining different types of biological
data. The purpose of this study was to characterize the transcriptional program induced by
etanercept therapy in patients with rheumatoid arthritis (RA). Etanercept is known to reduce
disease symptoms and progression in RA, but the underlying molecular mechanisms have not been
fully elucidated.
Results: Using a DNA microarray dataset providing genome-wide expression profiles of 19 RA
patients within the first week of therapy we identified significant transcriptional changes in 83 genes.
Most of these genes are known to control the human body's immune response. A novel algorithm
called TILAR was then applied to construct a linear network model of the genes' regulatory
interactions. The inference method derives a model from the data based on the Least Angle
Regression while incorporating DNA-binding site information. As a result we obtained a scale-free
network that exhibits a self-regulating and highly parallel architecture, and reflects the pleiotropic
immunological role of the therapeutic target TNF-alpha. Moreover, we could show that our
integrative modeling strategy performs much better than algorithms using gene expression data
alone.
Conclusion: We present TILAR, a method to deduce gene regulatory interactions from gene
expression data by integrating information on transcription factor binding sites. The inferred
network uncovers gene regulatory effects in response to etanercept and thus provides useful
hypotheses about the drug's mechanisms of action.
Background
The molecular interactions within a biological system give
rise to the function and behavior of that system. In sys-
tems biology, one aims to formulate the complex interac-
tions of biological processes by mathematical models. A
major focus of the field is the uncovering of the dynamic
and intertwined nature of gene regulation.
Published: 24 August 2009
BMC Bioinformatics 2009, 10:262 doi:10.1186/1471-2105-10-262
Received: 10 February 2009
Accepted: 24 August 2009
This article is available from: http://www.biomedcentral.com/1471-2105/10/262
© 2009 Hecker et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Manuscript II 36
BMC Bioinformatics 2009, 10:262 http://www.biomedcentral.com/1471-2105/10/262
Page 2 of 18
(page number not for citation purposes)
Gene expression is mainly regulated at the level of mRNA
transcription by proteins called transcription factors
(TFs), that specifically bind the DNA at the regulatory
region of their target genes. A number of collections of
experimentally defined TF binding sites (TFBS) have been
assembled. The most commonly used is the Transfac data-
base, which catalogs eukaryotic TFs and their known
binding sites [1]. The expression level of a gene usually
depends on the occupancy states of multiple TFBS. How-
ever, gene regulation is much more complex and includes
different layers of post-transcriptional control. The
entirety of gene regulatory processes constitutes a network
of genes, regulators, and the regulatory connections
between them – namely a gene regulatory network
(GRN). In the past, various modeling approaches have
been proposed to (partially) reconstruct GRNs from
experimental data on the basis of different mathematical
concepts and learning strategies, and distinct degrees of
abstraction [2-4]. A graph is always the basic modeling
scheme for a GRN, with nodes symbolizing regulatory ele-
ments (e.g. genes and proteins) and edges representing
(activatory and inhibitory) relationships between them.
Common mathematical formalisms of such a graph are
Boolean networks, Bayesian networks, association net-
works and systems of equations. Boolean networks
assume that genes are simply on or off, and apply Boolean
logic to model dynamic regulatory effects. In contrast,
Bayesian networks model gene expression by random var-
iables and quantify interactions by conditional probabili-
ties. Interactions in association networks are typically
undirected and derived by analyzing pairs of genes for co-
expression e.g. using mutual information as a similarity
measure. Systems of equations describe each gene's
expression level as a function of the levels of its putative
predictors. For specific types of functions they could draw
on well developed statistical techniques to efficiently fit
their model parameters. However, GRN inference is
always a challenging task because of incomplete knowl-
edge of the molecules involved, the combinatorial nature
of the problem and the fact, that often available data are
limited and inaccurate. Microarray gene expression data
are typically used to derive rather phenomenological GRN
models of how the expression level of a gene is influenced
by the expression level of other genes, i.e. the model also
includes indirect regulatory mechanisms. Obviously, the
incorporation of other types of data in addition to gene
expression data (e.g. gene functional annotations,
genome sequence data, protein-protein and protein-DNA
interaction data) as well as the integration of prior biolog-
ical knowledge (e.g. from scientific literature) supports
the inference process. Moreover, it is necessary to utilize
biological plausible assumptions considering the network
topology (e.g. structural sparseness). The integration of
diverse types of biological information and modeling
constraints allows for more accurate GRN models and is a
current challenge in network reconstruction. Bayesian net-
works and systems of linear equations have been most
studied for such combined analyses [3-5].
Organizing biological data in network models may help
understanding complex diseases such as human autoim-
mune diseases [6]. Many studies implicate hundreds of
genes in the pathogenesis of autoimmune diseases, but we
still lack a comprehensive conception of how autoimmu-
nity arises. Understanding structure and dynamics of
molecular networks is critical to unravel such complex
diseases. Network analyses may not only support the
investigation of autoimmune diseases but also the optimi-
zation of their treatment. Here, we focus on rheumatoid
arthritis (RA), which is a multifactorial polygenic disease
and might be termed a systems biology disease. RA is a
chronic inflammatory disorder primarily afflicting the
synovial joints, and autoimmunity plays a pivotal role in
its chronicity and progression. The disease is characterized
by autoreactive behavior of immune cells and the induc-
tion of enzymes which lead to the destruction of cartilage
and bone [7]. The inflammatory processes are triggered by
cytokines and other immune system-related genes that
form a complex network of intra- and intercellular molec-
ular interactions. A number of cytokine proteins play a
critical role as mediators of immune regulation. In RA, the
two cytokines TNF-alpha and IL-1 are considered master
regulators that act in a complementary and synergistic
manner [8,9]. By blocking TNF-alpha, etanercept inter-
venes this molecular network and thus is thought to re-
balance the immune system's dysregulation [10-12].
Etanercept therapy in RA patients has been proven to slow
disease progression, but the precise molecular mecha-
nisms remained unclear. To investigate the therapeutic
effects on transcriptional regulation, GRN inference tech-
niques can be applied. This could lead to a better under-
standing of the modes of action of etanercept as well as
the pathogenesis underlying RA. We may also understand
why the drug fails to control the disease in about 30% of
the patients (non-responders).
We studied a group of 19 patients suffering from RA for
which DNA microarrays were used to obtain genome-
wide transcriptional profiles within the first week of
etanercept administration [13]. A set of etanercept respon-
sive genes was attained. The majority of these genes are
known to control the body's immune response. Several
TFBS were identified as overrepresented in the genes' reg-
ulatory regions and we used the corresponding informa-
tion on TF-gene interactions as a template for modeling
the underlying GRN. A system of linear equations was
chosen to mathematically describe the regulatory effects
between the genes and TFs (i.e. the network nodes). We
used a hybrid of the Least Angle Regression (LARS) and
the Ordinary Least Squares regression (OLS) to find the
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model structure and estimate the coefficients. In doing so,
the modeling is constrained to include only a subset of the
putative TF-gene interactions. That way, our approach
considers that genes usually regulate other genes indi-
rectly through the activity of one or more TFs, which
makes the model straightforward to interpret in terms of
true molecular interactions. The resulting GRN was fur-
ther analyzed using e.g. gene ontology (GO) and clinical
information (figure 1). We found that our integrative
modeling strategy, namely the TFBS-integrating LARS
(TILAR), is able to reconstruct GRNs more reliably than
other established methods. This is one of the first studies
that utilizes network analysis to investigate transcriptional
regulation in response to a therapeutic drug in humans
[14].
Results and discussion
Effects of etanercept therapy on gene expression
We used the Affymetrix microarray dataset from Koczan et
al. [13] which provided expression levels of peripheral
blood mononuclear cells (PBMC) measured in 19
patients suffering from RA. For each patient, blood sam-
ples were taken before treatment (baseline) as well as 72
(day 3) and 144 hours (day 6) after start of immuno-
therapy by etanercept. Clinical response was assessed over
3 months and revealed 7 patients with persistent disease
activity (non-responders).
We analyzed the DNA microarray data in respect to com-
mon gene expression changes observed in the whole
group of patients after therapy onset. First of all, we pre-
processed the data to correct for systematic effects. More
importantly, signal intensities were calculated by applying
a custom chip definition file by Ferrari et al. that is com-
posed of custom-probesets including only probes match-
ing a single gene [15]. As such, a one-to-one
correspondence between genes and custom-probesets is
preserved, which deeply improves gene-centered analysis
of human Affymetrix data [16]. Finally, the data pre-
processing yields expression levels of 11,174 different
genes for each of the 55 microarrays in the dataset (for
details see the methods section).
Afterwards, we identified a set of genes significantly up- or
down-regulated in response to etanercept. It is important
to note that the filtering of genes is a crucial step in GRN
inference as there is a tight relationship between model
complexity (i.e. network size and level of detail of the
model), the amount of data required for inference and the
quality of the results. On the one hand, a small and
detailed network model might better fit the given data,
but only a sufficiently large model can capture the funda-
mental properties that constitute a GRN including scale-
freeness, redundancy and self-regulation. In this study, we
utilized a t-statistic in conjunction with an MA-plot-based
signal intensity-dependent fold-change criterion (referred
to as MAID filtering) to select genes with expression
changes in the first week of therapy (see methods).
Through this filtering we identified 37 genes as differen-
tially expressed at day 3 versus baseline, and 57 genes at
day 6. Altogether, 48 genes were found down-regulated
and 35 genes up-regulated, comprising a set of 83 genes in
total (additional files 1 and 2).
We searched for overrepresented terms of the GO biolog-
ical process ontology in the list of 83 selected genes and
found that most of the genes are known to control the
body's immune response (additional file 3, see methods).
Remarkably, genes of the I-kappaB kinase/NF-kappaB cas-
cade (GO:0007249) are enriched in the gene set and rep-
resented by 5 genes (NFKBIA, TNFRSF1A, TLR8, NOD2,
HMOX1). NF-kappaB is a key factor in the transcription of
many inflammatory genes and has been implicated in the
pathological processes of RA. The NF-kappaB cascade is
Workflow used to study gene regulatory effects in response to etanercept therapyFigure 1
Workflow used to study gene regulatory effects in response to etanercept therapy. A network model of transcrip-
tional regulation is inferred by integrating transcription factor binding site information.
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mainly activated by the proinflammatory cytokines IL-1
and TNF-alpha. As was shown, TNF-blocking agents such
as etanercept prevent TNF-alpha from binding to its recep-
tors, induction of signal transduction cascades and activa-
tion of TFs including NF-kappaB [10]. Here, we found
NFKBIA, that inactivates NF-kappaB by trapping it in the
cytoplasm, up-regulated early after therapy initiation. On
the other hand, genes known to activate the NF-kappaB
protein, e.g. NOD2 and TNFRSF1A (a TNF receptor), were
down-regulated after therapy onset. Thus, the result of our
filtering indicates the expected suppression of NF-kappaB
activity by etanercept. In addition, we found evidence for
a modulation of B cell mediated immunity. The corre-
sponding GO category (GO:0019724) comprises the
genes C1QB, CLU and TLR8 whose mean expression was
significantly lower at day 3 and 6 compared to baseline,
respectively. Interestingly, TLR8 signaling is linked to the
control of CD4+ regulatory T (Treg) cells. Treg cells
actively suppress host immune responses and, as a conse-
quence, play an important role in preventing autoimmu-
nity [17]. TLR8 is thought to initiate immune processes by
reversing the suppressive function of Treg cells [18]. Its
down-regulation by etanercept might be an important fac-
tor to control the disease.
Genes responsive to etanercept administration are proba-
bly under control of certain TFs, whose activities are
(maybe indirectly) affected by this drug. Therefore, we
analyzed the regulatory regions around the respective
transcription start sites (TSS) of these genes for occurrence
of overrepresented TFBS (see methods). Identifying TFBS,
particularly in higher eukaryotic genomes, is an enormous
challenge and cross-species sequence conservation is
often used as an effective filter to improve the predictions.
We found evolutionarily conserved binding sites enriched
for 12 TFs (represented by 19 Transfac binding profiles).
These 12 TFs connect 52 out of the 83 genes through 96
TF-gene interactions, whereas each TF is linked to at least
4 genes (table 1). The list of TFs includes C/EBP-beta,
which is an important transcriptional activator in the reg-
ulation of genes involved in immune and inflammatory
responses, including the cytokines IL-6, IL-8 and TNF-
alpha [19]. Binding sites for the TATA binding protein
(TBP) were detected in 14 genes. TBP binds DNA at the
TATA-element, and as a subunit of the TFIID complex
coordinates the initiation of transcription by RNA
polymerase. Although TBP is always involved, its TATA-
binding activity is dispensable for the positioning of the
RNA polymerase. In fact, approximately 76% of human
core promoters lack TATA-like elements [20]. However, in
the set of 83 genes, those genes having the TATA box were
overrepresented. The two TFs ZIC1 and ZIC3 were consid-
ered as one TF entity, as they have highly similar DNA
binding properties. None of the 12 TFs showed significant
transcriptional changes in the data. Nevertheless, the
information on predicted TF-gene interactions can be
used as a GRN template during inference. Before describ-
ing how this is done by TILAR we will outline the general
principles of the modeling approach.
Linear network modeling
We chose a system of equations to model the regulatory
interactions among the genes affected by etanercept ther-
apy. The concept of modeling gene regulation by a system
of equations is to approximate gene expression levels as a
function of the expression of other genes and environ-
mental factors. Modeling GRNs by systems of equations
has several benefits as they can describe regulatory effects
in a flexible, quantitative, directed manner, and take into
account that gene regulators act in combination. With sys-
tems of equations one can easily model positive and neg-
ative feedback loops, and describe even non-linear and
Table 1: Evolutionarily conserved binding sites were found to be enriched for 12 TFs. 
TF Name Transfac ID Official Full Name P-value Expected Count Count
TBP, TFIID V$TBP_01, V$TATA_C, V$TATA_01 TATA box binding protein 0.0042 6.41 14
C/EBPbeta V$CEBPB_01, V$CEBPB_02 CCAAT/enhancer binding protein beta 0.0112 5.03 11
Zic1, Zic3 V$ZIC1_01, V$ZIC3_01 Zic family member 1/3 0.0183 6.13 12
AP-2rep V$AP2REP_01 Kruppel-like factor 12 0.0264 1.68 5
HNF-1, HNF-1A V$HNF1_01, V$HNF1_C HNF1 homeobox A 0.0274 2.30 6
Lmo2 V$LMO2COM_01, V$LMO2COM_02 LIM domain only 2 0.0352 5.98 11
SRY V$SRY_02 sex determining region Y 0.0374 1.85 5
ATF-2 V$CREBP1_01 activating transcription factor 2 0.0408 1.30 4
Cart-1 V$CART1_01 ALX homeobox 1 0.0415 1.30 4
COMP1 V$COMP1_01 cooperates with myogenic proteins 1 0.0422 3.23 7
Hlf V$HLF_01 hepatic leukemia factor 0.0470 1.97 5
NF-1, NF-1/L V$MYOGNF1_01, V$NF1_Q6 nuclear factor I 0.0492 7.10 12
 = 96
The column "Count" denotes the number of genes that possess a TFBS for the respective TF. All in all, 96 TF-gene interactions were predicted 
(GRN template).
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dynamic phenomena of biological systems. However, as
more complex models require higher amounts of accurate
data to learn their parameters reliably, researchers often
utilize systems of linear equations (linear models). Linear
models have been successfully employed in many appli-
cations, e.g. to reconstruct GRNs relevant for development
of the central nervous system in rats [21], osteoblast dif-
ferentiation in mice [22,23], galactose regulation in yeast
[24] and immune response of human blood cells to bac-
terial infection [25]. Linear models assume that gene reg-
ulatory effects are limited to be linear and additive and a
simple one can be written as:
where vector xi contains the M expression levels measured
for gene i, N is the number of genes in the network, and
the weights wij define relationships between the genes.
When inferring a linear model we need to estimate the
weights wij (i.e. the model parameters) from the data. The
weights specify the existence of regulatory relationships
between genes, their nature (activation or inhibition) and
relative strength. If wij > 0 gene xj activates gene xi, if wij < 0
xj inhibits xi, and wij = 0 implies that xi is not under control
of xj. This simplicity makes linear models easy to interpret,
even if the encoded relationships have a wide range of
meanings: edges in the network might represent direct
physical interactions (e.g. when a gene encodes a TF regu-
lating another gene) or rather conceptual interactions
(e.g. when the expression levels of two genes merely cor-
relate).
Linear models can also be used to describe the dynamics
of the network. In this case, the model is a system of linear
difference equations that approximates the change of gene
expression in time. However, this approach is inappropri-
ate for our application as the time-series in the microarray
dataset consist of only 3 time-points and the time
between two subsequent measurements is rather long (3
days). Nevertheless, the modeling strategy illustrated here
can be easily adapted for the inference of dynamic mod-
els.
To fit the (static) linear model to the data, equation (1)
can be written in matrix form as follows:
These N systems can be coupled as:
Now, a GRN model can be inferred by estimating  (com-
prising all the model parameters in w) from input matrix
X (having M' = MN rows and N' = (N-1)N columns) and
output vector y using OLS regression.
However, despite the fact that linear models are a strong
simplification of the true GRN, equation (3) is already an
underdetermined system of linear equations in our partic-
ular study as the number of genes in the network (N = 83)
is greater than the number of measurements (M = 55).
That means, infinitely many solutions exist. Therefore,
biologically motivated constraints have to be included to
tackle this problem. The most commonly used modeling
constraint is the sparseness of GRNs. Sparseness reflects
the fact that genes are regulated only by a limited number
of regulators. The sparseness constraint minimizes the
number of edges, i.e. reduces the effective number of
model parameters. Sparse linear models can be recon-
structed via the Lasso (Least absolute shrinkage and selec-
tion operator) method [26], which effectively performs
simultaneous parameter estimation and variable selec-
tion. The Lasso is a version of OLS that constrains the sum
of the absolute regression coefficients :
The Lasso penalizes model complexity by shrinking the
coefficients j (and hence wij) toward 0, more so for small
values of s. A modification of the LARS algorithm imple-
ments the Lasso [27]. LARS builds up estimates for  in
successive steps, each step adding one covariate to the
model, so that gradually model parameters are set non-
zero. In simple terms, LARS is a less greedy version of tra-
ditional forward selection methods. LARS and its variants
are computationally efficient. The algorithm requires only
the same order of magnitude of computational effort as
OLS to calculate the full set of Lasso estimates (i.e. for all
s  0).
The Lasso approach was first introduced to infer regula-
tory interactions by van Someren et al. [28] and has since
been applied in several GRN studies [22,29]. However,
even if the network connectivity is constrained, there is a
limitation in inferring GRNs using gene expression data
only. Hence, there is a need to incorporate different types
of information during network reconstruction. Various
data and information from biomedical literature and
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databases can be utilized in combination with gene
expression levels to increase model accuracy.
An integrative learning strategy usually consists of two
steps. First, a template of the network is built, e.g. based
on known TF-DNA interactions or molecular interactions
automatically extracted from the literature by text mining.
This template represents a supposition of the true network
structure, that might be uncertain and incomplete. Sec-
ond, an inference algorithm is applied that fits the model
to the measured data while taking the template into
account, trading off data-fit and template-fit. When infer-
ring linear models, such template information can be
included by adapting the Lasso method. This is possible
by introducing additional weights  on the coefficients 
of the constraint in equation (4):
A relatively low weight j provokes that the edge corre-
sponding to j is preferred to be in the final model. Hence,
the modeler is able to incorporate partial prior knowledge
by setting the weights appropriately. Recently, this con-
cept was applied to integrate human microarray data with
regulatory relationships obtained by literature mining by
defining each j as a constant [23] and as weight function
of j [13], respectively.
TILAR – a TFBS-integrating linear modeling approach
Here, we propose TILAR – a TFBS-integrating inference
technique that differs from the adaptive Lasso approach,
and employs TF binding information as prior knowledge.
As we will show, it is even possible to combine the adap-
tive Lasso and TILAR. According to our modeling scheme,
we distinguish two types of network nodes: genes (that
were selected for inferring regulatory relationships
between them) and TFs (for which respective binding sites
are overrepresented in the gene set). Expression levels of
the gene set (that possibly includes genes encoding TFs)
are required for the modeling. The algorithm then aims to
assign (directed) TF-gene and gene-TF interactions (net-
work edges). A TF-gene interaction represents a physical
interaction, i.e. a TF binds the region that encompasses
the TSS of a certain gene and thus regulates its transcrip-
tion. In contrast, gene-TF interactions can have different
meanings: the gene itself might encode a transcriptional
regulator of the TF, or the gene product controls the activ-
ity of the TF at the proteomic level, or the gene triggers sig-
naling cascades that affect the TF, etc. Using both types of
interactions, the model reflects that genes regulate other
genes indirectly through a combination of TFs (figure 2).
As a reminder, the TFBS overrepresentation analysis
revealed 96 putative TF-gene interactions. Now, the idea is
to use this information as a GRN template by constraining
the modeling to include only a subset of these TF-gene
interactions. As the inference method not necessarily uses
all the given TF-gene interactions, we consider the fact that
they are computationally predicted and therefore not all
of them might refer to biologically functional binding
sites. In practice, the algorithm starts with the entire set of
TF-gene interactions and then iteratively removes avoida-
ble interactions through a backward stepwise selection
procedure (see methods). The information on (the cur-
rent set of included) TF-gene interactions is written in
matrix B, which is defined as:










































Illustration of our proposed modeling conceptionFigu e 2
Illustration of our proposed modeling conception. 
Here, we aim to reconstruct a gene regulatory network con-
sisting of 4 genes (dark blue) and 2 transcription factors (light 
gray). For simplicity, we assume that only one gene expres-
sion measurement was performed. The expression level of 
each gene is given in the gene nodes. (A) The GRN template: 
In this example, two genes possess at least one TF binding 
site in their regulatory region as indicated by 3 TF-gene inter-
actions (purple). (B) In that case, there are 5 possible gene-
TF interactions (i.e. model parameters ) in the network 
(dashed, orange). If available, we might consider prior knowl-
edge on gene-TF interactions during inference (adaptive 
TILAR). (C) A possible inference result including 3 gene-TF 
interactions (solid, orange). Here, the model perfectly fits the 
data (e.g. "8" = 2.0·"4") with two nominal model parameters 
set to zero. (D) We can use the inferred model to derive 
gene-gene relationships from the edges between genes and 
TFs (gray). The benchmarking was conducted on such gene-
gene interactions.
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In our particular study, 96 entries in B were set to 1 in the
first iteration. TILAR then assigns the parameters in the
model to gene-TF interactions, as follows:
where F is the number of TFs. For modeling the transcrip-
tional regulation in response to etanercept we have N = 83
genes, that showed significantly changed expression levels
after therapy onset, and F = 12 TFs, whose binding sites
are overrepresented in the regulatory regions of the
selected genes. In the model, each gene can exhibit a reg-
ulatory effect on each TF, except those TFs that hold a TF-
gene interaction to this gene (this restriction is dispensa-
ble when inferring a dynamic model). If wkj = 0, there is no
gene-TF interaction between gene j and TF k. Otherwise,
gene j controls the activity of TF k and thus regulates all
the genes that possess a TFBS for TF k. In this case, the
expression levels of gene j explain the expression of the
genes regulated by TF k. Again, to infer the GRN model, we
need to estimate the model parameters wkj from the gene
expression data while constraining the model to be sparse.
Similar to equation (3), we can couple the subsystems, as
follows:
where Nr is the number of genes possessing at least one
overrepresented TFBS, and #B is the number of TF-gene
interactions considered at the current iteration. The coef-
ficients  of this equation now correspond to gene-TF
interactions in the model. Finally, a sparse solution to
equation (8) can be found using the Lasso according to
equation (4).
The TILAR modeling approach proposed here is advanta-
geous for several reasons. First, TF expression levels are
not required, since the activity of TFs is modeled implic-
itly (like a hidden node). This is beneficial, as mRNA lev-
els of TFs are often low and do not necessarily correlate
with TF activity. In fact, TF proteins often need to be acti-
vated by phosphorylation. Second, the nominal number
of model parameters w in equation (7) is generally lower
than in equation (1). Therefore, our method tackles the
problem of having too many parameters in comparison to
limited amounts of experimental data. In our particular
application, equation (8) is an overdetermined system of
linear equations (as M·Nr = 55·52 = 2860 >F·N-#B =
12·83-#B = 996-#B, #B  96), i.e. we are able to infer a
complex network of 83 genes (and 12 TFs) without being
in conflict with the data requirements. Third, by using TF
binding predictions as prior knowledge we can recon-
struct GRNs more reliably. Besides, the inferred models
are relatively easy to interpret. Finally, the integration of
TFBS information is accomplished by simply specifying
the regression equation (i.e. input matrix X and output
vector y) adequately. Therefore, we can combine the
TILAR approach with the adaptive LARS, i.e. solve equa-
tion (8) according to equation (5) if prior knowledge on
gene-TF interactions is available (adaptive TILAR).
Modeling the gene regulatory response to etanercept
To examine the early transcriptional effects of etanercept
we applied the TILAR algorithm to construct a GRN model
on the basis of gene expression data and knowledge on
TF-gene interactions obtained by TFBS analysis. For this
purpose, the GRN inference problem was formulated
according to equation (8). The essential part of our mod-
eling approach is the LARS algorithm that is used to
obtain all possible Lasso solutions for this linear regres-
sion equation.
TILAR iteratively applies LARS in a backward stepwise
selection procedure in order to refuse TF-gene interactions
that do not fit the data well (see methods). Hence, the
learning strategy takes into account that the prediction of
TFBS might be error-prone. In this study, 12 out of 96 pre-
dicted TF-gene interactions were discarded. These 12
interactions may result from false positive TFBS predic-
tions, or the magnitude of the TF-gene interactions was
not enough for being confirmed based on the gene expres-
sion levels.
After we identified the subset of 84 TF-gene interactions,
we used LARS to define which gene-TF interactions have
to be included at different degrees of network connectiv-
ity. That means we used LARS only for variable selection,
but the actual coefficients were estimated by OLS (see
methods). This LARS/OLS hybrid technique usually
achieves sparser estimates and more accurate predictions,
and thus outperforms the ordinary Lasso [27,30]. Finally,
we selected the most parsimonious estimate with low 10-
fold cross-validation error (additional file 4). In this way,
the method avoids overfitting to the data and conse-
quently yields a sparse GRN model. The final model con-
sists of 22 inferred gene-TF interactions and 84 TF-gene
interactions, and was visualized using Cytoscape 2.6.0
(figure 3, additional file 5).
Model interpretation
Systems biological models need to be interpretable in
order to be useful. In general, the modeling goals of accu-
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interpretable models should be simple, but more accurate
models might be quite complex. The model reconstructed
here seems to satisfy both requirements. On the one hand,
the network model is fairly complex as it consists of 95
nodes and 106 edges while using 22 model parameters wij
(specifying the strength of the gene-TF interactions). Yet
the model is readily interpretable due to the intuitive lin-
ear modeling scheme.
Apparently, the inferred model is sparse, i.e. each network
node is under control of only few regulators. The maxi-
mum in-degree in the GRN is 5 (on average 1.12). Never-
theless, some nodes (named hubs) are highly connected
in the network, e.g. TBP which has an out-degree of 12. A
further characteristic and biologically meaningful prop-
erty of the network is its scale-free structure. Scale-freeness
denotes the phenomenon that the degree distribution in
biological networks often follows a power law, i.e. the
fraction P(k) of nodes in the network having k connec-
tions goes as P(k)~k-, where  is a constant. This means
that in scale-free networks most of the nodes are lowly
connected, while a few are relatively highly connected.
Scale-freeness indicates a network's decentralization and
structural stability, and in consequence its robustness
against random fluctuations [31]. The scale-free design of
GRNs is well studied in literature [32,33], and the GRN
reconstructed here is scale-free with  = 2.22 (as calculated
according to Clauset et al. [34], see figure 4).
A closer look at the interactions in the network revealed
gene sets co-regulated by a common TF. For example, 6
TF-gene interactions were assigned to the transcriptional
activator HNF-1 in the GRN template (table 1). Two of
them were not considered in the final model as they were
eliminated during backward stepwise selection. However,
the 4 remaining genes that are predicted to be under con-
trol of HNF-1 (AQP9, TCN2, CREB5, C4orf18) are all
down-regulated in the patients during first week of ther-
apy (figure 5A). AQP9 is assumed to have some role in
immunological response [35]. Hence, we can hypothesize
Reconstructed gene regulatory network of genes up- or down-regulated during first week of therapyFigure 3
Reconstructed gene regulatory network of genes up- or down-regulated during first week of therapy. The 
TILAR algorithm used gene expression data and transcription factor binding predictions to infer a network of 84 TF-gene and 
22 gene-TF interactions. The size of the nodes corresponds to their degree of connectivity. Three parts of the network model 
are shown in detail in figure 5. The full model is available as a Cytoscape session file of (additional file 5).
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that the activity of HNF-1 is lowered under etanercept
therapy, which has (barely explored) effects on specific
immune processes.
We also found that the network model highlights TFs that
regulate functionally related genes (as annotated by GO).
For instance, the model reveals TF-gene interactions of the
transcription initiation factor TBP and the genes NFKBIA,
POU2AF1, CXCR4 and CLU (figure 5B). These 4 genes not
only share the TATA binding site in their regulatory
region, but also belong to the same functional category
(immune system process, GO:0002376). Nevertheless,
they play different roles in inflammatory control. NFKBIA
inhibits the activity of the NF-kappaB complex, which
controls many genes involved in inflammation and is
chronically active in RA [10]. Interestingly, the data show
significantly elevated expression levels of NFKBIA in
response to etanercept. POU2AF1 is a B cell-specific tran-
scriptional co-activator that is known to stimulate immu-
noglobulin promoter activity [36], and CXCR4 is a
chemokine (C-X-C motif) receptor that guides lym-
phocyte migration [37]. These findings suggest that the
therapy by etanercept modulates the maladjusted
immune system at multiple levels.
Other important features of a GRN are feedback and
redundancy mechanisms. Regulatory feedback loops can
be positive (i.e. reinforcing) or negative (i.e. self-balanc-
ing). Redundant links in the GRN allow genes to maintain
their connection to other genes even if some genes are
malfunctioning. Redundancy and self-control provide
flexibility and adaptability to environmental changes, i.e.
robustness against noise and failures [31]. An exemplary
(positive) feedback loop in the inferred GRN model is the
regulatory chain "CREB5  C/EBP-beta  ASGR2 
HNF-1  CREB5". Notably, C/EBP-beta encodes a TF that
is important in the regulation of immune genes and has
been shown to bind the regulatory regions of several
cytokine and acute-phase genes. In RA, elevated levels of
acute-phase proteins have been associated with progres-
sive joint damage [38]. The feedback loop is finally
formed by the two gene nodes CREB5 (which encodes a
TF as well) and ASGR2. Both genes were down-regulated
after therapy onset. Therefore, we assume that etanercept
lowers the activity of C/EBP-beta while affecting a regula-
tory feedback mechanism.
The GRN model also contains a (positive) feedforward
loop composed of the two ways "NOD2  HNF-1" and
"NOD2  Lmo2  STAB1  HNF-1". NOD2 is a regula-
tor of NF-kappaB activity [39] and was found down-regu-
lated on days 3 and 6. The model predicts a gene-TF
interaction between NOD2 and HNF-1, while we pre-
sume a decreased activity for HNF-1 as described previ-
ously. Alternatively, NOD2 is linked to LMO2, which has
a crucial role in hematopoietic development and is con-
nected to STAB1 according to the model. In turn, STAB1,
a receptor which is supposed to function in angiogenesis
and lymphocyte homing [40], has a gene-TF interaction to
HNF-1, thereby closing the feedforward loop. Ultimately,
this demonstrates the cooperative action of genes in the
network.
As mentioned before, out of the 19 RA patients in the ana-
lyzed dataset 7 did not respond clinically to etanercept.
Considering the potential side effects and the high costs of
the therapy, the identification of patients who will most
likely respond would contribute to a more optimized
treatment of RA. To identify predictors (biomarkers) of
the therapeutic outcome one might seek for differences in
the gene expression of responder and non-responder
patients before or early in therapy. The work by Koczan et
al. is focused on this particular issue [13]. Here, we also
compared the transcriptional levels of both patient groups
using a two-sample t-test. At day 3, four network genes
were found to be differentially expressed at the signifi-
cance level  = 0.05 (additional file 1). Three of these
genes (NFKBIA, KLHL11, CLSTN3) were expressed lower
in the responder group and are regulated by a common TF
node (NF-1) in the GRN model (figure 5C). NF-1 (nuclear
factor I) constitutes a family of DNA-binding proteins
with similar binding specificity, that participate in both
cell type-specific transcription and replication [41]. Our
model suggests that NF-1 regulates genes that are possibly
Node degree distribution in log-log scaleFigure 4
Node degree distribution in log-log scale. The network 
is scale-free, while transcription factors are more connected 
than genes. The orthogonal linear regression line is shown in 
blue.
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relevant for the individual success of etanercept therapy,
while the prognostic value of NFKBIA mRNA levels is
already under discussion [13]. However, even if this
hypothesis still has to be verified, the analysis clearly dem-
onstrates the use of correlating clinical features with
molecular network structures [6,42].
The GRN model provides many testable hypotheses and
thus may be a starting point for new experiments. Those
could aim to study the expression changes of specific
genes in more detail, or to analyze their regulatory effects
thereby validating parts of the inferred network. Take for
instance the previously mentioned subnetwork of NF-1
and its target genes (figure 5C). The model suggests that
members of the NF-1 family bind the promoters of 10
etanercept-responsive genes. This might be tested by elec-
trophoretic mobility shift assays or chromatin immuno-
precipitation techniques. One could also investigate the
genes' transcriptional changes during therapy in a larger
cohort of RA patients by generating expression profiles
using real-time polymerase chain reaction. This would be
particularly useful for the three genes that were found sig-
nificantly lower expressed in the responder group. As a
next step, levels of the respective proteins and protein iso-
forms could be quantified using western plots and
enzyme-linked immunosorbent assays. For example, it
would be interesting to measure the amount of HNF-1
proteins as we postulate a lowered activity of this TF as a
molecular therapeutic effect. In the model all target genes
of HNF-1 are down-regulated in response to etanercept
administration (figure 5A). Similarly, other parts of the
network are worth to study, e.g. the inferred regulatory
feedback loop including C/EBP-beta and CREB5. Tran-
script and protein levels of in vitro cultures of PBMC cells
may also be analyzed in a time-dependent manner. This
allows for controlled perturbation experiments such as
siRNA mediated knock-down of NF-1 expression with or
without the presence of etanercept. Last but not least, one
could examine the cell type-specific expression of genes in
the network. Recent studies point out a functional impair-
ment of Treg cells in RA [17]. It would be attractive to fur-
ther elucidate the altered immunosuppressive capacity of
Treg cells, their role in the treatment of RA and the modu-
lation of Treg cells by Toll-like receptors such as TLR8 that
was down-regulated in the dataset.
Performance evaluation
To demonstrate the benefit of the TILAR modeling
approach, we tried to evaluate how reliable the structure
of the underlying GRN can be inferred. The assessment of
the GRN inference performance is a challenging task, as
evidently, true regulatory interactions are barely known
Detail views of the network model shown in figure 3Figure 5
Detail views of the network model shown in figure 3. (A) The modeling strategy takes into account that target genes of 
a transcription factor are often co-expressed. For example, all the genes that are regulated by HNF-1 are down-regulated after 
therapy onset. Outer parts are shown with lower opacity. (B) A set of genes associated with the GO category "immune sys-
tem process" is predicted to contain TATA-like elements in their regulatory regions. (C) Three genes were expressed lower in 
responders at day 3 and all of them are regulated by NF-1 according to the model.
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and curated datasets for benchmarking are missing,
though there are attempts to remedy this shortcoming
[43,44]. A further difficulty is that the knowledge used to
validate a GRN model must be different from the knowl-
edge integrated during modeling.
Here, we utilized gene-gene interaction information
obtained by text mining for performance evaluation (see
methods). By assessing the inference quality on literature-
derived (undirected) gene-gene links, we were also able to
compare our method with other inference techniques
which do not incorporate prior knowledge. It is important
to note that regulatory gene-gene interactions are implic-
itly defined in our network model by gene-TF and TF-gene
interactions, as genes are constrained to regulate other
genes via one or more TFs (figure 2D). For the inferred
network 158 gene-gene interactions can be deduced from
the 22 gene-TF and 84 TF-gene edges. However, literature
mining reports only 5 gene-gene relationships between
the 83 genes in the network, which is not nearly enough
for validation purposes. Since the biological role of many
selected genes remains to be investigated, we assume that
the lack of text mining information is mainly due to the
literature bias, by which genes that have been intensively
studied for many years (e.g. TNF-alpha) are cited more
often than less prominent genes.
To overcome this issue, we sought for genes well described
in the literature. For them we could expect many known
gene regulatory interactions, so that a systematic evalua-
tion of the performance of network reconstructions
becomes feasible. We finally chose genes that are most fre-
quently co-mentioned in the context of RA in PubMed. A
respective list of genes was obtained from the Autoim-
mune Disease Database (version 1.2 as of August 19,
2008), which is a literature-based database that provides
gene-disease associations of all known or suspected
autoimmune diseases [45]. Out of the top 50 genes catal-
oged for the disease term "rheumatoid arthritis", 42 genes
were measured in the Affymetrix dataset (additional file
6). We will denote the network of these 42 genes as the
benchmarking GRN in the following.
Genes in the benchmarking network include several
matrix-metallo-proteinases and a vast number of
cytokines, in particular interleukins and the therapeutic
target TNF-alpha. Overall, 389 gene-gene interactions
between these genes could be retrieved through text min-
ing. These interactions constitute a text mining network in
which all but two genes are connected. The genes with the
most connections are IL-6 (37), TNF-alpha (37) and IL-1
(33). We analyzed the regulatory regions of all the 42
genes and found overrepresented DNA-binding sites of 10
TFs (additional file 7). Amongst others, TFBS of NF-kap-
paB and AP-1 are significantly enriched, which is not sur-
prising as both TF complexes play central roles in immune
regulation and are proven to be involved in the pathogen-
esis of RA [10,46]. In the resulting GRN template these 10
TFs are linked to 31 genes by means of 67 TF-gene interac-
tions. When constructing a linear model of the bench-
marking GRN using our novel inference algorithm TILAR,
13 TF-gene interactions were discarded during the back-
ward stepwise selection procedure, i.e. 54 TF-gene interac-
tions remained in the model. LARS then provided model
predictions for different degrees of network connectivity
(in successive LARS steps representing the dependency on
parameter s).
Next, we tested whether the inferred edges between genes
exist or not in the text mining network containing 389
gene-gene interactions. For this purpose, we calculated the
measures recall, precision and false positive rate (FPR) for
different network connectivities. A plot of the precision
versus the recall performance of a method (in case of LARS
as a function of s) and the ROC (receiver operating char-
acteristic) curve, where recall is plotted against FPR, are
two widely used visualizations for performance evalua-
tion [43,44]. The ROC analysis allows comparison of the
inference quality against a random prediction by calculat-
ing the area under the curve (AUC), while an AUC(ROC)
close to 0.5 corresponds to a random forecast.
We utilized both recall-precision and ROC curves to assess
and compare the performance of our algorithm and four
different popular GRN inference methods: the conven-
tional Lasso approach, CLR [47], ARACNE [48], and
GeneNet [49] (see methods). While CLR and ARACNE use
mutual information, GeneNet computes a partial correla-
tion network. The resulting performance curves show that
the proposed TILAR algorithm outperforms the other
modeling algorithms (figure 6, additional file 8). When
using AUC(ROC) as a single metric for benchmarking, the
applied methods score as follows: Lasso – 0.478, ARACNE
– 0.500, GeneNet – 0.503 and CLR – 0.504, whereas
TILAR achieves an AUC(ROC) of 0.581. Next, we checked
whether the algorithms performed significantly better
than a random GRN prediction (RAND, see methods). We
found, that the predictions of our approach were signifi-
cantly better than RAND at the level  = 0.05 (P-value =
1.674e-05), while this was not the case for CLR, ARACNE,
GeneNet and Lasso. Interestingly, gene-TF-RAND,
another random algorithm that predicts gene regulatory
interactions by including all 67 putative TF-gene interac-
tions (i.e. the prior knowledge) into the model without
considering the gene expression data (see methods), also
yields a relatively high AUC(ROC) of 0.549 (P-value =
0.006). This suggests that TILAR performs well because of
both the quality of TFBS predictions and data-fitting using
LARS (figure 7).
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Nevertheless, the AUC(ROC) of the TILAR method is still
rather low. In our opinion this is not a general weakness
of the modeling, but due to the fact that the information
we used for model validation was obtained by text min-
ing. This information is therefore incomplete and error-
prone. A drawback is that the text mining network was
constructed by searching through all biological literature
and not only RA specific literature. Besides, text mining is
obviously inappropriate to assess so far unknown regula-
tory interactions. In fact, the GRN model now provides
new hypotheses that may be tested experimentally. How-
ever, there are several other factors that impede an accu-
rate GRN reconstruction or an adequate performance
evaluation. First, regulatory networks can exhibit large
dynamic topological changes [50]. Thus, among the inter-
actions in our network we might only identify the most
robust ones or those that are most relevant in the specific
study, implying that some other could be missed, even if
they have been biologically demonstrated. Second, the
contribution of different cell types is lost in the study.
Third, the text mining network contains undirected gene-
gene interactions. In contrast, the proposed modeling
approach assigns directed interactions between genes and
TFs, i.e. gene-gene interactions are only implicitly defined
in the model. Fourth, the network model might be too
simple to reliably infer more complex interactions. Here,
ROC curves for the benchmarking gene regulatory networkFigure 6
ROC curves for the benchmarking gene regulatory network. The better a method performs, the closer its curve will 
be to the upper-left corner. The black curve represents the rating of our method when including 54 of 67 predicted TF-gene 
interactions. Remarkably, TILAR not only outperforms CLR, ARACNE, GeneNet and the conventional Lasso, but can also be 
combined with the adaptive LARS if adequate prior knowledge on gene-TF interactions is available. Using both techniques in 
combination we could infer gene-gene relationships more reliably.
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we assumed that gene regulatory effects are linear and
additive, and precluded auto-regulation, i.e. a gene is not
allowed to control a TF for which it possesses a TFBS. The
latter because the data were not well suited for inferring a
dynamic model. Moreover, the inference algorithm is
based on co-expression at the transcriptional level, even if
the amount of mRNA may not correspond to the level and
(regulatory) activity of the proteins. However, more data
would be required to infer more accurate models.
Adaptive TILAR – combined use of two techniques
Until now, we have shown that the proposed modeling
approach, which utilizes gene expression data as well as
TFBS predictions, performs fairly well in the reconstruc-
tion of GRNs. However, the method is not only an alter-
native to the adaptive LARS, but can also be used in
combination with it (adaptive TILAR). The adaptive LARS
[30] specified in equation (5) penalizes the coefficients 
of equation (8) with weights , dependent on whether the
coefficient receives prior knowledge. In this way, we are
able to integrate prior knowledge on gene-TF interactions
as well. The lower we set the weights j for the coefficients
j that represent putative gene-TF interactions, the more
these interactions are a priori preferred to be in the model.
The weights  thus allow to trade off data-fit and confi-
dence in prior knowledge. However, accurate knowledge
on gene-TF edges is difficult to obtain due to their variable
meanings. For instance, intermediary molecules may
account for such relationships. Here, we again applied text
mining to retrieve potential gene-TF links (see methods).
This way, we found 71 gene-TF relationships for the
benchmarking GRN (e.g. the well-known activation of
NF-kappaB by IL-1). We then evaluated the adaptive
TILAR algorithm with three different weights for the pre-
ferred coefficients. As a result, the inference quality
increased considerably (figure 6 and 7). When setting j =
0.4 for the 71 preferred coefficients we obtained an
AUC(ROC) of 0.615 (P-value = 1.768e-09), for j = 0.1 a
value of 0.639 (P-value = 4.839e-13), and for a very low j
= 0.05 a value of 0.675 (P-value<2.2e-16). An even lower
j did not improve the result much. Thus, we can use infor-
mation on TF-gene and gene-TF interactions to infer a
GRN model, that predicts regulatory interactions between
genes more reliably. Nevertheless, the true use of the com-
Performance gain using integrative modelingFigure 7
Performance gain using integrative modeling. The expected AUC(ROC) of a random prediction is normally distributed 
around 0.5 as calculated by 1,000 repeated runs of RAND. The gene-TF-RAND algorithm considers the GRN template infor-
mation, but assigns gene-TF interactions randomly. In contrast, the TILAR algorithm utilizes gene expression data to infer gene-
TF interactions, while only a subset of the predicted TF-gene interactions is included into the final model. This significantly 
increases the inference quality. However, the method could be further improved by considering text mining information on 
which genes possibly regulate TF activity (adaptive TILAR). The combined inference method allows to strike a balance between 
data-fit and confidence in such putative gene-TF interactions by means of the parameters in .
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bination of adaptive and TFBS-integrating LARS requires
more investigation. For instance, the determination of the
weights  is not straightforward, as we might set different
weights for each gene-TF interaction and even relatively
high weights (i.e. j>1.0) if certain gene-TF relationships
can be excluded a priori. However, this is beyond the scope
of this paper.
Conclusion
We developed TILAR – a method for deriving transcrip-
tional regulatory networks from gene expression data by
integrating TF binding predictions. The algorithm is also
able to incorporate prior knowledge on the putative regu-
lators of TF activity (adaptive TILAR). Our linear, additive
modeling approach distinguishes genes and TFs in the
network, and identifies the connections between them
based on the fast LARS regression algorithm and specific
constraints on the network structure. The major advantage
of this modeling strategy is that only few model parame-
ters are sufficient for a complex network, which is still easy
to interpret. When applied on short-term gene expression
profiles of RA patients treated with etanercept, the
method uncovers molecular immunotherapeutic effects
and thus provides testable hypotheses about the drugs'
mechanisms of action. A closer look on the model
revealed genes co-regulated by a common TF and TFs that
regulate functionally related genes. Moreover, the recon-
structed GRN exhibits a scale-free, self-regulating and
massively parallel architecture.
We evaluated the inference quality using a text mining
network and found that our modeling method outper-
forms all other algorithms tested. Notably, TILAR allows
for a higher prediction accuracy than using just gene
expression data or TF binding information alone. More
efforts are needed to study different configurations of
TILAR, e.g. we could analyze a larger DNA region for over-
represented TFBS, and to assess the benefit of combining
this method with the adaptive LARS. Besides, further
experiments need to be performed to verify specific inter-
actions that were predicted by the model. However, even
if significant theoretical and experimental challenges
remain, we could demonstrate that organizing heteroge-
neous data and prior biological knowledge in systems
biological models can strongly support the investigation
of autoimmune diseases and their therapies. Supplemen-
tary materials including R codes are available at http://
www.hki-jena.de/index.php/0/2/490.
Methods
DNA microarray data pre-processing
We used the human DNA microarray dataset from Koczan
et al. [13] including expression profiles of 19 etanercept-
treated RA patients. Blood samples were taken for each
patient before treatment as well as 72 and 144 hours after
first application of etanercept. Transcriptional levels of
PBMC were then measured using Affymetrix Human
Genome U133A arrays. As for 2 patients the third time-
point is missing, the dataset consists of 55 microarray
experiments. In the applied Affymetrix microarrays most
probesets include probes matching transcripts from more
than one gene and probes which do not match any tran-
scribed sequence. Therefore, we utilized a custom chip
definition file (CDF), that is based on the information
contained in the GeneAnnot database [15,51]. GeneAn-
not-based CDFs are composed of probesets including
only probes matching a single gene and thus allow for a
more reliable determination of expression levels. We used
version 1.4.0 of the custom CDF and the MAS5.0 algo-
rithm to pre-process the raw probe intensities. Data nor-
malization was performed by a loess fit to the whole data
with span = 0.05 (using R package affy). Finally, the data
processing yields mRNA abundances of 11,174 different
genes.
Filtering differentially expressed genes
The filtering aims to identify a subset of genes significantly
up- or down-regulated within the first week of therapy. A
widely used filter criterion is the (logarithmized) fold-
change from baseline. However, a fixed fold-change
threshold ignores the inherent structure of DNA microar-
ray data. Therefore, we applied an MA-plot-based signal
intensity-dependent fold-change criterion (MAID filter-
ing) to select genes. The MAID filtering takes into account
that the variability in the log fold-changes increases as the
measured signal intensity decreases [52]. First, the filter-
ing procedure calculates for each gene the values A and M,
which are commonly used for visualizing microarray data
in an MA-plot. A is the log signal intensity of a gene aver-
aged over all patients, while M is the mean intensity log-
ratio between the baseline levels and the expression levels
at day 3 and 6, respectively. Then, the intensity-dependent
variability in the data is estimated by computing the inter-
quartile range (IQR) of the M values in a sliding window.
Afterwards, an exponential function f(x) = a·e-bx+c is fitted
to the IQR's by a non-linear robust regression, which in
turn is used to calculate so-called MAID-scores by dividing
each M value by f(A). As a consequence, the absolute
value of a gene's MAID-score is higher, the more its
expression level is altered after start of therapy. Further-
more, we assessed which genes are differentially expressed
according to a paired t-test comparing the expression lev-
els at day 3 and 6 versus baseline, respectively. Finally, we
selected the genes having |MAID-score|>2.5 and t-test P-
value < 0.05.
GO analysis
Overrepresented GO terms were found using GOstats, a
Bioconductor package written in R. Each GO term is tested
whether it is significantly associated to the list of filtered
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genes out of the 11,174 measured genes. The analysis was
performed for gene functional annotations of the biolog-
ical process GO category.
Identification of TF-gene interactions (GRN template)
TFBS were derived from the UCSC database build hg18
[53]. The database provides a TFBS conserved (tfbsCons-
Sites) track, that contains the location and score of TFBS
conserved in the human/mouse/rat alignment. The data
are purely computational and were generated using posi-
tion weight matrices (PWMs) for TFBS contained in the
public Transfac Matrix and Factor databases created by
Biobase. For the whole human genome 3,837,187 TFBS
predictions associated to 258 different PWMs (184
unique TF identifiers) can be found in the tfbsConsSites
track. We defined the regulatory region of each gene as the
1,000 bp up- and downstream of the TSS (as stated in
GeneCards database 2.38). This specification is in agree-
ment with current findings by the ENCODE pilot project
which revealed that regulatory sequences are symmetri-
cally distributed around the TSS with no bias towards
upstream regions [54]. Then, we scanned the regulatory
regions of the selected genes for overrepresented TFBS. In
doing so, each TF is tested whether its binding site occurs
in this region for more genes than would be expected by
chance. To take into account the inherent redundancy of
the Transfac database, a TF is supposed to regulate a gene
(TF-gene interaction) if any PWM for this TF matches the
DNA sequence at the gene's regulatory region. Using a
hypergeometric test analyzing the TF binding predictions
for all the 11,174 genes measured, we can identify a subset
of TFs associated to the genes in the network at the signif-
icance level  = 0.05. This leads to a list of predicted TF-
gene interactions that can serve as a template for GRN
modeling.
TFBS-integrating GRN inference (TILAR algorithm)
First, the expression levels of each gene were standardized
so that they have variance 1 and mean 0. Given these data,
we then defined a regression equation according to equa-
tion (8), while considering the full set of putative TF-gene
interactions. Afterwards, we calculated all LARS estimates
(steps) for this equation using the R package lars with
default settings. Each LARS estimate specifies a subset of
covariates, i.e. states which gene-TF interactions are
present in the model and which are not (in the latter case
the corresponding model parameter is set to zero). To
select a single estimate, we chose the model that mini-
mizes Mallows' Cp statistic [55], thereby preventing over-
fitting and ensuring sparseness. The whole procedure was
then repeated in a backward stepwise selection scheme in
which TF-gene interactions were iteratively eliminated (or
reinserted) if this allowed for a model that exhibits a
smaller residual sum of squares (RSS). In this way, a sub-
set of TF-gene interactions was found. For the regression
equation including this subset all possible Lasso estimates
(see equation (4)) are provided by LARS. We then calcu-
lated for each LARS step the OLS fit using only the respec-
tive covariates (LARS/OLS hybrid [27]). Hence, we used
LARS for variable selection, but not to estimate the model
coefficients. Moreover, we evaluated the 10-fold cross-val-
idation error (CVerror) for each LARS/OLS solution and
finally selected the most parsimonious model within 1
standard deviation from the CVerror minimum (additional
file 4). It should be noted that we used the Cp statistic as
a crude selection criterion during the backward stepwise
selection procedure, because the Cp is much faster to com-
pute than the CVerror.
To integrate prior knowledge on gene-TF interactions (as
we did for the benchmarking GRN) we strictly followed
the above learning strategy, except that we employed the
adaptive variant of the LARS algorithm according to Zou
[30]. The adaptive LARS assigns weights to each coeffi-
cient as written in equation (5). We penalized coefficients
j for which we have no prior knowledge with a neutral
weight j = 1.0. If literature mining suggested a gene-TF
interaction we penalized the corresponding coefficient
with a smaller j (0.4, 0.1 and 0.05, respectively) to
improve variable selection.
The learning strategy of the (adaptive) TILAR is summa-
rized as follows:
1. Define D as the given (standardized) gene expres-
sion data
2. Define P as the given set of putative TF-gene interac-
tions (GRN template)
3. Use D to specify regression equation L subject to P
according to equation (8)
4. Solve L using (adaptive) LARS and calculate
RSS(Cpmin), i.e. the RSS of the LARS estimate that min-
imizes Cp
5. Optional: Perform a backward stepwise selection on
P, i.e. iteratively and exhaustively remove or reinsert
elements in P and repeat 3. and 4., and stop when a
local minimum for RSS(Cpmin) is found
6. Recompute the regression coefficients to L in terms
of a LARS/OLS hybrid and return the most parsimoni-
ous estimate within 1 standard deviation of the 10-
fold CVerror minimum
Performance evaluation
We used gene-gene interaction information for bench-
marking. The software PathwayArchitect 2.0.1 was
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employed to automatically extract such gene-gene links
from the literature. We retrieved only gene-gene interac-
tions of context type "expression" and "regulation" as
labeled by PathwayArchitect. To obtain putative gene-TF
links (which were used for the adaptive TILAR) we also
considered interactions of type "protein modification".
The gene-gene information was applied to assess the infer-
ence quality of our and a total of four other easy-to-apply
GRN inference methods, namely CLR, ARACNE,
GeneNet, and the conventional Lasso, while we did not
take into account the directions of the relationships. CLR,
ARACNE and GeneNet are thought to build (undirected)
gene association networks and have been implemented by
use of the R packages minet and GeneNet. To compute the
entire set of Lasso solutions to equation (3) we used the
LARS modification (R package lars). All methods were run
on standardized gene expression levels with default set-
tings. Moreover, a random inference algorithm called
RAND was implemented, which randomly assigns con-
nections between genes until a fully connected network is
formed. The RAND method was further adapted to infer
networks of TF-gene and gene-TF interactions similar to
the proposed modeling scheme (gene-TF-RAND). More
specifically, gene-TF-RAND utilizes all the TF-gene inter-
actions predicted by the TFBS overrepresentation analysis
and randomly adds gene-TF edges to the network. As for
TILAR, gene-TF interactions were not allowed when gene
and TF were already connected by a TF-gene interaction,
and gene-gene links result implicitly. The AUC(ROC)
value of gene-TF-RAND was obtained by the mean of
1,000 repeated runs. Apart from that, we tested whether
any inference technique performed significantly better
than a random prediction. For this purpose, we calculated
P-values which specify the probability that an AUC(ROC)
value computed by RAND will be higher than the
AUC(ROC) value of the particular inference algorithm.
The P-values are calculated by 1 minus the cumulative
probabilities, which are evaluated at the AUC(ROC) value
of the respective method, of the normal distribution hav-
ing the mean and standard deviation of 1,000 RAND-cal-
culated AUC(ROC) values.
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List of 83 genes with significant expression changes during first week of 
therapy. The table provides diverse types of information for each gene, e.g. 
Entrez ID, official full name and the calculated MAID-scores.




Filtering of genes regulated in response to etanercept therapy. (A) Super-
imposed MA-plot visualizing the applied gene filtering method. Here, gene 
expression levels measured 3 days after therapy onset are compared with 
baseline levels. The MAID filtering takes into account that the variability 
in the mean log-fold changes (M) depends on the mean log signal inten-
sity (A). 37 genes showed an up- or down-regulation at day 3 (green). 
(B) In a similar manner, 57 genes were found higher or lower expressed 
at day 6 in comparison to baseline. In this way, 83 different genes were 
selected in total. (C) Mean time-courses of these 83 genes. 25 genes were 
found up- or down-regulated at day 3 (left), 45 at day 6 (middle) and 13 
at day 3 and 6 (right).




Overrepresented terms of the GO biological process ontology. P-values 
were computed for each GO term based on the hypergeometric distribu-
tion. Only functional categories with P-value < 0.01 and where at least 3 
out of 83 genes are associated ("Count") are shown.




Model selection using cross-validation. Training error (scaled by 10) and 
10-fold CVerror (RSS mean of 10 subsets) are shown for the LARS/OLS 
solutions of the first 300 LARS steps. The blue area represents the stand-
ard deviation of CVerror. The red line shows the LARS step selected for the 
final model, i.e. the most parsimonious model within 1 standard deviation 
from the CVerror curve minimum, for which 22 model parameters are non-
zero.
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ther increase the inference quality.
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Long-term genome-wide blood RNA expression 
profiles yield novel molecular response candidates 
for IFN-b-1b treatment in relapsing remitting MS
Multiple sclerosis (MS) is a chronic, inflamma-
tory, disabling disease of the CNS, and is the 
most frequent disorder that causes persistent def-
icits [1]. Since the early 1990s, disease-modifying 
drugs have played a major role in MS treatment, 
of which the most applied are IFN-b, glatiramer 
acetate and monoclonal antibodies [2]. Currently, 
the interferons are the most distinguished when 
undertaking an immunomodulatory therapy [3]; 
however, they are only partially effective, and 
precise molecular mechanisms remain unclear. 
Deciphering the pharmacogenomic effects of 
recombinant IFN-b (rIFN-b) treatment has 
proven to be a challenge, but integrated efforts 
(e.g., between molecular biology, neurology and 
bioinformatics) shall eventually lead to the eluci-
dation of the underlying complex processes that 
involve multiple genes [4,5].
The use of divergent experimental approaches 
based on transcriptomics and high-content micro-
arrays has resulted in the identification of various 
biological IFN-b response markers: for example, 
MX1, OAS and other interferon-stimulated genes 
(ISGs) [6–9]. Hence, genome-wide hypothesis-free 
expression ana lysis of IFN-b treated peripheral 
blood cells can document the broad effects of 
the drug well [10–26]. Huge amounts of quantita-
tive data and lists of differentially expressed genes 
(DEGs) were thereby generated, with antici-
pated IFN-b-induced genes being redundantly 
reported [27]. 
It is generally agreed that rIFN-b adminis-
tration ameliorates immune dysfunction, which 
is a dynamic multicomponent process covering 
the fields of immune cell regulation such as 
inhibition of T-cell proliferation, reduction of 
pathologic blood–brain endothelium perme-
ability, and respective T-cell trans migration via 
interference with cell adhesion and upregula-
tion of anti-inflammatory cytokines. The main 
cascades induced represent antiviral activity, 
chemotaxis, apoptosis, antigen presentation, 
Th1 differentiation, humoral immunity and 
dendritic cell maturation [28]. In the search for 
biomarkers, it became apparent that for several 
genes the sensitivity to rIFN-b appeared to be 
Aims: In multiple sclerosis patients, treatment with recombinant IFN-b (rIFN-b) is partially efficient in 
reducing clinical exacerbations. However, its molecular mechanism of action is still under scrutiny. Materials 
& methods: We used DNA microarrays (Affymetrix, CA, USA) and peripheral mononuclear blood cells from 
25 relapsing remitting multiple sclerosis patients to analyze the longitudinal transcriptional profile within 
2 years of rIFN-b administration. Sets of differentially expressed genes were attained by applying a 
combination of independent criteria, thereby providing efficient data curation and gene filtering that 
accounted for technical and biological noise. Gene ontology term-association ana lysis and scientific 
literature text mining were used to explore evidence of gene interaction. Results: Post-therapy initiation, 
we identified 42 (day 2), 175 (month 1), 103 (month 12) and 108 (month 24) differentially expressed genes. 
Increased expression of established IFN-b marker genes, as well as differential expression of circulating 
IFN-b-responsive candidate genes, were observed. MS4A1 (CD20), a known target of B-cell depletion 
therapy, was significantly downregulated after one month. CMPK2, FCER1A, and FFAR2 appeared as 
hitherto unrecognized multiple sclerosis treatment-related differentially expressed genes that were 
consistently modulated over time. Overall, 84 interactions between 54 genes were attained, of which two 
major gene networks were identified at an earlier stage of therapy: the first (n = 15 genes) consisted of 
mostly known IFN-b-activated genes, whereas the second (n = 12) mainly contained downregulated genes 
that to date have not been associated with IFN-b effects in multiple sclerosis array research. Conclusion: We 
achieved both a broadening of the knowledge of IFN-b mechanism-of-action-related constituents and 
the identification of time-dependent interactions between IFN-b regulated genes.
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fairly variable between patients with MS [29]. 
To more comprehensively investigate the effects 
on transcriptional regulation, gene network 
inference techniques can be applied. Initial 
efforts were made to explore gene regulation 
in response to IFN-b by incorporating net-
work ana lysis, thereby effectively combining 
data- and knowledge-driven ana lysis [20,23,30].
In most transcriptomic studies that cov-
ered the earlier time window instantly after 
drug administration, a significant fraction of 
genes showed rapid increase from baseline. 
However, most of these changes reverted, as 
shown by prolonged transcriptomic analyses, 
over days [13,23–25], months [18] or years [17,26]. 
Therefore, as a complementary measure, for 
2 years, we investigated the transcriptional 
effects of rIFN-b 1b treatment on peripheral 
mononuclear blood cells (PBMCs) at the end 
of the 48-h time window of the application regi-
men. The objective of this study was to examine 
the pharmacodynamic reaction of treated MS 
patients on the transcriptomic level, with focus 
on interaction structures between filtered genes 
(using PathwayArchitectTM information), as well 
as to highlight their biological functions (gene 
ontology [GO] terms) in time. The blood sam-
ples were obtained from all patients and were 
analyzed equally, following the principle of a 
nonhypothesis-/explorative-driven expression 
measurement. We furthermore deemed it impor-
tant that the effects of one exclusive rIFN-b 
therapy were investigated, as dose and route of 
administration act with distinctive effects [31]; 
if not on the substantially induced ISGs such as 
MX1, then more likely on the weaker induced 
ones. The outcome should provide opportuni-
ties to further understand IFN-b’s mechanism 
of action at a molecular level, independently 
from any clinical response status, and to con-
template what effects are to be expected when 
combination regimens are at issue.
Materials & methods
The study was approved by the University of 
Rostock’s (Rostock, Germany) ethics committee 
and was carried out according to the Declaration 
of Helsinki. Informed consent from study 
participants was collected prior to study onset.
A total of 25 Caucasian patients (Table 1) with 
diagnosed relapsing remitting MS (RRMS) 
according to the McDonald criteria [32] were 
prescribed a first immunotherapy of rIFN-b-1b. 
250 µg (8 MIU) of the drug were administered 
subcutaneously every other day. None of the 
patients had previously been medicated with 
immunomodulatory or immunosuppressive 
agents or had ever received cytotoxic treatments, 
and all were free of glucocorticoid treatment 
for at least 30 days prior to blood extraction. 
15 ml of peripheral venous EDTA treated blood 
were withdrawn prior to first and consecutive 
drug administrations, providing ex vivo mate-
rial before (baseline) as well as 2 days (D2), 
1 month (M1), 1 year (M12) and 2 years (M24) 
post-therapy initiation (PTI). Samples were 
always collected at the same time of day and 
processed within 1 h; the range of intervals of 
blood collection did not exceed 1 h. 
n RNA extraction & hybridization of 
Affymetrix HGU133 A & B microarrays
Total RNA of Ficoll-treated PBMCs from each 
sample were isolated following the manufac-
turer’s protocol (RNeasy, Qiagen, Hilden, 
Germany). Initial RNA and final cRNA concen-
trations were determined spectrophotometrically 
by a Nanodrop® 1000 (Thermo Fisher Scientific, 
MA, USA), and quality control was performed 
by native ethidium bromide agarose gel electro-
phoresis. Samples of RNA (total 7 µg) were 
labeled and hybridized according to the supplier’s 
instructions (Affymetrix, CA, USA). The arrays, 
interrogating 44,928 probesets, were scanned at 
3-µm resolution using the GeneArray® Chip 
Scanner 2500 (Hewlett Packard, CA, USA).
Validation of microarray data by means 
of real-time PCR
Quantitative real-time reverse transcription 
PCR (real-time PCR) was applied to confirm 
observed changes in gene expression. Transcript 
levels of 15 selected genes were measured in a 
subset of the samples. Details on the experi-
mental procedure and on the ana lysis of the 
real-time PCR data are described in the Online 
SupplemenTary  maTerial  1  (www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152).
n Data ana lysis: data preprocessing, 
curation & filtering
Primary data ana lysis and quality control was 
carried out using the GeneChip® operating soft-
ware (GCOS 1.4, Affymetrix) and the MAS5.0 
(Microarray Suite 5.0, Affymetrix) statistical 
algorithms for probe level ana lysis. To discover 
transcriptional effects with regard to rIFN-b-1b 
subcutaneous administration, we initially 
applied two criteria based on MAS5.0 labels to 
erase noninformative probesets (data curation) 
and, subsequently, three criteria that delivered 
an output of DEGs (gene filtering).
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Cleaning the dataset of noninformative 
probesets was performed by removing probesets 
consistently labeled ‘absent’ in all 25 individu-
als, and removing probesets consistently labeled 
‘no change’ in all 25 individuals (Table 1). One 
element of the subsequent filtering is described 
as follows. An accepted filtering criterion is 
the (log) fold-change from baseline; however, 
a fixed threshold ignores the inherent struc-
ture of DNA microarray data [33]. Therefore, 
we applied a MA-plot-based signal intensity-
dependent fold-change criterion (MAID filter-
ing) to identify strongly regulated probesets [34]. 
In brief, MAID considers that the variability in 
log fold-change increases as the measured sig-
nal intensity decreases [33]. Values ‘A’ and ‘M’ 
were calculated; ‘A’ represents the average log 
intensity for a probeset, while ‘M’ is the mean 
intensity log-ratio between baseline and the 
respective subsequent time point (Figure 1). The 
intensity-dependent variability was estimated by 
computing the interquartile range (IQR) for the 
M values in a moving window. An exponential 
function f(x) = a × e-bx + c was then fitted to 
the IQRs by a nonlinear robust regression. By 
dividing each M value by f(A), we calculated 
so-called MAID-scores. Finally, to filter signifi-
cantly up- and downregrulated probesets rela-
tive to baseline, we combined outlined MAID-
scores, outcomes of a paired two-sample t-test, 
and increase and decrease of MAS5.0 generated 
labels [35] (Figure 2): |MAID-score| greater than 2; 
statistical significance below p = 0.05; minimum 
50% of patients per probeset display increase 
and decrease, respectively.
n Affymetrix probeset quality control 
applying GeneAnnot
Improvements in genome sequence annotation 
revealed discrepancies in the original probeset-
gene assignment of Affymetrix microarrays. In 
the applied generation of Affymetrix human 
GeneChips, numerous probesets include probes 
matching transcripts from more than one gene 
and probes that do not match any transcribed 
sequence [36]. To remove such equivocal probe-
sets from the data, we utilized a probeset speci-
ficity cutoff (0.7) that was based on the infor-
mation contained in the GeneAnnot database 
version 1.7 [37].
n Functional ana lysis (gene ontology 
term enrichment)
Functional annotation analyses based on the asso-
ciation of GO biological process terms [38] with 
filtered DEG sets were carried out by application 
of GOstats, which is a Bioconductor package 
written in R [39]. It allows the testing of GO terms 
for over-representation by computing a probabil-
ity based on the hyper geometric distribution, 
which assesses whether the number of selected 
genes associated with the term is larger than that 
expected by chance. As a reference dataset, that 
is, the gene universe, we used all unique Entrez 
IDs (n = 12.377) of HG-U133A/B. 
Table 1. Demographic data of analyzed individuals.
Variable Value
Subjects (n) 25
Gender ratio (female:male) 16:9
Age at study, years (mean ± SD) 39.6 ± 10.9
Patients with EDSS Q25–Q75 2.2 (1.0–3.0)
Relapse rate (mean ± SD) 1.6 ± 0.9
EDSS: Expanded disability status scale; SD: Standard deviation.
Figure 1. Superimposed MA plot visualizes the applied intensity dependent 
probeset filter on the microarray data. MAID filtering of 44,928 probesets in 
response to IFN-b-1b subcutaneous treatment considers the intensity-dependent 
variability in the log-fold changes; attained from peripheral mononuclear blood cell 
mRNA of relapsing remitting multiple sclerosis patients (n = 25). Averaged 
expression intensities of probesets and respective changes from baseline to 48 h 
post-therapy initiation are depicted as grey points. ‘A’ represents the average log 
intensity for a probeset; ‘M’ the mean intensity log-ratio of the expression at the 
baseline and day 2. An exponential function is fitted to the shape of the data by a 
nonlinear robust regression (curved line, MAID regression curve). Hence, the 
MAID-score is low when the signal intensity of a probeset is marginal or not 
affected by recombinant IFN-b-1b. The gene-filtering criteria, p < 0.05 and 
|MAID-score| >2, are introduced in this visualization (MAID score cutoff curve); 
probesets that withhold these are shown as diamonds. 









Gene, p < 0.05
Selected gene
|MAID score| >2, p < 0.05
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n Knowledge-based 
network construction
In order to build networks of interacting genes, 
we placed our filtered DEGs in a systems 
perspective by consulting interaction infor-
mation of the Pathway Architect (PA) 2.0.1 
database (Stratagene Inc., CA, USA) [101]. We 
used biological relationships that PA distin-
guishes, such as ‘positive regulation = stimu-
lation’ and ‘negative regulation = inhibition’, 
and basic connections ‘regulation’, ‘binding’, 
‘expression’, ‘metabolism’, ‘transport’ and 
‘protein modification’. The multiple interac-
tions between genes were visualized using 
Cytoscape 2.6.1 [40].
Results
Longitudinal RNA samples taken at baseline, 
2 days, and 1, 12, and 24 months were col-
lected from 25 patients with RRMS and were 
each hybridized onto Affymetrix HG-U133 
microarray sets. The expression dataset of 250 
A- and B-chip measurements have been depos-
ited in the National Center for Biotechnology 
Information Gene Expression Omnibus 
(GEO; [102]) and are accessible through GEO 
Series accession number (in process). 
n Filtering differentially 
expressed genes
To select genes showing significant transcript 
changes in response to rIFN-b in PBMCs, we 
applied five filtering criteria (see ‘Methods’ 
section; FigureS 1 & 2). Exemplarily, at D2 PTI, 
data curation sieved both nonexpressed and 
non informative probesets, the latter repre-
senting genes that were expressed but not 
changed owing to rIFN-b application. A 
total of 16,978 probesets remained (Figure 2). 
Subsequent data filtering generated a list of 55 
differentially expressed probesets at D2 ver-
sus baseline; respectively 285, 153 and 181 
at later time points. Removal of unspecific 
Affymetrix probesets yielded the final DE 
probesets, as listed in Online SupplemenTary Table 1 
(www.futuremedicine.com/doi/suppl/10.2217/
pgs.09.152). GeneAnnot did not provide any 
information for Affymetrix control probesets 
Data curation
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Figure 2. Workflow and overview of data curation and filtering. 
Manuscript III 58
RNA profiles in response to IFN-b-1b in MS ReseaRch aRticle
www.futuremedicine.com 151future science group
(e.g., AFFX-HUMISGF3A/M97935_MB_
at binding STAT1) and several others 
(e.g., 223501_at binding to TNFSF13B). 
Filtered probesets and corresponding genes 
for each time pair are displayed in Figure  3. 
Plotting the data for each time point versus 
baseline as a function of p-values and MAID-
scores produced so-called volcano plots. The 
distributions depicted preferential upregula-
tion throughout time, in particular 1 month 
after first rIFN-b injection (Figure  3  &  Online 
SupplemenTary Table 2; www.futuremedicine.com/
doi/suppl/10.2217/pgs.09.152). Table 2 provides 
the enumeration and listing of the identified 
DEGs. Altogether, 339 unique probesets repre-
senting 269 genes were considered to be signifi-
cantly regulated, with the maximum of DEGs 
determined at M1 (n = 175) (Figure 2, Table 2). 
The most consistently modulated genes 
throughout the analyzed time (n = 19 out of 
269 DEGs) were divided into 18 up- and one 
downregulated genes (Table 2). As expected, the 
majority represent established ISGs with antivi-
ral properties, such as influenza-virus resistant 
gene MX1, and members of the 2–5A synthe-
tase family (OAS-2/-3), as well as EIF2AK2, 
RSAD2, IFI-44/-44L, IFIT-1/-2/-3 and ISG15, 
whereas to date CMPK2, FFAR2 and FCER1A 
have not been identified in this context. When 
constricted time windows were analyzed, that 
is, until 1 year into therapy (n = 21 of 225 
DEGs), or, excluding the first time point, until 
2 years PTI (n = 48 of 252 DEGs), and the 
respective pairs possible, the greater overlap of 
reappearing DEGs was seen at later time points. 
Whereas most genes maintained the direc-
tionality over time, CLU and IL1R2 switched 
from category increase at D2 to decrease at M1, 
respectively (Table 2; lower section).
Complementary to intersections in time were 
the varying amounts of newly appearing genes 



























































































































Figure 3. Overview of curated and filtered probeset numbers at each time point as result of pairwise comparison to 
baseline. Volcano plots provide visual summaries of test statistics for all measured probesets in rIFN-b-1b treated relapsing remitting MS 
patients (n = 25). The MAID score deflection is shown on the x-axis. The vertical bars at 2 and -2 indicate the cutoff used for differential 
expression of the represented genes. On the y-axis is the negative base 10 logarithm of the paired t-test value. The horizontal bar 
indicates the chosen significance threshold. Probesets that are significant at the a = 0.05 level are shown in the lighter color. Probesets 
that have been filtered following all three criteria as described in methods are displayed in diamond shape, located in upper right 
(increased expression) and upper left squares (decreased expression). The ratios compare the number of up- and down-regulated genes. 
*See Online SupplemenTary Table 1 (www.futuremedicine.com/doi/suppl/10.2217/pgs.09.152).
**see Online SupplemenTary Table 2 (www.futuremedicine.com/doi/suppl/10.2217/pgs.09.152).
DE: Differential expression; MAID: MA-plot-based signal intensity-dependent fold-change criterion.
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comparison with D2, 169 (111 up, 58 down) 
further genes were filtered at M1, and 140 
(74 up, 66 down) and 99 (60 up, 39 down) 
between subsequent time points, respectively 
(Online SupplemenTary Table 3; www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152.). 
To further describe the dynamics of the 
19 consistently regulated genes, Figure 4 depicts 
time courses as a function of the MAID-score 
and the expression value, respectively (see val-
ues in Online  SupplemenTary  Table  4;  www.future-
medicine.com/doi/suppl/10.2217/pgs.09.152). 
FCER1A was the exclusive gene to be down-
regulated throughout time and the accentu-
ated peak of the transcriptional effect at M1 
PTI became apparent. Online SupplemenTary Figure 1 
(www.futuremedicine.com/doi/suppl/10.2217/
pgs.09.152) confirms the maximal change within 
the 25 individuals through the illustration of 
change calls per gene.
The patterns of gene expression revealed by 
real-time PCR were similar to those obtained 
from microarrays 1 month into therapy versus 
baseline. The mRNA measurements of both 
techniques correlated significantly for 14 out of 
15 genes. Details on real-time PCR experiments 
and respective correlations are presented in Online 
SupplemenTary  maTerial  1  (www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152).
n Gene ontology ana lysis
To functionally interpret the set of 269 selected 
genes, eight gene lists were tested for over-
represented GO terms, stratified for each time 
pair for up- (n = 173) and down-regulation 
(n = 96) (Table 3, bOx 1 & Online SupplemenTary Table 5; 
www.futuremedicine.com/doi/suppl/10.2217/
pgs.09.152). The significantly over-represented 
GO categories containing exclusively upregulated 
DEGs denote responses to viruses/other organ-
isms/biotic stimuli, multiorganism processes 
(Table 3 & bOx 1), homeostatic processes, immune 
effector processes, innate immune responses, 
(chemo)taxis, and regulation of programmed 
cell death, the latter being complemented by 
four additional genes (EIF2AK2, GZMB, PRF1 
and RHOB) in programmed cell death (Online 
SupplemenTary Table 5; www.futuremedicine.com/
Table 2. Temporal intersection of number of differentially expressed genes and respective change direction 
(increase or decrease). 












269 genes 225 genes 254 genes 42 genes 175 genes 103 genes
2 days 42 19 (18,1)* 21 (20,1)‡
1 month 175 19 (18,1)* 21 (20,1)‡ 48 (46,2)§ 24 (21,3)¶
12 months 103 19 (18,1)* 21 (20,1)‡ 48 (46,2)§ 23 (22,1) 69 (64,5)#
24 months 108 19 (18,1)* 48 (46,2)§ 21 (20,1) 55 (52,3) 56 (52,4)**
Total 428
Consistently IFN-b-1b subcutaneous responding genes throughout analyzed time (n = 19 of 269) were divided in 18 up- and one down-regulated genes. 
48 differentially expressed gene (DEGs) of M1/12/24 are reflected in 69 identically regulated DEGs between M1 and M12, and 56 DEGs when intersecting M12 
and M24.
Genes sorted by change direction and alphabetically:
*19 (18,1):  
Increase = APOBEC3A, CMPK2, EIF2AK2, EPSTI1, FFAR2, HERC5, IFI44, IFI44L, IFIT1, IFIT2, IFIT3, ISG15, LY6E, MX1, OAS2, OAS3, RSAD2, SIGLEC1 
Decrease = FCER1A
Lists ‡,§ include additional 19 DEGs from list *:
‡21 (20,1):
Increase = IFI6, ZCCHC2 
Decrease = 
§48 (46,2): 
Increase = BAFF, CCR1, DDX58, DDX60, DDX60L, FBXO6, HERC6, IFI16, IFI27, IFI35, IRF7, ISG20, MARCKS, MS4A4A (alias CD20), MX2, OAS1, OASL, PARP14, 
PARP9, PLSCR1, PRIC285, RNF213, SAMD9, SAMD9L, SCO2, SP110, TNFSF10, XAF1
Decrease = ITGA2B
Lists ¶,#,** include additional 21 DEGs from list ‡ and additional 48 DEGs from list §, respectively:
¶24 (21,3): 
Increase = KLRF1
Decrease = CLU, IL1R2
#69 (64,5): 
Increase = C3AR1, CHMP5, GBP1, HPSE, IFI6, IFIH1, IFIT5, LGALS3BP, LOC26010, MAFB, NCOA7, SCO2, STAT1, TRIM22, TYMP, UBE2L6, ZCCHC2
Decrease = C12orf39, ELOVL7, ITGB3
** 56 (52,4):  
Increase = ACSL1, ANKRD22, FPR2, LILRB2, MXD1, SAT1
Decrease = GZMK, HOPX
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doi/suppl/10.2217/pgs.09.152). At D2 PTI, 
leuko cyte-mediated immunity and humoral 
immune response, represented by C1QA, C1QB 
and CLU, were found to be over-represented, as 
were JAK-STAT cascade (CCL2, NMI, STAT1) 
and cytolysis (GZMB, PRF1) at M1 PTI.
In comparison with the overall pronounced 
induction of genes, there was a smaller number 
of downregulated DEGs, which, in turn, were 
manifold appointed to GO terms of miscel-
laneous functions, including IL-3 production, 
serotonin secretion and metabolic and biosyn-
thetic processing of lipids, icosanoids, leuko-
trienes and alkenes earlier in therapy (Online 
SupplemenTary Table 5; www.futuremedicine.com/
doi/suppl/10.2217/pgs.09.152). At M1 PTI 
cell adhesion, antiapoptosis, blood coagulation 
(FCER1A and IL-8), and at M12 PTI, cell surface 
receptor-linked signal transduction (ITGA2B, 
ITGB3, KLRB1, KLRG1 and TGFBR3) were 
significantly enriched in the gene set.
Up- and down-regulated genes were asso-
ciated with 11 common GO terms. These 
categories belong mainly to immune defense 
programs, for example, response to stimulus, 
immune response, and defense response were 
found in upregulated DEGs throughout time 




n Construction of gene networks
A total of 269 DEGs were inspected for evidence 
of ‘direct interactions’, applying the PA biologi-
cal database. The resulting gene networks are 
Table 3. Biological process.
Biological process Gene size Time DEG Count ExpCount Ratio p-value






























































































































































































Significantly over-represented gene ontology terms and respective upregulated DEGs at four time points versus baseline. Column by column, the table first lists the 
biological process term, for example, ‘response to stimulus’, its corresponding gene size (n = 2109) of the contrasted gene universe (n = 12,377), the time post-
therapy initiation (day 2) and respective number of regulated DEGs (n = 38), of which 17 genes (count) belong to ‘response to stimulus’. With an expected count of 
5.96, this led to an odds ratio of 4.6 and a p-value of 1.6E-05. At the lower end, category ‘response to virus’ contained 90 related gene symbols, of which 5, 17, 16 
or 15 appeared in respective upregulated DEG list, yielding a maximal odds ratio of 50 and p-value of 3.5E-20, respectively. A total of 11 gene ontology terms 
appeared in up- and down-regulated DEG lists containing functionally related elements (see Online SupplemenTary Table 5).
D: Day; DEG: Differentially expressed gene; M: Month.
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shown in Figure 5 and Online SupplemenTary Figure 2; 
www.futuremedicine.com/doi/suppl/10.2217/
pgs.09.152. To survey their dynamics through-
out the analyzed time course, time courses of 
genes are depicted as functions of the MAID 
score and expression value. 
Taken together, 54 of 269 DEGs were con-
nected at least once in networks, 15 genes of 
which appeared repeatedly (highlighted in 
Figure  5 and Online  SupplemenTary  Figure  2;  www.
futuremedicine.com/doi /suppl /10.2217/
























































































Figure 4. Time courses of 19 genes consistently modulated over 2 years in response to subcutaneous IFN-b-1b as function of 
MAID score (A) and mean expression (B), respectively. Order of gene symbols in (A): if similar values at M24, gene symbol 
sequences correspond to higher values at preceding time point, that is, M12 or M1. See Online SupplemenTary Table 4 (www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152) for a more comprehensive data listing.
D: Day; MAID: MA-plot-based signal intensity-dependent fold-change criterion; M: Month.
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at M1 and M12. In total, 84 molecular inter-
actions were attained. Of the 42 DEGs after 
2 days into treatment, seven genes were con-
nected (Online SupplemenTary Figure 2; www.future-
medicine.com/doi/suppl/10.2217/pgs.09.152). 
Of the 175 DEGs 1 month into therapy (Figure 5), 
27 were arranged in two larger networks with 
overall stimulatory interactions in one network 
(Figure  5a), and functional linkage to mainly 
downregulated genes in the second (Figure 5b). 
The remaining 15 genes build an interacting 
trio (Figure 5C) and six pairs (Figure 5D–i). Out of 
the 103 genes modulated after 1 year of therapy, 
14 were linked, and 2 years PTI 11 of 108 DEGs 
yielded two networks of five and four nodes, and 




We report on genome-wide longitudinal gene 
expression changes in response to rIFN-b-1b 
subcutaneous administration and present can-
didate genes for molecular response that have 
been identified in the PBMCs of 25 patients 
with RRMS. Differential gene expression was 
assessed using DNA microarrays and a combi-
nation of filtering criteria. As observed by other 
investigators using PBMCs from patients with 
MS diseases [12–28], our analyses showed the 
expression of multiple genes confirming the pres-
ence of IFN-b. It has been shown that changes 
in mRNA expression can be seen within 2–4 h 
after drug administration [13,24,26,41]. However, 
our study was intended to grasp the ‘latest pos-
sible’ window of IFN-modulated genes, repre-
senting the high-hanging fruits of rIFN-b-1b 
response. In Gilli et al., MX1 gene expression 
at 24 h after therapy initiation was 6.5-times 
higher in 19 IFN-b-1b treated patients [41] and 
at 42 h after drug injection, Reder et al. reported 
modest but statistically significant upregula-
tion of antiviral response genes in nine MS 
patients [24]. In conjunction with quantitative 
real-time PCR validation of presented micro-
array findings (see Online SupplemenTary maTerial 1; 
www.futuremedicine.com/doi/suppl/10.2217/
pgs.09.152), the authors’ confidence of genuine 
detection of regulated genes at 48 h is solid.
In order to account for cross-hybridizing 
Affymetrix probes [36], differentially expressed 
‘promiscuous’ probesets were discharged based 
on information contained in the GeneAnnot 
database [37]. This lack of probeset specificity 
was neglected by preceding MS transcriptomics 
studies. Hence, several DEGs that may basically 
suit MS and IFN-b questions were reported, 
which are offered here for reconsideration 
(Online SupplemenTary Table 1; www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152). Of note 
was a metallothionein MT2A probeset, cross-
hybridizing with 18 additional genes, which 
was reported manifold as being differentially 
expressed [23–25,29], along with MT1H [25] and 
MT1X [24,25]. Furthermore, previously commu-
nicated probesets represent the proteasome acti-
vator (PSME2) [23], the ubiquitin specific pepti-
dase (USP18) [22,23] and leucine aminopeptidase 
(LAP3) [9,22,24]. In contrast to others [24,29], 
dubious Affymetrix control probesets were 
eliminated. After discarding cross-hybridiz-
ing probes, one might lack genes that belong 
to functionally related and highly conserved 
multigene families, such as ribosomal proteins 
or immunoglobulins. However, occasionally, 
‘promiscuous’ probesets can be superseded by a 
more specific alternative probeset for the same 
gene, thereby excluding the risk of cross-hybrid-
ization with any family member, whether they 
are presumed functionally identical or not. In 
the analyzed dataset, this was the case for the 
TNFSF13B, GBP1 and HBB probesets (Online 
SupplemenTary Table 1; www.futuremedicine.com/
doi/suppl/10.2217/pgs.09.152).
We ultimately f iltered 269 DEGs, and 
thereof a subset of 96 previously reported 
ISGs [10–26,29] and 173 genes that have not 
been recognized to date in MS expression-array 
research with similar study design. Upregulated 
probesets representing type I IFN signaling 
molecules appeared in filtered lists, includ-
ing RNA helicases DDX58 and IFIH1, IFN 
regulatory factors IRF7, IRF9, NMI, STAT1 
Box 1. Gene ontology category ‘response to stimulus’. A (n=61 
increased differentially expressed genes.
2 days
  C1QA, C1QB, CD163, CLU, EIF2AK2, IFI44, IFI6, IL1R2, ISG15, LY6E, MX1, OAS2, 
OAS3, PTGDS, RSAD2, SIGLEC1, TNFAIP6
1 month
  BAFF, BST2, C3AR1, CCL2, CCR1, CXCL10, CYSLTR1, DDX58, EIF2AK2, GBP1, 
HPSE, IFI16, IFI35, IFI44, IFI6, IFIH1, IFITM1, IL1RN, IRF7, ISG15, ISG20, LGALS3BP, 
LY6E, MX1, MX2, NMI, OAS1, OAS2, OAS3, OASL, PLSCR1, PRF1, RSAD2, RTP4, 
SERPING1, SIGLEC1, STAT1, TAP1, TLR7, TNFSF10, TOR1B
12 months
  ADM, AQP9, BAFF, C3AR1, CCR1, CLEC4E, DDX58, EIF2AK2, FCAR, FPR1, GBP1, 
HPSE, IFI16, IFI35, IFI44, IFI6, IFIH1, IL1RN, IRF7, ISG15, ISG20, LGALS3BP, LILRB2, 
LY6E, MX1, MX2, NFIL3, OAS1, OAS2, OAS3, OASL, PLSCR1, SAD2, SERPING1, 
SIGLEC1, STAT1, TNFAIP6, TNFSF10, TRIM22, TYMP
24 months
  BAFF, BST2, CCR1, CYSLTR1, DDX58, EIF2AK2, FAS, IFI16, IFI35, IFI44, IRF7, IRF9, 
ISG15, ISG20, LILRB2, LY6E, MX1, MX2, OAS1, OAS2, OAS3, OASL, PLSCR1, 
RSAD2, RTP4, SIGLEC1, STAT2, TNFSF10, TREM1
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and STAT2 [7,8], as well as lymphocyte activa-
tion marker IFITM1. Within the first month 
of treatment, RNAs for genes implicated in 
antiviral response (MX-1/ -2, OAS-1/ -2/ -3, 
GBP1, EIF2AK2/PKR, RSAD2, ISG15, ISG20 
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Figure 5. IFN-b-1b subcutaneous specific gene networks derived from 175 differentially expressed genes and literature 
database information: baseline versus 1 month post-therapy initiation. See facing page.
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Figure 5. IFN-b-1b subcutaneous specific gene networks derived from 175 differentially expressed genes and literature 
database information: baseline versus 1 month post-therapy initiation. Upper-part IFN-b-1b subcutaneous specific gene 
interaction networks derived for differentially expressed genes using Pathway Architect database information. Numeration in the lower 
left corner depicts the number of genes (differentially expressed genes) that were integrated in the network construction (N), stratified 
for up- and down-regulation in brackets. In the network plots, upregulated genes are indicated by a plus symbol and downregulated 
genes by minus. The degree of connectivity is visualized through the proportional node size, thereby stressing the relevance of selected 
differentially expressed genes. Important directed attributes were those of positive or negative regulation, that is, stimulation and 
inhibition (black arrows). Remaining interactions are presented by gray arrows and accompanying attribute labels. Genes appearing 
repeatedly over time are highlighted in gray. Gene symbols with an attached asterisk belong to the group of 19 genes with sustained 
expression changes over 2 years. Lower-part time courses of network relevant IFN-b-1b subcutaneous responding genes for 2 years as 
function of the MAID score. Gene symbols with an attached asterisk belong to group of 19 consistently regulated genes over 2 years. 
The according time window of network construction is highlighted.  
MAID: MA-plot-based signal intensity-dependent fold-change criterion.
The experimental design of our ana lysis 
complements existing chip studies by describ-
ing expression dynamics over 2 years. In con-
trast to the small number of attained DEGs at 
day 2 PTI (n = 42), an early window of therapy 
thoroughly investigated by others [13,23,24], the 
most intense transcriptional effect was seen at 
1 month PTI (n = 175). A comparable range 
of up to 3 or 6 months was covered by a few 
groups [17,18,21]. DEGs at year 1 (n = 103) and 2 
(n = 108) described a relative steady state, and 
both revealed new genes in addition to those 
seen at earlier time points.
Of the 19 consistently modulated genes 
(Table 2), all genes but mitochondrial cytidine 
monophosphate kinase 2 (CMPK2), free fatty 
acid receptor 2 (FFAR2) and Fc fragment of 
IgE (FCER1A) were previously reported in 
other IFN-b-related studies. Notably, still after 
2 years of treatment, the 16 established genes 
are sustained indicators for biological IFN-b 
responsiveness. Therefore, unrecognized upreg-
ulated CMPK2 and FFAR2 and downregulated 
FCER1A enlarge this group. The identification 
of the latter is promising in the sense that the 
associated g-chain of the IgE receptor was 
found to be differentially expressed by other 
MS groups using Ficoll [19] or PaxGene [23], but 
the fact that it also forms subunits with alter-
native Fc receptors complicated its functional 
assignment. Mitochondrial membrane-bound 
proteins act as specific signaling adaptors, and 
the identified kinase CMPK2 is a component 
of the salvage pathway for nucleotide synthe-
sis. Interestingly, two participating enzymes of 
the pathway were recently detected by other 
MS researchers, namely deoxynucleotidase-2 
(NT5M) [22] and deoxyguanosine kinase 
(DGUOK) [23]. The plasma membrane-bound 
short chain fatty acid receptor (FFAR2) has not 
been mentioned in context with IFN-b or MS 
yet, but its contribution to the mechanisms of 
signal transmission through therapeutic drugs 
has received attention lately [42,43].
To learn more about the biological function 
of ISGs, GO term ana lysis provides a useful 
method to detect over-represented functional 
categories. Enriched GO annotations of DEGs 
revealed dual roles (up- and down-regulation) 
in mainly immune, inflammatory and defense 
responses (Table 3, bOx 1 & Online SupplemenTary Table 5; 
www.futuremedicine.com/doi/suppl/10.2217/
pgs.09.152). Diverse categories delivered typical 
upregulated constituents of inflammatory cas-
cades, such as the complement system (C1QA, 
C1QB and C3AR1), chemotactic signaling 
(CCL2, CCR1, CXCL10, FPR1 and TYMP), 
cell signaling (NMI) and cell binding (CLU). 
As expected, the category ‘response to virus’ was 
over-represented among exclusively upregulated 
genes, containing interferon-induced genes, inter-
feron regulatory factors, Toll-like receptors and 
others (Table 3 & bOx 1). The same applied to the 
‘homeostatic process’, disclosing the promising 
candidate gene AQP9 [22] and the ‘innate immune 
response’. The IFN-b specific upregulation of 
TLR7, a cytoplasmatic receptor that recognizes 
ssRNA, might be an important factor to control 
the disease and has been discussed as therapeu-
tic target elsewhere [44,45]. Accordingly, other 
members of the Toll-like receptor family were 
repeatedly detected in MS array research, such as 
increased TLR1 [22,23], TLR3 [19] and TLR5 [11,18]. 
Moreover, with regard to the known action of 
IFN-b, we noticed potentially concurring fea-
tures of DEGs that were assigned to GO terms 
of opposed function. One illustrative example was 
that 12 apoptosis regulator genes were induced, 
while four apoptosis inhibitors (ALOX12, CLU, 
PROK2 and SNCA) were suppressed (Online 
SupplemenTary Table 5; www.futuremedicine.com/doi/
suppl/10.2217/pgs.09.152). Similarly, six upregu-
lated genes belonging to ‘chemo taxis/taxis’ were 
functionally complemented to downregulated 
IL-8 in ‘regulation of chemotaxis’. 
Eventually, GO term analyses provided data- 
based evidence of interaction between deter-
mined DEGs, thus requiring the itemization 
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of term constituents and their interconnection 
as nodes for IFN-b specific gene networks. The 
gene interaction networks obtained from PA 
are of a rather phenomenological nature, as 
the provided interactions also include indirect 
relationships conveyed through intermediary 
molecules we do not know yet. Nonetheless, 
attained genes and respective interaction 
assignments presented in Figure  5 and Online 
SupplemenTary  Figur e  2 (www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152) provide 
new insights into IFN-b mechanism of action. 
They confirm previously reported genes with 
identical or changed accessory targeting or reg-
ulating genes, and propose genes that have not 
been recognized in MS therapy chip research 
so far. For instance, three genes of the network 
of DEGs at D2 reappeared at M1: ‘FFAR2 
influences expression of CLU ’ and IFI44 [24] 
(On l i n e  Su ppl e m e n Ta ry  Figu r e  2 ;  www.future-
medicine.com/doi/suppl/10.2217/pgs.09.152), 
but the latter was initially regulated by IL8 [12] 
and then bound by HBB (Figure 5H). Further 
interactions of known and unknown DEGs 
during the first month of therapy were ‘C1QA 
binds C1QB ’, ‘PTGS1 [19] binds PROS1 that 
inhibits C3AR1 [22]’, ‘MARCKS [23] interacts 
with NRGN ’, ‘TPM1 stimulates CALD1’, 
‘MX1 [10] binds SP100 [19]’, and ‘JUP [12] 
inhibits RAB8A’.
The largest gene network (Figure  5a) com-
prises 15 upregulated genes. Of these, 13 genes 
had been previously detected in MS therapy 
research – IRF7, ISG15, TAP1 [11], CXCL10, 
IL1RN [10], STAT1, OAS1 [12], IFI35, NMI [23], 
CCR1, SERPING1 [22], CCL2 [18] EIF2AK2 [13] 
– whereas CISH (alias SOCS1) and IGFBP7 
were novel. By contrast, another gene network 
denoted nine downregulated versus three upreg-
ulated genes (Figure 5b). At least four genes were 
acknowledged: CD38 [25], CD9 [19], RSAD2 [24] 
and SELP [10]. Here, ITGA2B and ITGB3 were 
highly connected, as well as downregulated 
CD1c acting as stimulator for downregulated 
B lymphocyte cell surface antigen CD20.
At 1 year, FPR1 [22] was connected to three 
other known MS-related genes: C3AR1 [22], 
GNLY [23] and FPR2 [24] (Online  SupplemenTary 
Fig u r e  2 ;  w w w.futuremedicine.com/doi /
suppl/10.2217/pgs.09.152), Here, C3AR1 
emerged as being functionally different to the 
members of a preceding network (Figure 5C). The 
interaction of upregulated B cell-activating 
cytokine BAFF [23,26] with fatty acid-degrading 
ligase ACSL1 in the context of MS and IFN-b 
expression ana lysis was yet unknown. 
Online SupplemenTary Figure 2 (www.futuremedi-
cine.com/doi/suppl/10.2217/pgs.09.152) also 
revealed regulatory interactions between four 
prominent MS related genes at 2 years PTI, dis-
playing FAS [10] as a regulator of XAF1 [24] and a 
stimulator of TRAIL [12], the latter being inhib-
ited by TNFRSF10C, a decoy receptor of this 
cytokine. The significance of downregulated 
MBP may be both disease and drug related. 
The second network contained four established 
members of the IFN-b signaling cascade [28], 
illustrating the regulatory action of IRF9 [18], 
which forms a trimer with STAT-1 and -2 [19]. It 
acts upon interferon-responsive genes IFIT2 [25] 
and ISG15 [11], the latter being also described as 
a stimulator of CXCL10 at M1 PTI (Figure 5a). 
Notably, the crucial function of CXCL10 in an 
autoimmune disease such as Type I diabetes was 
recently supported [46].
Within the extracted gene networks, feed-
back and redundancy mechanisms were noticed. 
Regulatory feedback loops can be positive 
(reinforcing) or negative (self-balancing), and 
redundant links allow genes to sustain their effects 
on others even if some malfunction occurs. An 
exemplary positive feedback loop would be the 
regulatory chain ‘CXCL10→CCL2→CXCL10’ 
(Figure  5a), and redundancy of interaction 
was evident between ‘IFI44–IL8–MMP9 ’, 
‘ITGA2B–ITGB3’ and ‘IRF9–STAT2 ’. Such 
findings support the understanding of the 
IFN-b mechanism of action, but intermediary 
steps that were not grasped with the applied tran-
scriptomics approach still cause missing links in 
displayed gene networks, for example, the pleio-
tropic effects of a cytokine such as IL8 (Online 
SupplemenTary Figure 2; www.futuremedicine.com/
doi/suppl/10.2217/pgs.09.152). 
Focusing further on the novelties of this study, 
we assume that administered rIFN-b lowers the 
activity of integrin-mediated signaling pathways 
(Online SupplemenTary Table 5; www.futuremedicine.
com/doi/suppl/10.2217/pgs.09.152) through 
the influence on a regulatory feedback mecha-
nism, with downregrulated ITGA2B and ITGB3 
as the most evident backbone (Figure 5b & Online 
SupplemenTary Figure 2; www.futuremedicine.com/
doi/suppl/10.2217/pgs.09.152). The latter 
also forms the cell surface glycoprotein IIb/
IIIa, which mediates platelet aggregation by 
functioning as receptor for fibrinogen. This 
receptor serves as a target for several drugs. In 
addition, we found evidence for a modulation 
of B-cell-mediated immunity: the mean expres-
sion of CD20 gene was significantly decreased 
at M1 compared with baseline. In the network 
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(Figure 5b), this target of rituximab therapy was 
downregulated by CD1c, an antigen-presenting 
protein that binds self and nonself lipid antigens 
and presents them to T-cell receptors on natural 
killer T-cells. Additionally, BAFF was upregu-
lated in accordance with the literature [47]. 
Extended time dynamic knowledge of the sur-
face molecule CD20 will be of crucial interest 
when considering the combination with rIFN-b 
and questioning what kind of effects to expect: 
synergistic, unaltered or counteractive. 
Finally, it is important to note that neutral-
izing antibodies are a recognized phenomenon 
in some people receiving rIFN-b treatment. The 
determination of such interfering antibodies 
directed against rIFN-b-1b and their biological 
significance is based on the most investigated 
ISG in MS research, MX1 [48–50]. In presented 
expression data, a subgroup of patients did not 
reveal consistent MX1 upregulation (Online 
SupplemenTary maTerial 2; www.futuremedicine.com/
doi/suppl/10.2217/pgs.09.152), which was pos-
sibly due to the presence of neutralizing anti-
bodies. However, regarding the inherent hetero-
geneity when analyzing ex vivo biomaterial and 
expected diverse responses to a low-dosage drug, 
our applied filtering system accounted for this 
by tolerating potential biological interference or 
pharmacogenetic nonresponses. Hence, ISGs 
down the cascades are still determined among 
the larger group of biologically responding 
patients, and represents a valuable insight into 
the mechanism of action of IFN-b.
The clinical outcome was not the object of 
the presented ana lysis, and remained blinded 
to the main investigators. It is expected that 
biologically and/or clinically nonresponding 
patients are reflected in the generated dataset by 
unchanged or opposed gene expression. However, 
the confidence in detecting genuine mechanism-
of-action players stands, as the applied filtering 
system accounts for such a degree of biological 
nonresponse (affecting ~30% of patients) in 
that tolerates up to 49% of patients showing no 
changes. The question of clinical response to 
rIFN-b has been addressed by several research 
groups [12,17,26,51], and will be approached by our 
group in the near future, that is, performing 
subgroup classification on the basis of mRNA 
levels and developing predictive models of clini-
cal response to rIFN-b. This clinical branch 
will demand an exhaustive ana lysis, including 
the validation of clinically useful molecular 
biomarkers in larger cohorts, but would clearly 
reach beyond the currently stated question of 
IFN-b-1b mechanism of action in time.
Conclusion
The aim of the presented work was to analyze 
the pharmacogenomic effects in response to 
rIFN-b-1b in time. It showed that the field of 
IFN-b-regulation deserves further exploration, 
and we described previously unrecognized 
genes (CMPK2, FCER1A and EPST1) and 
maximal interactions 1 month into treatment. 
At 1 and 2 years PTI, data of disease progres-
sion and drug effects might be intertwined, 
but the consistent differential expression of 
ISGs suggests that, in the majority of ana-
lyzed individuals, the medication still affects 
the system and no adaption has set in. While 
the biological role(s) of many selected genes has 
been captured so far, it is essential to examine 
their molecular interactions that lead to regu-
latory cascades and signaling pathways, which 
still represent a large field that lies idle in MS 
therapy research. 
Future perspective
In drawing the concept of personalized medi-
cine closer to MS patients, it is necessary 
to combine interrelating research areas, for 
example, pharmacogenomics with pharmaco-
genetics, which has already received thorough 
attention [52,53]. In addition, in order to define 
additional ISG identities and establish their 
functional relevance to the modulation of 
disease development and/or progression, that 
is, the immunological and beneficial effects 
of the pleiotropic agent IFN-b, the employ-
ment of further accessible systems biology 
approaches [4,5,54–56] will be needed.
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Executive summary
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  To discover genuine transcriptional effects, data curation (eliminating noninformative probesets), gene filtering (paired student’s t-test 
(p < 0.05), adjusted fold-changes (MAID score > 2), and increase/decrease labels (≥12 individuals) were carried out. 
  To consider cross-hybridizing Affymetrix probes, ‘promiscuous’ probesets were discharged based on the information contained in the 
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  Network constructions for each time point depicted interactions between new genes found to be influenced by rIFN-b and enlarged 
information about established markers (e.g., BAFF) of biological response to treatment.
  This study shows the benefit of using microarray technology in determining biological response genes to rIFN-b therapy. It has generated 
novel information likely to be of importance in furthering our understanding of Type I interferon biology in multiple sclerosis. 
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Abstract
Interferon-β (IFN-β) is one of the major drugs for multiple sclerosis (MS) treatment. The purpose of 
this study was to characterize the transcriptional effects induced by intramuscular IFN-β-1a therapy 
in  patients  with  relapsing-remitting  form of  MS.  By  using  Affymetrix  DNA  microarrays,  we 
obtained genome-wide expression profiles of peripheral blood mononuclear cells of 24 MS patients 
within the first four weeks of IFN-β administration. We identified 121 genes that were significantly 
up- or down-regulated,  in particular one week after  start of therapy. Eleven transcription factor 
binding sites (TFBS) are overrepresented in the regulatory regions of these genes, including those 
of IFN regulatory factors and NF-κB. We then applied TILAR, a novel integrative algorithm for 
deriving gene regulatory networks from gene expression data and TFBS information, to reconstruct 
the underlying network of molecular interactions. An NF-κB-centered sub-network of genes was 
higher expressed in patients with IFN-β-related side effects. Expression changes were confirmed by 
real-time PCR and literature mining was applied to evaluate network inference accuracy.
Keywords: interferon-beta, multiple sclerosis, DNA microarray, network analysis
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Introduction
Multiple sclerosis (MS) is an idiopathic inflammatory disorder of the central nervous system and 
the most common disabling neurologic disease of young adults. It is a life-long disease that affects 
the  nervous  system by destroying  the  protective  covering  (myelin)  that  surrounds  nerve  fibers, 
thereby provoking impaired nerve conduction. Genetic susceptibility, environmental exposure and 
immune dysregulation are thought to play a significant role in its pathogenesis. An autoimmune 
basis  is  assumed  to  cause  lesions  in  the  brain  and  spinal  cord,  but  it  is  less  clear  how  the 
autoimmune processes originate and maintain [1-3]. At present there is no cure for MS, and existing 
therapies are designed primarily to prevent lesion formation and brain atrophy, decrease the rate and 
severity  of  relapses  and  delay  the  resulting  disability  by  reducing  levels  of  inflammation. 
Interferon-β (IFN-β) is currently the most established treatment for controlling the exacerbations in 
relapsing-remitting MS and several studies have confirmed its clinical benefit [4-6].
IFN-β  is  a  natural  human  pleiotropic  cytokine  with  antiproliferative  and  immunomodulatory 
activities that is produced by various cell types including fibroblasts and macrophages. It exerts its 
biological effects by binding to specific cell surface receptors. This binding initiates a cascade of 
intracellular events which leads to the activation of transcription factors (TFs) including STATs, 
IFN regulatory factors and NF-κB [7]. These translocate to the nucleus and drive the expression of 
numerous genes that could serve as biological markers of IFN-β activity (e.g. MX1, TNFSF10, 
B2M and IFIT1). Transcript levels of these biological response markers increase within 12 hours of 
IFN-β administration and remain elevated for at least 3 days [8-11]. While the initial steps of the 
intracellular signaling pathways that are triggered by IFN-β have been delineated in great detail, the 
mechanisms instrumental for its therapeutic efficacy in MS are still poorly understood. It is likely 
that of the many (immune system) processes that are influenced by IFN-β - directly or indirectly as 
a consequence of the activity of induced proteins - only a small proportion is responsible for the 
clinical benefit. This suggests a cascade of events following IFN-β administration, in which some 
are beneficial, others may have no effect on MS, and still others may be deleterious and cause side 
effects.  The balance of all  these effects  is favorable  in most MS patients  and leads to reduced 
disease activity and lowered accumulation of disease burden. However, clinical trails demonstrated 
that  MS patients  exhibit  considerable  interindividual  heterogeneity  in  their  clinical  course  and 
response  to  IFN-β  therapy.  Approximately  one-third  of  the  patients  suffers  from  a  higher  or 
identical annual relapse rate while on treatment than before (non-responders) [12]. At present, no 
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established markers capable of predicting either favorable or detrimental  responses to IFN-β are 
available.
Today, different IFN-β medications are available for MS. Three have been approved as first-line 
therapies  for  the  treatment  of  relapsing-remitting  MS  in  the  mid-1990s:  Avonex  (IFN-β-1a 
intramuscular; Biogen Idec, Cambridge, MA, USA), Rebif (IFN-β-1a subcutaneous; Merck Serono, 
Darmstadt,  Germany)  and  Betaferon  (IFN-β-1b  subcutaneous;  Bayer  Schering,  Leverkusen, 
Germany). Intramuscular (i.m.) IFN-β-1a is given once a week, while subcutaneous (s.c.) IFN-β-1a 
and IFN-β-1b require three to four injections per week. IFN-β-1a i.m. appears to be well tolerated 
with 4% of treated patients discontinuing injections due to adverse events in the pivotal clinical trial 
[5]. Moreover, it has the lowest incidence (approximately 2%) of neutralizing antibodies [13].
It has been repeatedly demonstrated that IFN-β-mediated gene regulatory effects can be accessed by 
expression profiling of peripheral blood cells using DNA microarrays [14,15]. In the recent past, a 
few high-throughput  analyses  have  been  completed  in  an attempt  to  explicitly  characterize  the 
global transcriptional changes in the blood that occur in response to IFN-β-1a i.m. (table 1). In a 
pharmacogenomic study by Weinstock-Guttman et al. ~4000 genes were measured, of which about 
1500 were identified as up- or down-regulated after the first dose and after chronic administration 
of IFN-β-1a i.m. [10]. This showed that the therapy induces changes in the expression of many 
genes  (e.g.  cytokines  and  cell  adhesion  molecules),  and  that  IFN-β  has  effects  on  multiple 
processes.
However,  existing studies primarily explored the immediate gene expression changes few hours 
after therapy onset, and to a lesser extent the (possibly indirect) regulatory effects of IFN-β that 
appear at a late stage between two subsequent injections and sustain for a longer period of time. 
Moreover, most reports just list differentially expressed genes, but since genes tend to interact, it is 
more meaningful to arrange them in gene regulatory networks (GRNs) based on expression data and 
known molecular interactions. A GRN, in principle, denotes the assembly of regulatory effects that 
conduct the mutual transcriptional control of a set of genes.  Various modeling approaches have 
been proposed to reconstruct GRNs from experimental data on the basis of different mathematical 
concepts  and  learning  strategies,  and  distinct  degrees  of  abstraction.  Novel  network  inference 
algorithms integrate diverse types of data (e.g. gene expression data and protein-DNA interaction 
data),  incorporate  prior  biological  knowledge  (e.g.  from  scientific  literature)  and  use  specific 
modeling  constraints  to  obtain  more  accurate  GRN models  [18,19].  A network  analysis  could 
provide  testable  hypotheses  about  the  drug's  mechanisms  of  action  and  may  have  clinical 
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implications by accentuating gene sub-networks with expression differences between responders 
and partial responders or patients with and without side effects to therapy. In 2007, Fernald et al. 
published the first and only study that incorporated computational network inference to investigate 
gene regulation in response to IFN-β-1a i.m. [17]. They used mutual information as a similarity 
measure to derive a large network of genes.
Here,  we  used  DNA  microarrays  to  measure  the  transcriptional  profile  of  peripheral  blood 
mononuclear cells (PBMC) from 24 MS patients within the first month of weekly intramuscular 
injection of IFN-β-1a. The data allowed to assess sustained changes in expression and we analyzed 
the  functional  characteristics  and  TF binding  sites  (TFBS) of  the  genes  up-  or  down-regulated 
during therapy. Using an integrative modeling approach we reconstructed a GRN in which TFs are 
linked  to  the  modulated  genes  to  provide  a  deeper  molecular  understanding  of  the  underlying 




A total of 24 Caucasian patients (18 females / 6 males, mean age 35.8 years; table 2) diagnosed with 
relapsing-remitting MS by McDonald criteria [20] were analyzed in this study. The patients were 
prescribed a first therapy with 30 μg, once-weekly, intramuscular IFN-β-1a (Avonex; Biogen Idec, 
Cambridge,  MA,  USA).  None  of  the  patients  had  previously  been  medicated  with 
immunomodulatory or immunosuppressive agents or had ever received cytotoxic treatments, and all 
were free of glucocorticoid treatment for at least 30 days prior to blood extraction. Patients were 
assessed neurologically and rated using the Expanded Disability Status Scale (EDSS) at regular 
intervals. The study was approved by the University of Rostock's ethics committee and carried out 
according to the Declaration of Helsinki.
Gene expression analysis using microarrays
With informed consent, 15 ml peripheral venous EDTA blood samples were taken from all patients 
immediately before first, second and fifth IFN-β injection, i.e. at baseline as well as one and four 
weeks post therapy initiation. The samples were always collected at the same time of the day and 
processed within one hour. Total RNA of Ficoll-isolated PBMC from each sample was extracted 
following manufacturer's protocol (RNeasy; Qiagen, Hilden, Germany). We used PBMC instead of 
whole  blood  to  reduce  interferences  of  globin  RNA  and  thus  increase  the  sensitivity  of  the 
microarray  hybridization  results.  Initial  RNA and  final  cRNA concentrations  were  determined 
spectrophotometrically by a Nanodrop 1000 (Thermo Fisher Scientific, Waltham, MA, USA) and 
quality control was performed by native ethidium bromide agarose gel electrophoresis. Samples of 
7 μg total RNA were labeled and hybridized to Affymetrix Human Genome U133 A and B arrays in 
accordance with the supplier's instructions. The arrays were scanned at 3 micron resolution using 
the Hewlett Packard GeneArray Scanner G2500A (Affymetrix, Santa Clara, CA, USA). The raw 
data  were  stored  according  to  the  MIAME  standard  and  are  available  from Gene  Expression 
Omnibus (accession number GSE19285, http://www.ncbi.nlm.nih.gov/geo/).
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Validation of the microarray data by real-time PCR
Quantitative real-time reverse transcription polymerase chain reaction (real-time PCR) was used to 
confirm changes in gene expression revealed by the DNA microarray experiments. We measured 
the expression levels of 15 selected genes in a subset of the samples. Details on the experimental 
procedure as well as on the analysis of the real-time PCR data are described in the supplemental 
document.
Microarray data preprocessing
In the applied Affymetrix microarrays most probesets  include probes  matching transcripts  from 
more  than  one  gene  and probes  which  do  not  match  any  transcribed  sequence.  Therefore,  we 
utilized custom chip definition files (CDFs)  that  are based on the information contained in the 
GeneAnnot  database  version  1.8  [21]  (http://bioinfo2.weizmann.ac.il/geneannot/).  GeneAnnot-
based CDFs are composed of probesets including exclusively probes matching a single gene and 
thus  allow for a  more reliable  determination of transcript  levels.  We used version 1.5.0 of the 
custom CDFs (for HG-U133 A and B) and the MAS5.0 algorithm to preprocess the raw probe 
intensities. Data normalization was performed, separately for the arrays of type A and B, by a loess 
fit  to  the  data  with  span=0.05  (using  R  package  affy).  Each  A-  and  B-chip  yielded  mRNA 
abundances of 11220 and 6771 human genes, respectively. For the 2257 genes that were measured 
with both chip types, we used the signal intensities of the A-chip.
Filtering differentially expressed genes
To identify genes substantially up- or down-regulated within the first month of therapy, we used a 
combination of two criteria: a test of statistical significance and a fold-change variant. First, we 
analyzed which genes show significant expression changes by use of a paired t-test comparing the 
baseline expression levels with the levels  at  one week and four weeks into therapy.  To further 
narrow down the  filtering  result,  we  evaluated  signal  intensity-dependent  fold-changes  (MAID 
filtering) [22] (http://www.hki-jena.de/index.php/0/2/490). In this way, we took into account that 
the variability in the (log) fold-changes increases as the measured signal intensity decreases [23]. 
The absolute value of a gene's MAID-score is higher, the more its expression level is altered after 
start  of  therapy,  and it is generally lower for weakly expressed genes.  Finally,  we selected the 
protein-coding genes having |MAID-score|>3.0 and t-test P-value<0.01 as IFN-β-responsive genes.
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To provide an estimate of the number of genes passing the filtering by chance, a permutation test 
was performed.  The data set  was permutated 1000 times by randomly rearranging the temporal 
sequence of the data of each patient. The same filtering criteria as described above were applied to 
each permutation.
In addition, we analyzed the genes with significant expression changes to identify a subset of genes 
whose expression correlates with IFN-β-related side effects.  For this purpose,  we compared the 
baseline transcript levels of patients with and without side effects using a two-sided two-sample t-
test with the significance level at α=0.05.
Gene Ontology analysis
We examined the set of IFN-β-responsive genes for overrepresented Gene Ontology (GO) terms 
using  GOstats,  a  software  package  written  in  R [24].  Each  GO term was  tested  whether  it  is 
significantly associated to the list of filtered genes in comparison to the 15734 genes measured in 
total.  The analysis was performed for gene functional  annotations of the biological process GO 
category  provided  by  the  Bioconductor  annotation  package  org.Hs.eg.db  version  2.2.6 
(http://www.bioconductor.org).
Transcription factor binding site analysis
To reconstruct the regulatory interactions between the genes with expression changes in response to 
IFN-β,  we  applied  a  GRN  inference  algorithm  that  integrates  information  on  TFBS  as  prior 
knowledge. Evolutionarily conserved TFBS were derived from the tfbsConsSites track of the UCSC 
database build hg18 (http://genome.ucsc.edu). The track data were generated using position weight 
matrices  (PWMs)  of  TFBS  contained  in  the  public  Transfac  database  (version  7.0, 
http://www.gene-regulation.com/cgi-bin/pub/databases/transfac/).  For  the  whole  human  genome 
3837187  TFBS  predictions  associated  to  258  different  PWMs  can  be  retrieved  from  the 
tfbsConsSites  track (as  of November  19,  2009).  With this  at  hand,  we screened the  regulatory 
region of each of the 15734 measured genes  for TFBS occurrences.  The regulatory region was 
specified as the genomic sequence 1000 bp up- and downstream of the transcription start site stated 
in  the  GeneCards  database  version  2.39  (http://www.genecards.org).  Furthermore,  to  take  into 
account the inherent  redundancy of the Transfac database,  we grouped very similar or identical 
sequence motifs by use of STAMP [25]. In this way, we could reduce the 258 Transfac PWMs to 
101  distinct  DNA-binding  patterns.  Using  a  hypergeometric  test,  we  identified  a  subset  of 
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(consolidated)  TFBS  motifs  overrepresented  in  the  regulatory  regions  of  the  genes  at  the 
significance level  α=0.1. This information corresponds to a list of predicted TF-gene interactions 
that can serve as a template for inferring the GRN. A TF-gene interaction represents a physical 
interaction, i.e. a TF (or a group of TFs with similar binding specificity) binds at least once the 
DNA at the region that  encompasses the transcription start  site of a gene and thus presumably 
regulates its transcription.
Integrative gene regulatory network modeling
We applied the TFBS-integrating least angle regression (TILAR) algorithm to construct a GRN 
model  of  IFN-β-responsive  genes.  TILAR  is  a  novel  method  for  inferring  GRNs  from  gene 
expression  data,  incorporating  known  or  predicted  TFBS  and,  if  available,  literature  mining 
information (adaptive TILAR) [22].  The modeling approach distinguishes two types  of network 
nodes: genes (that were selected for identifying the regulatory interactions between them) and TFs 
(whose binding sites are overrepresented in the regulatory regions of the genes). The algorithm then 
assigns (directed) TF-gene and gene-TF interactions (network edges) by fitting a system of linear 
equations  to  the  genes'  expression  levels.  In  comparison  to  TF-gene  interactions,  gene-TF 
interactions  can  have  different  meanings,  e.g.  the  gene  itself  might  encode  a  transcriptional 
regulator of the TF, or the gene product controls (possibly via a signaling cascade) the activity of 
the TF at the proteome level. Using both types of interactions, the modeling considers that genes 
usually regulate other genes indirectly through the activity of one or more TFs.
The  actual  GRN inference  problem is  formulated  as  a  linear  regression  equation  that  satisfies 
specific constraints on the network structure. The model is constrained to be sparse reflecting that 
genes are regulated by a limited number of regulators. Moreover, TILAR includes only a subset of 
the putative TF-gene interactions obtained from TFBS analysis. As TILAR not necessarily employs 
all those TF-gene interactions, the method considers the fact that they are predicted and therefore 
not all of them might refer to biologically functional binding sites. The regression coefficients (i.e. 
the nominal parameters in the model) to be estimated by least angle regression [26] then specify the 
presence and strength (edge weights) of each possible gene-TF interaction. The final model was 
determined by 10-fold cross-validation (to avoid overfitting to the data), visualized with Cytoscape 
2.6.0 [27],  and  tested  for  scale-freeness  according  to  Clauset  et  al. [28].  For  a  more complete 
description of the modeling approach, we refer to our original paper on TILAR [22].
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The major advantage of this inference technique is that only few model parameters are sufficient to 
define a complex network, which is still readily interpretable in terms of true molecular interactions. 
Moreover, TF expression levels are not required for the network reconstruction, since the activity of 
TFs is modeled implicitly. This is beneficial, as TF expression seldom correlates with TF activity. 
We evaluated and compared the performance of TILAR (including the adaptive variant) and five 
different  GRN inference  methods  using literature  mining information.  A detailed report  on this 
benchmarking analysis can be found in the supplemental document. We supply R codes for TILAR 




The demographic and clinical  characteristics of the 24 patients  in our study are summarized in 
table 2. Twenty patients had systemic side effects such as flu-like symptoms (including fever, chills, 
asthenia, myalgia and headaches) within the first 3 months on treatment. Two patients experienced 
a relapse in this observation period.
Transcriptional changes in response to IFN-β therapy
The preprocessing of the microarray data resulted in an expression data set of 15734 different genes 
and 72 PBMC samples. By filtering for genes significantly up- or down-regulated after  therapy 
onset, we detected gene expression changes that were common among the patients. We identified 
102 genes as differentially expressed at week 1 versus baseline, and 24 genes at week 4. Altogether, 
72 genes were found up-regulated and 49 genes down-regulated, comprising a set of 121 genes in 
total (supplemental table). Most of the filtered genes showed significant expression changes during 
the first week of IFN-β-1a i.m. therapy (figure 1).
The permutation test disclosed that the number of 121 differentially expressed genes is significantly 
higher than would be expected by chance. When randomly shuffling the sampling time points for 
each patient for 1000 times and analyzing each permutated data set for modulated genes, between 8 
and 89 genes were filtered (on average 21.4). Hence, the number of filtered genes was below 121 in 
each permutation, which implies an empirical P-value for the actual filtering result of <0.001. This 
shows that (most of) the identified mRNA changes are due to the therapy.
The overall patterns of gene expression revealed by real-time PCR were similar to those obtained 
using microarrays. The mRNA measurements of both techniques correlated significantly for all 15 
remeasured genes. When comparing the expression levels before first and second IFN-β injection, 
real-time PCR analysis also confirmed the significance of expression changes for all of these genes. 
Full results of the real-time PCR experiments are presented in the supplemental document.
Functional analysis of IFN-β-responsive genes
The  result  of  the  GO  analysis  (table  3)  shows  that  most  of  the  filtered  genes  are  known  to 
participate  in  immune  system  processes.  Genes  associated  to  "positive  regulation  of  immune 
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response" are significantly enriched in the gene set. The corresponding GO category (GO:0050896) 
comprises 26 out of the 121 genes, including TNFSF10, TLR7, FCER1A, IL1R2, OAS1 and AQP9. 
These genes have quite diverse immune functions. OAS1, a member of the 2-5A synthetase family, 
is an essential IFN-inducible protein involved in the innate immune response to viral infection [29]. 
The  water-selective  membrane  channel  AQP9  is  thought  to  play  a  role  in  the  immunological 
function  of  leukocytes  [30].  FCER1A  is  an  Fc  receptor  for  IgE  molecules  and  has  been 
demonstrated to induce NF-κB activation in monocytes [31]. Apart from that, 10 of the genes in the 
category "positive regulation of immune response" constitute a subgroup of genes annotated with 
the GO term "B cell mediated immunity" (GO:0042221).
G proteins  (GNAZ and GNG8) and G protein-coupled receptors  (GPR20,  GPR44,  GPR56 and 
GPR97) also showed significant expression changes in response to the therapy. Modifications in the 
activity of GPRs characterize lymphocytes from different chronic immune disorders including MS, 
and it is assumed that IFN-β-1a affects the expression of molecules responsible for GPR regulation 
[32].  Besides,  we noted an up-regulation of specific adhesion molecules including the integrins 
(JAM3,  ESAM,  ITGA2B  and  ITGB3).  Adhesion  molecules  are  believed  to  regulate  the 
transmigration of blood leukocytes across the blood-brain barrier (see discussion).
Comparison with other expression profiling studies on IFN-β-1a i.m.
Several of the 121 filtered genes have already been described as genes altered at the transcript level 
in response to intramuscular IFN-β-1a therapy. In the study by Fernald  et al., the genes CSF1R, 
CST7, OAS1 and SNCA were found modulated by the treatment, too [17]. Their study focused on 
the blood expression changes within two days after drug administration. CSF1R, which was down-
regulated after one and four weeks into therapy in our study, is a receptor for colony stimulating 
factor 1, a cytokine that controls differentiation and function of monocytes and macrophages [33]. 
The  down-regulation  of  CSF1R  was  confirmed  by  real-time  PCR  analysis  (supplemental 
document).  In another study, Singh  et al. examined 5 MS patients  before and 24 h after  initial 
therapeutic dose of IFN-β-1a i.m. and identified a set of 132 differentially expressed genes [16]. At 
least 8 of these genes also occur in our filtering result: TNFSF10, OAS1, JUP, AQP9, FGFBP2, 
MS4A4A, TYMP and FAM26F.  The mRNA levels of TNFSF10 are known to be increased in 
PBMC from MS patients  compared to healthy controls [34] and even have been reported to be 
predictive of clinical  responsiveness  to IFN-β [35].  TNFSF10 encodes  a cytokine of the tumor 
necrosis factor (TNF) ligand family that induces apoptosis and activation of NF-κB. Regulation of 
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TNFSF10 function takes place at the level of receptor expression, while decoy receptors such as 
TNFRSF10C can inhibit TNFSF10 from binding to TNF receptors capable of mediating apoptosis 
[36]. We found TNFRSF10C significantly up-regulated after first injection of IFN-β-1a i.m., but the 
expression returned to baseline levels at the 4 weeks time point.
Identification of putative TF-gene interactions
Genes responsive to IFN-β-1a are under control of TFs, whose activities are (indirectly) affected by 
the drug. Therefore, we analyzed the genes' regulatory regions for occurrence of overrepresented 
TFBS. Conserved binding sites were found enriched for 11 consolidated TFs. These 11 TFs connect 
77 out of the 121 genes through 152 TF-gene interactions, and each TF is linked to at least 8 genes 
(table 4). This information was used as a template for inferring the underlying GRN by TILAR.
It is important to note that some TFs with highly similar DNA-binding properties were grouped to 
one TF entity, e.g. the interferon regulatory factors (IRF) 1 and 2. IRF1 and IRF2 are structurally 
similar and bind to the same regulatory elements. However, they have distinct or even antagonistic 
functions.  IRF2  is  a  repressor  that  competitively  inhibits  the  IRF1-mediated  transcriptional 
activation of interferons and IFN-inducible genes [37].
A subset of 21 genes possess at least one TFBS for NF-κB (NFKB1, NFKB2, REL, RELA). NF-κB 
proteins are key regulators in the transcription of many inflammatory genes and are activated by 
various intra- and extra-cellular stimuli, e.g. cytokines like IFN-β. They can be found in numerous 
cell types that express cytokines, cell adhesion molecules and acute phase proteins.
Integrative network modeling
On the basis  of the gene expression data  (121 genes,  72 samples) and the (predicted)  TF-gene 
interactions,  we  constructed  a  GRN  model  using  the  TILAR  algorithm.  The  modeling  was 
constrained to use only a subset of the putative TF-gene interactions.  Here, 102 out of the 152 
predicted TF-gene interactions were included into the model. Overall, 28 nominal model parameters 
were  set  non-zero  specifying  the  presence  of  gene-TF  interactions.  Only  one  of  those  edges 
(ESAM→ TFAP4) received a negative weight and hence describes a repressing effect. The final 
model thus consists of 28 inferred gene-TF interactions and 102 TF-gene interactions, and 72 of the 
121 genes are connected to at least one TF (figure 2, supplemental Cytoscape session file).
Network  inference  by  TILAR  outperformed  all  other  algorithms  tested  in  the  benchmarking 
analysis  described  in  more  detail  in  the  supplemental  document.  TILAR  allowed  for  a  higher 
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prediction accuracy than using just gene expression data or TFBS information alone, and performed 
best  when  incorporating  text-mining  information  as  well  (adaptive  TILAR).  Therefore,  we 
confirmed that the integrative modeling strategy is able to reconstruct GRNs more reliably than 
other established methods.
Network characteristics
The inferred network  is  fairly complex but  still  readily  interpretable  due to  the  intuitive linear 
modeling scheme. Each network node is under control of only few regulators rendering the network 
sparse. The maximum in-degree in the GRN is 5 (on average 1.57). Nevertheless, some nodes (in 
particular TFs) are highly connected in the network, e.g. the NF-κB complex with an out-degree of 
15 (figure 3B). Overall, most of the nodes are lowly connected and only a few are relatively highly 
connected.  The  node  degrees  are  roughly  distributed  according  to  a  power-law  (scale-free 
topology), with the fraction P(k) of nodes in the network having k connections being estimated to 
follow P(k)~k-2.16.
A closer look at the interactions in the model revealed gene sets co-regulated by a common TF 
(figure 3A). In the network, 9 genes are under transcriptional control of TFCP2, of which all but 
one were up-regulated after first week of IFN-β-1a i.m. administration (e.g. ALOX12, GPR97 and 
CMTM5). Similarly, TF node ZIC1|ZIC2|ZIC3, which represents a group of ZIC family zinc finger 
proteins,  is linked to 7 genes.  Of these,  6 genes showed lowered mRNA levels in the patients' 
PBMC one week post therapy initiation in comparison to baseline (e.g. JUP, FAM26F and EGR2). 
The TFs ZIC1, ZIC2 and ZIC3 were grouped during TFBS analysis as they bind the same or at least 
very similar DNA sequences [38].
The GRN model contains 4 regulatory feedback loops and 25 feedforward loops of minimal length. 
An  exemplary  feedback  loop  in  the  reconstructed  network  is  the  regulatory  chain  "NF-κB→ 
EHD3→ TFCP2→ ALOX12→ NF-κB" (supplemental Cytoscape session file). EHD3 and ALOX12 
were both found up-regulated immediately before second IFN-β injection.
Patients  with and without adverse reactions within the first 3 months  of IFN-β therapy showed 
significant differences in the transcript levels of the IFN-β-responsive genes. There were 6 genes 
that not only displayed elevated amounts of mRNA after one-week therapy with IFN-β-1a i.m., but 
that were also higher expressed before start of treatment in the group of patients with side effects 
(figure  4,  supplemental  table).  Interestingly,  5  of  these  genes  (ESAM,  GNAZ,  SLC24A3, 
ANKRD9, ALOX12) and 2 TFs (NF-κB, TOPORS) form a regulatory sub-network (figure 3B). 
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DNA-binding sites for NF-κB were found in the regulatory region of 3 of these genes. Our GRN 




We analyzed transcriptional  changes in response to 30 μg once-weekly, intramuscular IFN-β-1a 
treatment. A set of 121 genes was found significantly altered in the MS patients' PBMC during the 
first four weeks of drug administration. In this set, GO analysis revealed an overrepresentation of 
immunologically relevant genes (table 3). The impact of IFN-β therapy on gene expression was 
greater after one week of therapy than after one month, possibly suggesting a homeostatic response 
to the drug. We further determined the putative TFs mediating the gene regulatory effects of IFN-β 
and constructed a GRN model  on the basis of the data.  Subsequent  network analysis identified 
"network motifs", i.e. frequent interaction patterns such as feedback and feedforward loops. A sub-
network of genes was found more active in patients reporting side effects, demonstrating that the 
inferred molecular network could explain clinical heterogeneity.
Studies on pharmacogenomic effects of IFN-β in PBMC often differ in their experimental design. 
Gene expression changes have been investigated in response to different IFN-β treatment regimes 
(IFN-β-1a i.m. and s.c., as well as IFN-β-1b s.c.), sometimes pooling patients receiving any of these 
therapies. We examined a homogeneous cohort of patients who all were treated with IFN-β-1a i.m. 
at standard dose so that the findings are not distorted by differences in form, dose and route of drug 
administration. On the other hand, the observation period may range from a few hours until years 
into therapy. The dynamics during the first hours have been studied particularly intensively. It was 
shown that changes in expression can be seen within 2-4 h after drug administration [8-11]. Among 
the early IFN-β-induced genes are MX1, B2M, TNFSF10 and OAS1. Their mRNA and protein 
levels decline to baseline between 96 and 144 h after IFN-β administration [9-11,39,40]. Hence, 
once-a-week dosing of IFN-β-1a i.m. does not maintain these genes above baseline throughout a 
week. In our study, blood samples were drawn from the patients immediately before first, second 
and fifth intramuscular injection of IFN-β-1a. The data revealed the genes that are affected by the 
therapy even one week after last injection - presumably indirectly as a consequence of the activity 
of early IFN-induced genes - and therefore unveil the more persistent changes to the transcriptome.
Some of the 121 filtered genes have been mentioned in related studies on other IFN-β treatment 
regimes. For instance, OAS1, JUP and TNFSF10 have been described as up-regulated in PBMC of 
MS patients receiving IFN-β-1b s.c. for at least 6 months [41]. Apart from that, we observed an 
elevated expression of ESAM in agreement with the results of Annibali et al. [42]. In comparison to 
our  study they  used microarrays  to obtain long-term expression profiles of  PBMC from 7 MS 
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patients receiving IFN-β-1a subcutaneously. We recently published a pharmacogenomic study were 
we applied Affymetrix microarrays to measure the PBMC expression levels of 25 patients treated 
with IFN-β-1b s.c. [43]. In this data set, FCER1A was the only gene consistently down-regulated 
over the whole observation period of 2 years. FCER1A was also found significantly decreased after 
start of IFN-β-1a i.m. therapy in the present work. Its down-regulation was confirmed by real-time 
PCR experiments in both studies. We thus conclude that FCER1A is generally repressed by IFN-β 
treatment.
It is assumed that IFN-β contributes to reduced lesion formation by modulating the inflammatory 
events at the blood-brain barrier. Our study provides some evidence that IFN-β therapy improves 
the integrity of the blood-brain barrier via the activation of adhesion molecules and fibroblasts. 
Changes in the composition of adhesion molecules in the peripheral blood of MS patients receiving 
IFN-β have already been discussed in the literature [44,45]. We found the two integrins ITGA2B 
and ITGB3 significantly up-regulated at one week into therapy. They are known to form a complex 
(the GPIIb/IIIa complex), which mediates platelet aggregation by acting as a membrane receptor for 
fibrinogen and thus plays a crucial role in coagulation [46]. Up-regulated cell adhesion molecule 
ESAM that is under control of NF-κB in the GRN, as well as the down-regulated aminoacyl-tRNA 
synthetase WARS have been linked to the regulation of angiogenesis [47,48]. We further found an 
increased expression of FGFBP2, which might be important for fibroplasia and granulation tissue 
formation  [49].  However,  it  remains  an  open  question  how  these  individual  effects  exactly 
contribute to the strengthening of the blood-brain barrier.
Evidently,  the  broad  effects  of  IFN-β  are  not  purely  anti-inflammatory  and  beneficial.  IFN-β 
treatment in relapsing-remitting MS can frequently induce systemic side effects such as flu-like 
symptoms with fever. A number of adverse effects emerge at the early phase after therapy initiation 
and then lessen over time, but a considerable amount of patients suffer from persistent or recurring 
side  effects  which  may cause  them to cease  the  treatment.  To improve  the  clinical  success  of 
therapy an individualized tolerability management  may be supported by molecular markers, but 
studies in this field are rare. Montalban et al. supposed that patients who develop fever during IFN-
β therapy generally have increased levels of IL-6 [50]. In our study, some (late) IFN-β-responsive 
genes were found significantly higher expressed at baseline in the group of MS patients with side 
effects  during the first 3 months of medication.  Interestingly,  NF-κB occurs as a regulator of a 
subset of these genes in the reconstructed GRN and its activity therefore potentially correlates with 
treatment-related adverse effects (figure 3B). Apart from that, HNF1A is connected to 7 genes in 
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the  network.  This  TF  is  required  for  the  expression  of  several  liver-specific  genes,  and  we 
hypothesize that its involvement coincides with liver function abnormalities common in patients 
who are treated with IFN-β [51]. However,  the clinical relevance of the differentially expressed 
genes and the potential roles of NF-κB and HNF1A remain to be further examined.
To  better  understand  the  pharmacologic  effects  of  IFN-β  in  MS,  it  is  crucial  to  unravel  the 
regulatory interaction structure of genes responsive to the immunotherapy. According to the GRN 
inferred by TILAR, IFN-β mediates immune regulation through diverse TFs including some so far 
unrecognized  in  MS research.  The  inferred  network  reflects  many  fundamental  properties  that 
constitute a GRN including sparseness, scale-freeness, decentralization, self-regulation (feedback) 
and co-regulation. Moreover, the model reveals network regions, for instance genes down-regulated 
by ZIC family members and a highly interconnected NF-κB (figure 3), and thus provides testable 
hypotheses about the drug's mechanisms of action.
To date, our knowledge on the biological processes underlying MS and the efficacy and safety of 
available drugs is still limited. Individualized treatment and monitoring strategies are necessary to 
use these drugs in a more cost-effective way. An improved pharmacodynamic understanding at the 
transcript level should help to assess and individually optimize MS treatments with IFN-β. Once 
established,  this  would protect  the  patients  against  unnecessary  drug exposure  and side effects. 
Several IFN-β-responsive genes with potential prognostic value have already been discussed in the 
literature  [35,41,52].  In  this  study,  we  described  sustained  PBMC gene  expression  changes  in 
response to IFN-β-1a i.m. and derived the regulating TFs. We identified a network region of genes 
associated to therapeutic side effects and linked to NF-κB activity. A potential regulatory feedback 
loop with NF-κB has been found. FCER1A, which is known to induce NF-κB [31], was affirmed as 
one of few genes significantly repressed by IFN-β. We further discussed a set of genes that might 
reflect  blood-brain  barrier  changes.  To  conclude,  we  showed  that  network  analysis  integrating 
different types of biological data could provide new insights into treatment-affected processes, and 
expose  clinically  relevant  molecular  differences  in  the  patients.  Supplementary  information  is 
available at The Pharmacogenomics Journal website.
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Tables
Table 1 : Blood expression profiling studies on intramuscular IFN-β-1a treatment in MS.
Four  microarray  studies  have  been  conducted  in  this  field  since  2003.  The  table  provides  the 
number of patients examined and the sample material used to measure mRNA levels. Moreover, the 
blood sampling time-points as well as the number of genes found modulated in expression during 
therapy (on the basis of different filtering criteria, "#Genes ↑↓") are shown. GEO = gene expression 
omnibus, PBL = peripheral blood lymphocytes, h = hour, W = week, M = month.
Author Year #Patients Sample Microarray GEO Accession Sampling #Genes ↑↓
This study 2010 24 PBMC Affymetrix HG-U133 A and B GSE19285 0h, 1W, 1M 121
Weinstock-Guttman et al. [10,11] 2008, 2003 22 PBL GeneFilters GF211 DNA arrays not available 0h, 8x within 1W, 1M, 6M, 12M 1539
Singh et al. [16] 2007 5 PBMC CodeLink UniSet Human I Bioarray GSE5574 0h, 24h, ~6M 136
Fernald et al. [17] 2007 2 Whole blood UCSF Human 21k Oligo array GSE5678 0h, up to 7x within 1W ~1000
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Table 2 : Clinical and demographic characteristics of the patients.
SD = standard deviation.
Patient ID Gender Age (years)
Pat01 Female 47 2.5 3.0 No No
Pat02 Female 45 1.5 1.5 No Yes
Pat03 Female 30 2.5 2.5 No Yes
Pat04 Female 40 1.0 1.0 No Yes
Pat05 Female 28 1.5 1.5 No No
Pat06 Female 31 1.0 1.0 No Yes
Pat07 Female 44 1.0 1.0 No Yes
Pat08 Female 45 1.5 1.5 No Yes
Pat09 Female 24 0.0 1.0 No Yes
Pat10 Male 44 1.5 1.5 No Yes
Pat11 Male 43 1.0 1.0 No Yes
Pat12 Male 27 1.0 1.0 No No
Pat13 Female 39 0.0 0.0 No No
Pat14 Male 22 0.0 0.0 No Yes
Pat15 Female 34 0.0 0.0 No Yes
Pat16 Female 20 1.5 1.5 Yes Yes
Pat17 Female 30 1.0 1.0 No Yes
Pat18 Female 38 0.5 1.0 No Yes
Pat19 Male 41 1.5 1.5 Yes Yes
Pat20 Female 35 0.0 0.0 No Yes
Pat21 Female 38 2.0 1.5 No Yes
Pat22 Female 49 0.0 0.0 No Yes
Pat23 Male 26 1.0 1.0 No Yes
Pat24 Female 40 1.5 1.5 No Yes
Mean 35.8 1.0 1.1










Table 3 : Overrepresented terms of the GO biological process ontology.
P-values  were  computed  for  each  GO  term  based  on  the  hypergeometric  distribution.  Only 
functional categories with P-value<0.01 and where at least 3 out of the 121 IFN-β-responsive genes 
are associated ("Count") are shown. "Expected count" gives the expected number of genes in the list 
of filtered genes to be found at each tested category term. BP = biological process.
GO BP ID GO Term P-value Expected Count Count
GO:0006955 immune response <0.0001 3.89 14
GO:0002376 immune system process 0.0001 5.34 16
GO:0009605 defense response 0.0005 4.47 13
GO:0030334 I-kappaB kinase/NF-kappaB cascade 0.0019 0.53 4
GO:0009611 positive regulation of immune system process 0.0025 2.92 9
GO:0050896 positive regulation of immune response 0.0026 15.03 26
GO:0051270 protein kinase cascade 0.0028 0.59 4
GO:0007218 inflammatory response 0.0028 0.59 4
GO:0051046 regulation of immune system process 0.0030 0.60 4
GO:0051047 regulation of immune response 0.0034 0.30 3
GO:0042108 positive regulation of multicellular organismal process 0.0036 0.31 3
GO:0006954 fatty acid metabolic process 0.0046 2.07 7
GO:0006916 immunoglobulin mediated immune response 0.0062 1.16 5
GO:0042221 B cell mediated immunity 0.0078 4.11 10
GO:0051050 activation of immune response 0.0086 0.42 3
GO:0009967 lymphocyte mediated immunity 0.0090 1.28 5
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Table 4 : TFBS overrepresented in the regulatory regions of up- and down-regulated genes.
Evolutionarily conserved TFBS of 11 TF entities were found enriched. The list includes IRFs and 
NF-κB,  which  are  known  TFs  in  IFN-β  signaling  [7].  Highly  similar  Transfac  motifs  were 
consolidated before calculating the P-values. The column "Count" shows the number of genes that 
possess  a  DNA-binding  site  for  the  respective  TF.  In  sum,  there  are  152  predicted  TF-gene 
interactions.
TF Symbol Transfac Accession Official Full Name P-value Expected Count Count
SRF M00152, M00186, M00215 0.003 8.22 17
TFCP2 M00072 transcription factor CP2 0.019 5.37 11
TOPORS M00480 topoisomerase I binding, arginine/serine-rich 0.019 5.40 11
HOXA9, MEIS1, TGIF1 0.022 12.46 20
HNF1A M00132, M00206 HNF1 homeobox A 0.040 3.85 8
TBP M00216, M00252, M00471 TATA box binding protein 0.081 6.84 11
IRF1, IRF2 M00062, M00063 interferon regulatory factor 1 and 2 0.086 5.33 9
ZIC1, ZIC2, ZIC3 M00448, M00450, M00449 Zic family members 1-3 0.091 9.48 14
MEF2A myocyte enhancer factor 2A 0.094 7.86 12
TFAP4 M00175, M00176, M00005 0.097 13.01 18
NFKB1, NFKB2, REL, RELA 0.098 15.68 21
Σ = 152
serum response factor (c-fos serum response 
element-binding transcription factor)
M00418, M00419, M00420, 
M00421
homeobox A9, Meis homeobox 1, TGFB-
induced factor homeobox 1
M00006, M00232, M00231, 
M00233, M00026
transcription factor AP-4 (activating enhancer 
binding protein 4)
M00051, M00052, M00053, 
M00054, M00194, M00208
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells family members
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Figure legends
Figure 1 : Clustering analysis and graphical representation of the data.
Heatmap of 102 genes identified as up- (60 genes, gray labeled rows) or down-regulated (42 genes, 
green)  one  week  after  first  intramuscular  injection  of  IFN-β-1a.  Hierarchical  clustering  was 
performed based on the complete linkage method and Pearson's correlation coefficient as a measure 
of  similarity.  Signal  intensities  were  centered  and  scaled  row-wise  (yielding  z-scores)  for 
visualization purposes. Despite a strong interindividual variability, the clustering tends to separate 
baseline measurements (green labeled columns) from gene expression levels obtained at one week 
into therapy (gray). The row labels of the heatmap are given in the supplemental table.
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Figure 2 : Gene regulatory network inferred by TILAR.
Gene expression data and TFBS predictions were utilized to build a GRN model of 102 TF-gene 
and 28 gene-TF interactions. The network comprises 72 of the 121 genes that were found up- or 
down-regulated during therapy. The remaining genes are not shown here. Two parts of the network 
are presented in detail in figure 3. The full model is available as a Cytoscape session file in the 
supplementary material.
Manuscript IV 100
Figure 3 : Detail views of the GRN model shown in figure 2.
(A) Network inference by TILAR takes into account that TF target genes are often co-expressed. 
All  but  one of the  genes  that  are regulated by TFCP2 are up-regulated after  therapy initiation. 
Similarly, a set of down-regulated genes is predicted to contain DNA-binding sites for ZIC family 
members in their regulatory regions. Both TFs receive multiple regulatory inputs. (B) Some of the 
filtered genes have potential relevance to treatment-related adverse effects. The figure on the right 
shows a sub-network of genes that are higher expressed at baseline in patients experiencing side 
effects. Three of these genes are regulated by NF-κB according to the model. Outer parts are shown 
with lower opacity.
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Figure 4 : Expression differences between patients with and without side effects.
Of the 121 filtered genes, 6 genes were found significantly higher expressed (t-test  P-value<0.05) 




Supplemental table (supplemental_table.xls,  XLS Excel  spreadsheet): List of 121 genes  up- or 
down-regulated  during  first  four  weeks  of  intramuscular  IFN-β-1a  treatment.  Genes  with 
transcriptional  changes  in  response  to  therapy  initiation  were  identified  by  use  of  the  MAID 
filtering method and a test of statistical significance. There were 72 genes higher expressed and 49 
genes lower expressed at week 1 or 4 versus baseline in the PBMC of the 24 MS patients in our 
study. The table provides diverse types of information for each gene, e.g. Entrez ID, official full 
name and the calculated MAID-scores.
Supplemental document (supplemental_document.pdf, PDF document): This document is divided 
into  two  parts.  The  first  part  is  on  the  validation  of  the  microarray  data  by  real-time  PCR 
measurements.  In  the  second  part,  we  describe  how we evaluated  the  inference  quality  of  the 
TILAR algorithm using text-mining information.
Supplemental Cytoscape session file (supplemental_cytoscape_file.cys,  CYS Cytoscape session 
file): Cytoscape  session  file  of  the  inferred  GRN  model.  The  network  model  describes  the 
regulatory interactions between TFs and the genes with expression changes during first month of 
IFN-β administration. A simplified visualization of the network is shown in figure 2, while detail 
views are shown in figure 3.
This file could not be submitted due to the Journal's submission restrictions. Therefore, we provide 





In the works presented here, transcriptional effects were studied in response to three different 
autoimmune disease therapies. The starting point of each analysis was a genome-wide RNA 
expression dataset. These measurements provided expression levels in blood for RA and MS 
patients at different therapy time points: immediately before first drug injection (baseline), as 
well as after a few days, weeks or even after two years of immunomodulatory treatment. The 
(regulatory) interactions between genes up- or down-regulated during each particular therapy 
were examined by use of integrative GRN modeling and network analysis.
The implementation of methods for Affymetrix microarray analysis and the development of 
the  integrative  GRN  inference  algorithm  TILAR  were  main  parts  of  this  work.  In  the 
following, the biological results from manuscript II-IV are briefly reviewed and compared 
among the different therapies. Afterwards, the methods are discussed in more detail and an 
outlook is given on network inference and its use in computational medicine.
7.1. Discussion of main results
When comparing to baseline transcript levels, stronger gene expression changes were always 
observed  relatively  early  in  therapy,  suggesting  adaptations  that  occur  as  a  homeostatic 
response to the drugs. Functional analysis of the up- and down-regulated genes revealed an 
overrepresentation  of  immunologically  relevant  genes:  For  all  three  therapies,  genes 
associated to the Gene Ontology (GO) terms "immune system process", "immune response" 
and "defense response" were significantly enriched in the sets of filtered genes. However, 
genes  annotated  with  these  high-level  GO terms  may  accomplish  quite  diverse  immune 
functions,  and  only few genes  were  found influenced  by each of  the  three  investigated 
biologic agents. As shown in figure 3A, three genes were significantly modulated not only in 
response to Etanercept in RA patients, but also in response to both IFN-β preparations in MS 
patients:  junction  plakoglobin  (JUP),  clusterin  (CLU),  and  Fc  IgE  receptor,  alpha 
polypeptide (FCER1A). All three genes were differentially regulated between the therapies 
(figure 3B) and it is therefore difficult to judge their general therapeutic role. Nevertheless, 
common cellular and molecular components are presumably influenced by the treatments. 
As could be expected, there is a considerable overlap (27 genes) when comparing the lists of 
filtered genes of the both MS therapies.
In the pharmacodynamic studies on Etanercept and Avonex, the regulatory regions of the 
genes with significant expression changes were screened for overrepresented evolutionarily 
Discussion 105
conserved TFBS. In this way, TFs were identified that putatively play a role in mediating the 
drugs' gene regulatory effects. For instance, the DNA sequence motif for CCAAT/enhancer 
binding protein beta (CEBPB), a TF that has been associated to chronic inflammation in RA 
[27], was found for 11 out of the 83 genes responsive to Etanercept. Binding sites for NF-κB 
and the IFN regulatory factors 1 and 2, which are known TFs in IFN-β signaling [26], were 
overrepresented in the promoter region of genes modulated during first month of IFN-β-1a 
therapy. TATA-like elements and binding sites for Zic family members (ZIC) 1-3 as well as 
hepatic nuclear factor 1 homeobox A (HNF1A) were found enriched in both analyses. This 
again indicates that the therapies might share some immunoregulatory activities.
The  information  on  overrepresented  TFBS  was  then  used  to  reconstruct  the  regulatory 
interactions between respective TFs and the filtered genes using the novel TILAR inference 
method. TILAR stands for TFBS-integrating least angle regression. "TFBS-integrating" here 
means that the method integrates gene expression data and TF binding predictions to infer a 
linear GRN model,  and the "least angle regression" (commonly abbreviated LARS) is an 
Figure 3. Several genes were found modulated in more than one of the three studies. (A) 
Overall, 83 genes were up- or down-regulated during first week of Etanercept therapy in RA 
patients. Similarly, 193 and 121 genes were filtered by analyzing the expression profiles of 
MS patients receiving Betaferon and Avonex, respectively. For the latter two, the first month 
into treatment was considered here for better comparability, even if in the Betaferon study 
gene expression was also measured at later time points (after  one and two years).  Three 
genes occur in each of the gene lists. (B) These three genes are differentially regulated in 
response  to  the  different  treatments  (up-regulation:  red  arrow,  down-regulation:  green 
arrow).  However,  the  therapeutic  effects  can  only  be  compared  qualitatively  rather  than 
quantitatively.  The studies are about different therapies to different diseases, and as their 
comparison was not an issue from the very beginning, the obtained microarray data were 
analyzed independently, e.g. using different chip definitions and gene filtering criteria.
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efficient regression algorithm that was employed to determine the model parameters on the 
basis of the data [28]. TILAR considers genes and TFs as two distinct types of nodes in the 
network and defines directed TF-gene and gene-TF interactions as network edges (figure 4). 
Only  the  transcript  levels  of  the  genes  are  required  for  learning  the  model.  TF protein 
activities are described implicitly by the genes that influence the TFs. TILAR constrains the 
model to include a TF-gene interaction only when the TF is predicted to bind the regulatory 
region of the gene and is thus presumably involved in its transcriptional regulation. Hence, 
TF-gene interactions can be interpreted as true physical interactions between TF proteins and 
gene promoter DNA sequences. In contrast,  gene-TF interactions can have very different 
meanings and may represent indirect effects (e.g. through a signaling cascade). They are 
therefore difficult to augment by external information in general. For reverse-engineering the 
GRNs  relevant  to  Etanercept  and  Avonex  therapy  no  prior  knowledge  on  gene-TF 
interactions was incorporated. However, it has been demonstrated in both studies that if such 
knowledge would be available to a certain degree (e.g. from text-mining), it can be utilized 
to further increase the quality of the inferred networks (adaptive TILAR). Moreover, in both 
works, TILAR and its adaptive variant outperformed all other tested inference algorithms 
that utilize either gene expression data or TFBS information alone. The performance was 
evaluated  using gene interaction  information  provided by the software PathwayArchitect 
2.0.1. PathwayArchitect contains molecular relationships which have been extracted from 
biomedical  literature  using  text-mining  and  different  curated  biological  databases.  Data-
driven modeling by TILAR was not (yet)  applied to the Betaferon dataset.  Here, filtered 
gene  lists  were  just  imported  into  PathwayArchitect  to  retrieve  interactions  between the 
genes modulated during long-term therapy.
As a result, relatively large gene interaction networks were built in each study. The networks 
reveal insights into gene regulatory processes that may play a crucial role in the treatment of 
RA  and  relapsing-remitting  MS,  and  thus  are  useful  for  generating  new  and  testable 
hypotheses  on  the  drugs'  molecular  mechanisms  of  action.  To  further  scrutinize  the 
transcriptional effects in particular early in therapy, respective complex interaction patterns 
were  then  analyzed  in  more  detail.  Sparseness  /  scale-freeness,  decentralization,  self-
regulation and co-regulation are characteristic for the inferred networks. These features are 
discussed to enhance a GRN's robustness in terms of structural stability [4,29]. Some genes 
that are annotated to the same GO term share a common TFBS in the models. An example 
was  given  in  manuscript  II,  where  four  network  genes  belonging  to  "immune  system 
process" are all regulated in a TATA-dependent manner. Beyond, to some extent, the GRNs 
reconstructed  by  TILAR  could  show  clinical  heterogeneity  among  the  patients:  Genes 
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differentially expressed between responders and non-responders were connected to the same 
TF (NF-1) in the Etanercept RA therapy study. Similarly, in the Avonex study, an NF-κB-
centered network region of IFN-β-responsive genes was found to coincide with therapeutic 
side effects.  This  demonstrated  that  improving the knowledge on gene regulation during 
therapy and correlating expression differences in the network with clinical data may disclose 
signatures that could allow the prognosis of beneficial and adverse responses to the drugs.
7.2. Discussion of methods
7.2.1. Experimental approach
In each of the presented works, gene expression profiles were analyzed for a homogeneous 
cohort of patients who all were prescribed the same treatment (co-medications ignored) at 
the same clinic. The microarray data used in manuscript II provided expression levels for 19 
RA patients. Each patient was given a standard dose of 25 mg Etanercept subcutaneously 
twice  weekly,  and blood was  taken  before  first,  second  and third  drug injection,  i.e.  at 
baseline as well  as after  3 and 6 days.  The pharmacodynamic  effects  of the both IFN-β 
preparations were investigated separately to account for differences in dose and route of drug 
administration, and their different immunogenic properties [30]. For instance, the frequency 
of injections differs: Avonex is given once a week, while Betaferon is given every other day. 
Figure 4. The GRN model from figure 1 and its representation according to the TILAR 
modeling approach. (A) Figure 1B revisited: When inferring a network from gene expression 
data only, one seeks for influences between RNA transcripts. In this case, edges in the model 
not necessarily correspond to true/causal molecular relationships. (B) In comparison, TILAR 
incorporates  TFBS  predictions  and  constrains  genes  to  regulate  other  genes  via  TFs. 
Interactions  between  genes  are  then  implicitly  defined  in  the  network  by  gene-TF  and 
TF-gene interactions. In this exemplary model, two genes control the activity of a TF and 
therefore  the  transcription  of  its  target  gene,  which  is  a  bit  closer  to  the  more  realistic 
regulation scheme shown in figure 1A.
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Blood samples were again drawn always immediately before injection, i.e. two days and one 
week  after  previous  IFN-β injection  in  case  of  Betaferon  and  Avonex,  respectively.  In 
comparison to Betaferon, which is given subcutaneously,  the serum concentrations of the 
latter (IFN-β-1a) may be sustained after its intramuscular administration due to prolonged 
absorption from the injection site. Though, as discussed in manuscript IV, the list of genes 
with expression changes during Avonex therapy is expected to contain many genes indirectly 
modulated  as  a  consequence  of  the  activity  of  early  IFN-β-responsive  genes.  This  also 
explains  the certain  but  relatively small  overlap  (27 genes)  when comparing  the lists  of 
filtered genes of both IFN-β treatments (figure 3A).
Another important consideration is that the microarray data revealed the gene expression 
levels  of  PBMC.  The  PBMC  fraction  contains  monocytes  and  lymphocytes,  the  latter 
comprise  natural  killer  cells  (NK cells),  T  cells  and B cells.  Therefore,  even if  PBMC 
generally allow to immunologically assess therapeutic effects, one should be aware that the 
contribution of the different  cell  types  was neglected in the studies.  In consequence,  the 
reconstructed  molecular  networks  represent  complex  intracellular  as  well  as  intercellular 
interactions. Ongoing research efforts aim to further fractionate the immune cell populations 
to analyze the behavior of specific cells. Besides, to better understand autoimmune disease 
processes and the mechanisms of immunomodulatory drugs, it is also crucial to investigate 
the role of the target tissues, in connection with the infiltrated cells of the immune system. 
As the presented analyses followed an immune-centered view and focused on the expression 
alterations  of  immune  cells,  the  mutual  interactions  between  immune  system and target 
tissue factors (e.g. of the synovium in case of RA) were out of scope.
7.2.2. Microarray data preprocessing
Before  reconstructing  the  regulatory  interactions  between  genes  up-  or  down-regulated 
during  therapy  via  TILAR,  the  microarray  data  were  preprocessed  using  custom  chip 
definition files (CDF). The original Affymetrix chip definitions contain probes which do not 
match any transcript and probes which cross-hybridize to transcripts of multiple genes. They 
also  represent  many  genes  by  more  than  one  probeset,  which  often  leads  to  discordant 
expression signals for the same transcript. Custom CDF provide an improved annotation of 
Affymetrix  probesets  and  realize  a  one-to-one  correspondence  to  genes  [31].  In 
consequence,  when the data  are  preprocessed by use of  a  custom CDF, genes and their 
expression levels can be unequivocally assigned to nodes in the network model. In general, 
this makes it easier to extend and validate the interaction network with external molecular 
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information from biological databases. In addition, it not only alleviates an integrative GRN 
modeling,  but  also  eases  the  interpretation  of  such  networks.  In  the  pharmacogenomic 
studies on anti-TNF-α and intramuscular IFN-β treatment, up-to-date custom CDF that are 
based on information contained in the GeneAnnot database were used to process the raw 
probe intensities [31,32]. Custom CDF for microarrays for other organisms than human are 
available elsewhere [33].
Next, genes differentially expressed during therapy compared to baseline were selected to 
infer the underlying regulatory interactions from the data. As described in more detail  in 
manuscript I, there is a strong relationship between network complexity (i.e. network size 
and level of detail of the model), the amount of data required for inference and the quality of 
the  results.  In  the  presented  works,  the  self-developed  MAID  filtering  approach  in 
combination with a paired t-test statistic was used to filter genes with significant expression 
changes  during  treatment.  MAID  considers  the  shape  of  MAS5.0-processed  (and  loess 
normalized) Affymetrix microarray data and yields signal intensity-dependent fold-changes 
(see also section "Methods" in manuscript II). Afterwards, the TILAR algorithm was applied 
to reconstruct the network of 83 filtered genes measured on 55 microarrays in the Etanercept 
study, and the network of 121 genes (72 microarrays) in the study on the effects of Avonex 
administration. Since the TILAR strategy generally reduces the number of free linear model 
parameters (see discussion below), the respective amount of expression data was considered 
sufficient for modeling such medium scale GRNs. From the mathematical perspective, the 
inference of even larger networks is possible, but would certainly generate structures that are 
less reliable and more difficult to study further.
7.2.3. Integrative network inference
Network inference by TILAR is based on the linear modeling approach. In comparison to 
other modeling formalisms, linear models have a number of benefits: they allow to describe 
the direction of interactions as well as feedback and feedforward loops, and take into account 
that gene regulators act in combination. Moreover, as regulatory relationships are specified 
quantitatively, no prior discretization of the data is necessary (as e.g. for Boolean networks). 
A disadvantage is that linear models are only crude linearizations of the true system as in 
fact gene regulation is a dynamic non-linear process including saturation and stochasticity. 
However, as a system of non-linear equations consists of much more model parameters, and 
because the "true" form of these equations is usually not known, linear models are often 
preferred for modeling GRNs. In general,  linear  functions are  appropriate  to capture the 
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main features  of a GRN when similar  conditions  have been measured in  the microarray 
experiments [34].
The  major  advantage  of  linear  models  is  that  computationally  very  efficient  (and 
deterministic) algorithms exist to estimate the model parameters, i.e. to fit the model to the 
given  data.  TILAR  utilizes  the  Lasso  (least  absolute  shrinkage  and  selection  operator) 
method for linear regression [35]. The Lasso minimizes the residual sum of squares subject 
to the sum of the absolute value of the model parameters being less than a constant (bound 
s). In dependence on this tuning value s, this constraint produces some parameters that are 
exactly zero and hence gives sparse models. The implementation of TILAR employs the 
efficient LARS procedure for fitting the entire Lasso sequence (i.e. for all values of s) with 
the cost of a single ordinary least squares (OLS) fit [28]. It is also possible to compute all 
Lasso solutions if the system of linear equations is underdetermined, that is, if there are more 
model  parameters  (p)  than  equations  (n).  As  a  drawback,  there  is  a  conflict  of  optimal 
parameter setting (low fitting error) and consistent parameter selection in the Lasso, which 
led to the use of a LARS/OLS hybrid in TILAR [28]. Other regression concepts have been 
proposed to better solve this conflict, e.g. the relaxed Lasso and the elastic net [36,37]. The 
elastic  net has the capacity of selecting groups of highly correlated  p and is  particularly 
suited for the  p>>n case. The strength of the elastic net was observed in a DREAM 2008 
(dialogue  on  reverse-engineering  assessment  and  methods)  challenge,  where  the  best 
performing  algorithm  in  predicting  missing  gene  expression  measurements  utilized  the 
elastic net [38]. However, relaxed Lasso and elastic net define in their constraint function a 
second tuning value in addition to s, which needs to be determined e.g. by cross-validation 
and therefore increases the computational efforts.
TILAR is an integrative GRN modeling approach that merges information from different 
types of data to increase the chance of inferring true regulatory effects. It combines the RNA 
expression  data  with  TFBS  predictions  and,  if  available,  literature-mining  information 
(adaptive  TILAR).  A  soft  integration  is  the  concept  to  include  the  additional  but  also 
uncertain information [34]. That means prior knowledge on TF-gene and gene-TF edges is 
used to increase the probability for an edge, and not merely as a filter. TILAR incorporates 
only a subset of the predicted TF-gene interactions obtained from TFBS analysis. This was 
realized  by  a  backward  stepwise  selection  procedure  that  iteratively  applies  LARS  for 
respective  subsets until  a local  error minimum is found. As a remark,  although a single 
LARS calculation takes only a few seconds, this backward selection can be computationally 
demanding if  the network to be inferred  is  very large.  Besides,  in  the adaptive  TILAR, 
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literature evidence from PathwayArchitect  is  softly integrated  by putting less penalty on 
model parameters that represent gene-TF interactions suggested by text-mining than on those 
not  suggested.  Due  to  the  TFBS-integrating  constraint  in  TILAR,  all  target  genes  of  a 
particular TF receive the same regulatory input. More importantly, the number of free model 
parameters is generally reduced: p is bound by the product of the number of genes and the 
number of TFs in the GRN. It is therefore feasible to reconstruct relatively large networks.
The inference quality of TILAR not only depends on the quality of the gene expression data, 
but also on the accuracy of TFBS (and text-mining) information. For human, experimental 
evidence  for  TFBS  is  still  scarce  and  scattered,  but  different  databases  provide 
computationally predicted TFBS. Most of them rely on known binding motifs searched in 
the genome and filtered for cross-species sequence conservation and/or motif combinations 
(i.e. co-localized TFBS clusters). Examples for such databases are UCSC tfbsConsSites (that 
was used in the studies), cisRED, SwissRegulon and oPOSSUM [39-42]. The latter three 
also contain TFBS for other organisms than human, but limit the predictions to predefined 
promoter regions, and all differ in their contents. Moreover, not all predicted TFBS refer to 
biologically functional  binding sites as TF-DNA bindings depend on several factors,  e.g. 
nucleosome occupancy. A further issue is that often more than one (similar) binding motif is 
associated to a particular TF in these databases.  However, sufficient  prior knowledge on 
gene-TF interactions  is even more difficult  to obtain because of their  variable  meanings. 
In the  proposed  adaptive  TILAR,  text-mining  information  was  integrated  as  prior 
knowledge.  A  text-mining  approach  is  able  to  detect  indirect  gene  interactions,  but  a 
drawback is that such information (independently of the software used) is always incomplete 
and biased (there are  per se less interactions described in the literature for less prominent 
genes), error-prone (in particular concerning the direction of interactions), and not disease- 
or cell type-specific.
7.2.4. Evaluation of inference performance
The performance evaluation of a GRN inference method, i.e. the assessment of sensitivity 
and specificity of reconstructed interactions, is a fundamental problem in the field. Only first 
attempts  have  been  made  to  establish  standardized  benchmarking  systems  and  criteria. 
Notably, the DREAM initiative is dedicated to the understanding of limitations and strengths 
of methods for inferring networks from biological data [43]. The project aim is to create gold 
standards  for  network  inference  by  providing  datasets  and  defining  common  objective 
evaluation  measures.  Since  2007,  DREAM  arranges  annually  competitions  on  reverse-
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engineering networks and on predicting expression levels using networks. The true structure 
of  these  networks  (and/or  additional  experimental  data)  is  known to  the  organizers,  but 
hidden  to  the  community.  Research  groups  are  asked  to  submit  the  results  of  their 
algorithms,  thereby  getting  the  opportunity  to  assess  and  compare  them  with  the 
performance of others.
However, TILAR has not been evaluated within DREAM since so far the challenges did not 
(or only in parts) include the issue of integration of various types of data. For real network 
data  gene  names  were  sometimes  withheld  and  in  silico data  can  not  be  augmented  by 
additional  information  at  all.  The  performance  of  TILAR  has  therefore  been  rated  by 
comparing  the  inferred  networks  (i.e.  the  respective  path  of  models  produced  by  the 
algorithm,  from  an  empty  to  a  fully  connected  network)  with  gene-gene  interactions 
extracted from PathwayArchitect (manuscript II and the supplemental material to manuscript 
IV given in the appendix). For this analysis, genes well-described in literature were selected 
so that PathwayArchitect delivered hundreds of interactions. As TILAR distinguishes genes 
and TFs, the information integrated during modeling was different from the information used 
to evaluate the method. Performance measures that were also proposed in DREAM [44], 
namely RPC (recall-precision curves) and ROC (receiver operating characteristic)  curves, 
have been applied in the benchmarking.  As a result,  TILAR achieved superior accuracy 
compared  to  other  GRN  inference  algorithms  in  both  benchmarking  studies,  which 
independently demonstrated the benefit of an integrative modeling. Still, for a general two-
class prediction problem, the attained areas under the RPC and ROC curves might seem 
rather  modest.  However,  this  is  somewhat  misleading  as  discussed  in  more  detail  in 
manuscript I. A main reason for "low" performance lies in the text-mining information used 
for  the  assessment.  This  is  incomplete  and  contains  errors,  and  thus  is  only  a  "bronze 
standard". In consequence, even a GRN inference method which delivers almost the "true" 
network would not reach areas under these curves close to 1 (figure 5).
Still,  the outcome of a GRN reconstruction should always  be taken with some care and 
validated  by  arguments  outside  the  analysis.  This  may  include  the  confirmation  of 
expression changes (e.g. for selected genes), the verification of regulatory effects postulated 
in the network (e.g.  the DNA-binding of certain TFs), the determination of protein level 
alterations (e.g. for TFs in the GRN) and new cell type-specific in vitro perturbation assays 
to quantify time-dependent responses. The GRN models thus may be a starting point for 
additional experiments.
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7.3. Open issues and outlook
7.3.1. Prediction of clinical responses
The three drugs, for which the blood transcriptional responses were investigated, are well 
established in the therapy of RA and MS today. Nevertheless, the frequency of injections, 
the side effects that particularly occur at the beginning of therapy, and the treatment failures 
are all reasons to search for optimized treatment strategies. The ultimate goal is to identify, 
as early as possible, the patients that will benefit the most from a specific medication. This 
would  eventually  allow  for  a  more  individualized  treatment  and  disease  monitoring 
(personalized  medicine),  and increase both clinical  efficacy and cost-effectiveness  of the 
therapies.  The  identification  of  patients  with  a  favorable  prognosis  must  also  consider 
potential side effects. A better drug tolerability usually leads to enhanced compliance, and 
thus can positively affect long-term clinical outcomes [45,46].
Different therapeutic responses might be reflected in transcriptional differences between the 
patients, possibly in the magnitude of transcriptional changes early in therapy. Therefore, an 
improved pharmacodynamic understanding can help to individually optimize autoimmune 
disease therapies. Molecular markers to discriminate "good" from "poor" responders and to 
discern patients at high risk for (persistent) adverse effects have already been proposed in the 
literature for RA [47,48] and MS [49-51]. In perspective, transcript analyses of such genes 
Figure  5. Relationships  among  inferred,  text-mining-based,  and  real  network.  The  text-
mining network (in each of both independent  benchmarking analyses)  was composed of 
PathwayArchitect-retrieved  regulatory  gene  interactions  and  contains  some  incorrectly 
assigned false positives.  This network is a subset of the actual (genome-wide and multi-
level) transcriptional network, represented in the figure as the "real network". The network 
reconstructed using TILAR or another algorithm ("predicted network") also includes falsely 
identified connections. A small overlap of the predicted and the text-mining network leads to 
relatively low performance measures.
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with prognostic value could become part of a routine laboratory screening and serve as input 
for  algorithm-based  risk-benefit  prediction.  In  the  studies  on  Etanercept  and  Avonex 
(manuscript  II  and IV),  coherent  sub-networks were found, which are enriched of genes 
differentially expressed between patient subgroups (according to clinical response and side 
effects,  respectively).  However,  the  true  clinical  relevance  of  these  genes  remains  to  be 
further examined.
7.3.2. Further development of TILAR
One  can  think  of  many  extensions  and  possible  improvements  to  the  integrative  GRN 
modeling  using  TILAR.  For  instance,  the  modeling  framework  can  be  adapted  to  infer 
dynamic models given appropriate time-course data (i.e. with short intervals between two 
successive measurements). Such a dynamic model can be interpreted as a linearization of the 
true non-linear regulatory functions around a working point (first-order approximation). As 
outlined in the introduction,  the model then corresponds to a system of linear difference 
equations and assumes equidistant intervals between the time points. If non-equidistant data 
are given, one might therefore interpolate intermediary time points before inference (see also 
section "data requirements" in manuscript I). Dynamic linear models allow to simulate and 
analyze the behavior of the network. An eigenvalue analysis of matrix W (that contains the 
gene-gene edge weights) can show whether the network is stable in time against random 
fluctuations (dynamical  stability).  Though, so far, no efficient algorithm for learning this 
kind of models exists that includes dynamical robustness as a modeling constraint.
A linear model may be dynamically unstable just because stabilizing non-linear effects are 
not captured. Other researchers therefore introduced non-linear functions, while still utilizing 
the  efficient  mathematical  techniques  for  fitting  linear  models  [52,53].  For  instance,  a 
sigmoid influence function may be used for dynamic models to take into account saturation 
effects. Such non-linearity can be simply realized by transforming the gene expression data 
accordingly.  The  trick  is  that  the  reverse-engineering  problem  becomes  linear  on  the 
transformed data. If the model is then used for simulation studies, the model outputs must be 
retransformed again. However, the use of (possibly coupled) non-linear terms might be in 
conflict with experimental data requirements and can increase the risk of model overfitting 
and complicate model interpretation.
Furthermore, the TILAR method can be modified to softly integrate knowledge on (binary) 
protein-protein interactions (PPI), e.g. from the IntAct database [54]. Here, one could follow 
an approach that was applied by Nariai et al. [55] and Bonneau et al. [56]: In brief, the idea 
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is to describe PPI in the network model by use of virtual nodes corresponding to protein 
complexes.  This  can be done by inserting additional  columns  (model  parameters)  to  the 
regression matrix of the regression problem that is solved by LARS. The final model then 
might (softly) include a protein complex if this allows for a better fit to the expression data. 
PPI were not incorporated in the presented studies, because only one protein hetero-dimer 
was found in the list of anti-TNF-α-responsive genes (EBI-360918: NFKBIA-TUBA1A) and 
none for the genes transcriptionally modulated by IFN-β.
Other  biological  databases  can  be  used  either  to  obtain  prior  evidence  on  gene-TF 
interactions or as an alternative way to evaluate the inference performance. For instance, one 
can use publicly available microarray data, e.g. from the Gene Expression Omnibus database 
[57]. In general, the quality of external gene expression data is difficult to assess. Besides, 
the data comprise various experimental conditions that are not related to RA and MS disease 
conditions and where different regulatory processes are active.  Although the benefit may 
thus be limited, it is possible to softly integrate such data during GRN inference, in TILAR 
by defining lower penalties for gene-TF edges if the external data support a transcriptional 
correlation between the gene and the TF or the gene and a gene putatively controlled by the 
TF. Microarray databases also contain TF binding data (e.g. from tiling arrays) which can 
provide  useful  information  on  TFBS  (and  therefore  TF-gene  edges).  The  capability  of 
including public microarray data into the learning of linear GRN models via a Lasso-type 
shrinkage was shown by Gustafsson et al. [38].
A more difficult challenge is to integrate signaling pathway information, which would mean 
to link signaling networks with GRNs – from a historical point of view two distinct classes 
of cellular networks. The major difficulties here are that many different pathway databases 
with different data formats exist [58] and that the contained signaling cascades are rarely 
associated to the transcription of specific gene sets. Two efforts should be mentioned that 
promise to ease the central access and the use of such information in the future. First, the 
Pathway Commons project which aims to provide a convenient point of access to biological 
pathway  information  collected  from  public  pathway  databases  [59].  Second, 
ConsensusPathDB, a (meta-)resource of curated human signaling pathways that also lists 
genes  transcriptionally  regulated  by  the  pathways  [60].  When  using  such  databases, 
respective  gene relationships  (even indirect  ones,  i.e.  if  two genes  are  connected  via  an 
interaction path) may be integrated by TILAR as prior knowledge on gene-TF or TF-gene 
interactions.
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Further  extensions  in  TILAR are conceivable:  1)  A scale-free constraint  might  be more 
powerful  than  the  sparseness  constraint  realized  by  the  Lasso.  However,  no  efficient 
algorithm  to  consider  scale-freeness  during  reconstruction  of  linear  models  has  been 
developed yet. 2) The backward stepwise selection step in TILAR is a bit time-consuming 
and  might  be  improved  by  use  of  other  heuristics  or  by  prioritizing  predicted  TF-gene 
interactions by additional criteria (e.g. motif score or distance to the transcription start site). 
3) Penalties for known gene-TF edges might be set lower the more often this interaction can 
be found in the literature-mined information or if an molecular biology expert considers this 
interaction as particularly important.
7.4. Concluding remarks
Manuscript  II-IV demonstrate  the use of network analysis  to provide novel  insights into 
functional  mechanisms  of  immunomodulatory  therapies  for  RA  and  MS.  The  newly 
developed TILAR approach, which allows to integrate different types of data during GRN 
modeling, may find applicability in a wider context, e.g. to infer gene regulatory interactions 
relevant in other conditions or even in other organisms. The reconstructed networks yield 
useful information on the genes responsive to the respective treatments, and the TFs that are 
assumed to mediate their transcriptional regulation. The networks show the existence of hubs 
and network motifs (e.g. feedback loops), and a scale-free distribution of node degrees. They 
also  describe  sub-networks  of  genes  co-regulated  by  a  common  TF  and  genes  with 
functional similarity (e.g. genes known to participate in certain immune system processes). 
In  addition,  specific  network  regions  expose  expression  differences  of  possible  clinical 
relevance in the patients. Therefore, this work is one further step towards understanding the 
molecular mechanisms underlying the effects of biologic agents in RA and MS patients.
Still, there is a gap to close between molecular events and clinical outcomes. Little is known 
about the precise factors that account for beneficial and adverse therapeutic effects in the 
individual patient. To increase the efficacy of available drugs it is important to identify and 
establish  predictive  biomarkers  that  allow  for  a  more  individualized  medication  and 
treatment monitoring. In future, such markers may guide clinicians in choosing the optimal, 
tailored treatment dependent on the patient's molecular and clinical attributes. Besides, novel 
drugs will offer improved mechanisms of targeting autoimmune diseases while minimizing 
side effects. As a single drug seems less likely to entirely block a polygenic complex disease 
like RA or MS, combination therapies may be the key for a more successful treatment.
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These promising perspectives require an improved knowledge on the biological processes 
related to these diseases. Integrative bioinformatics in the field of computational medicine, 
which here includes the investigation of GRNs, can help to better understand the biology of 
human diseases and their treatment. In the long term, advancements in bioinformatics and 




Autoimmune diseases are disorders where an aberrant immune response leads the body to 
attack  its  own  cells  and  organs.  Two  common  diseases  with  an  autoimmune  basis  are 
rheumatoid arthritis (RA) and multiple sclerosis (MS). Their complex genetic background in 
concert with environmental factors causes considerable differences between the patients in 
clinical  presentation  and response to  treatments.  The introduction  of  immunomodulatory 
biologic  drugs  significantly  improved  the  treatment  of  these  diseases.  For  instance, 
TNF-α-antagonists  (e.g.  Etanercept)  and  IFN-β (e.g.  Betaferon  and  Avonex)  have  been 
proven to reduce symptoms and progression of RA and relapsing-remitting MS, respectively. 
However, to date, our knowledge on the underlying molecular mechanisms and the efficacy 
and safety of these drugs is still limited.
In this  work,  the transcriptional  effects  induced by these three therapies  were studied to 
provide a deeper molecular understanding of the drugs' immunotherapeutic mechanisms. The 
analyses included network inference techniques to reconstruct the gene regulatory networks 
(GRNs) of therapy-responsive genes. The starting point of each analysis was an Affymetrix 
DNA microarray dataset. For groups of patients, the data provided gene expression levels in 
peripheral  blood  mononuclear  cells  (PBMC)  immediately  before  first  and  selected 
subsequent  drug  administrations.  This  allowed  to  investigate  the  general  changes  in 
expression  within  the  first  days  (Etanercept),  weeks  (Avonex)  and years  (Betaferon)  of 
therapy.  Newly  devised  MAID scores  were  utilized  to  filter  genes  that  characterize  the 
biological response to the treatments. After start of each therapy, many genes were signifi-
cantly up- or down-regulated compared to their expression before therapy initiation. Most of 
them are known to participate in immune system processes. The transcription factors (TFs) 
that are putatively involved in the regulation of these genes were ascertained by screening 
the genes' regulatory regions for overrepresented TF binding sites (TFBS) (Etanercept and 
Avonex study only). Several TFBS were detected, e.g. as could be expected, DNA-binding 
sites for IFN regulatory factors (IRF) were enriched for IFN-β-1a-modulated genes.
Afterwards,  interactions  between  the  genes  with  significant  expression  changes  during 
therapy were examined. In the study on the effects of Betaferon treatment, gene interaction 
networks were built  using literature-mining information.  In the other two studies,  a self-
developed network inference algorithm called TILAR was used to deduce a model of the 
underlying GRN from the gene expression data. TILAR distinguishes genes and TFs in the 
network  and mathematically  describes  the  mutual  regulatory  effects  between them by a 
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system of linear equations. TILAR is an integrative modeling strategy that constrains the 
model to only include a TF-gene interaction,  when the TFBS overrepresentation analysis 
predicts that the TF binds at the regulatory region of the gene. The method is also able to 
(softly) incorporate evidence on gene-TF interactions, if some genes are known to control TF 
activities (adaptive TILAR). According to the presented approach, genes are supposed to 
regulate other genes in a linear additive relationship indirectly via one or more TFs. This 
results  in  a  relatively  low  number  of  free  model  parameters  and  makes  the  models 
straightforward  to  interpret.  Two  benchmarking  analyses  demonstrated  that  TILAR 
reconstructs GRNs more reliably than other established inference algorithms. Moreover, the 
integrative modeling allows for a higher prediction accuracy than using just gene expression 
data or TFBS information alone. Apart from that, TILAR is adaptable and extensible and 
thus may be applied also in other applications.
As a result, complex interaction structures were obtained, which describe the gene regulatory 
effects in response to each of the three treatments and thus provide useful hypotheses about 
the drugs' molecular mechanisms of action.  The networks show a self- and co-regulatory 
organization  and  a  scale-free  topology.  Moreover,  the  GRNs  inferred  by  TILAR  were 
analyzed  in  the  context  of  clinical  data:  An NF-κB-linked gene  sub-network was found 
higher expressed in MS patients with side effects to intramuscular IFN-β-1a administration. 
Similarly,  a  network  region  was  lower  expressed  in  clinical  responders  in  the 
pharmacodynamic study on Etanercept RA therapy.
These findings showed that GRN analysis integrating different types of data as well as prior 
biological knowledge can contribute to the investigation of treatment-associated processes, 
and reveal different expression patterns in the patients.  Implications of clinical  relevance 
have been discussed for RA and MS therapy. Further studies are required to establish early 
indicators of long-term therapeutic outcomes and potential adverse effects. In future, new 
techniques  in  biotechnology  and  bioinformatics  and  the  growing  amount  of  available 
experimental data should allow for more comprehensive network models of transcriptional 
regulation, and thus help to study (individual) molecular therapeutic effects in more detail.
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9. Zusammenfassung
Autoimmunerkrankungen sind Krankheiten, bei denen sich eine fehlgeleitete Immunantwort 
gegen  körpereigene  Zellen  und Organe  richtet.  Unter  anderem werden die  Rheumatoide 
Arthritis (RA) und die Multiple Sklerose (MS) als Autoimmunkrankheiten eingestuft. Ein 
komplexes,  bisher  unverstandenes  Zusammenspiel  aus  Umweltfaktoren  und  genetischer 
Veranlagung spielt bei der Pathogenese dieser beiden Krankheiten eine entscheidende Rolle 
und  führt  dazu,  dass  Krankheitsausprägung  und  -verlauf  von  Patient  zu  Patient  recht 
verschieden sind. Zur Behandlung dieser Krankheiten werden auch immunmodulatorische 
biologische Medikamente eingesetzt. So können TNF-α-Blocker (z.B. Etanercept) im Falle 
der  RA  und  IFN-β-Präparate  (z.B.  Betaferon  und  Avonex)  im  Falle  der  schubförmig 
remittierenden  MS  Krankheitssymptome  lindern  und  das  Fortschreiten  der  Erkrankung 
verzögern. Bis heute sind jedoch die zugrunde liegenden molekularen Mechanismen dieser 
Therapien weitestgehend unbekannt.  Zudem ist  ihre Wirksamkeit  und Verträglichkeit  bei 
einigen Patienten unzureichend.
In dieser Arbeit wurde die transkriptionelle Antwort auf die drei genannten Therapien unter-
sucht, um die Wirkungsweise dieser biologischen Medikamente besser zu verstehen. Dabei 
wurden Methoden der Netzwerkinferenz eingesetzt,  mit  dem Ziel,  die genregulatorischen 
Netzwerke (GRNs) der in ihrer Expression veränderten Gene zu rekonstruieren. Ausgangs-
punkt  dieser  Analysen  war  jeweils  ein  Affymetrix-Mikroarray-Datensatz.  Diese  Daten 
lieferten für eine Gruppe von Patienten Informationen über die Genexpression peripherer 
mononukleärer Blutzellen (PBMC) zu verschiedenen Therapiezeitpunkten: unmittelbar vor 
der  ersten  Injektion  sowie  vor  ausgewählten  nachfolgenden  Medikamentengaben.  Der 
Beobachtungszeitraum  erstreckte  sich  dabei  über  mehrere  Tage  (Etanercept),  Wochen 
(Avonex) bzw. Jahre (Betaferon). Mit Hilfe der neu entwickelten MAID-Scores wurden die 
Gene gefiltert, die nach Therapiebeginn besonders stark hoch- bzw. herunterreguliert sind. 
Es stellte sich heraus, dass die Mehrheit dieser Gene bei Immunsystemprozessen beteiligt ist. 
In  der  Avonex-  und  Etanercept-Studie  wurden  anschließend  die  genregulatorischen 
Regionen  dieser  Gene  auf  überrepräsentierte  Transkriptionsfaktor-Bindestellen  (TFBS) 
analysiert,  um  so  auf  Transkriptionsfaktoren  (TF)  zu  schließen,  die  potentiell  deren 
Expression maßgeblich regulieren.
Anschließend wurde untersucht, welche wechselseitigen Interaktionen zwischen den Genen 
bestehen, die unter Therapie moduliert werden. In der Betaferon-Studie wurden dazu ent-
sprechende  Geninteraktionsnetzwerke  mit  einer  Text-Mining-Software  erstellt.  In  den 
Zusammenfassung 121
anderen  beiden  Studien  wurde  ein  neu  implementierter  Netzwerkinferenz-Algorithmus 
(TILAR)  verwendet,  um  GRN-Modelle  direkt  aus  den  Genexpressionsdaten  abzuleiten. 
TILAR unterscheidet grundsätzlich zwischen Genen und TF und beschreibt die regulator-
ischen Effekte zwischen diesen durch ein lineares Gleichungssystem. TILAR verfolgt dabei 
eine integrative Modellierungsstrategie, da nur solche TF-Gen-Interaktionen erlaubt sind, für 
die die TFBS-Überrepräsentationsanalyse ergab, dass der TF in der regulatorischen Region 
des Gens binden kann. Die Methode erlaubt auch Vorwissen über bekannte Gen-TF-Inter-
aktionen adaptiv einzubeziehen. Diese bilden ab, dass ein Gen (möglicherweise indirekt) die 
Aktivität eines TFs kontrolliert. Vorteile dieses linearen, integrativen Modellierungsansatzes 
sind zum einen die  relativ  geringe  Anzahl  freier  Modellparameter  und zum anderen  die 
einfache Interpretierbarkeit der resultierenden Modelle. Zwei unabhängige Benchmark-Tests 
zeigten, dass TILAR eine bessere Netzwerkrekonstruktion ermöglicht als andere Inferenz-
verfahren. Die Modellgüte ist höher, als wenn nur Genexpressionsdaten oder nur TFBS-Vor-
hersagen für die Inferenz der genregulatorischen Interaktionen verwendet werden würden.
Im Ergebnis wurden komplexe Netzwerkstrukturen rekonstruiert, welche die regulatorischen 
Beziehungen zwischen den Genen beschreiben, die im Verlauf der Therapien differentiell 
exprimiert  sind.  Aus  diesen  lassen  sich  neue  Hypothesen  über  die  Wirkungsweise  der 
Medikamente ableiten. Die Netzwerke beinhalten Rückkopplungsmechanismen und besitzen 
eine  skaleninvariante  Topologie.  Die  mit  TILAR  berechneten  GRNs  wurden  weiterhin 
zusammen mit klinischen Daten ausgewertet.  Hier zeigte sich in der Avonex-Studie, dass 
NF-κB möglicherweise ein Teilnetz reguliert,  das Gene enthält,  die bei MS-Patienten mit 
deutlichen  Nebenwirkungen  höher  exprimiert  sind.  Analog  wurde  eine  GRN-Region 
gefunden, die ein niedriges Expressionsniveau bei RA-Patienten aufweist, die sehr gut auf 
die Therapie mit Etanercept ansprechen.
Die Analyse von GRNs kann zu einem besseren Verständnis Therapie-relevanter Prozesse 
beitragen und transkriptionelle Unterschiede zwischen den Patienten aufzeigen. Die Modell-
berechnung  kann  dabei  verschiedene  Typen  von  Daten  sowie  biologisches  Vorwissen 
integrativ berücksichtigen. Weitere gezielte Studien sind nötig, um Biomarker zu etablieren, 
die die langfristige klinische Wirkung und Verträglichkeit von RA- und MS-Therapien früh-
zeitig  und individuell  vorhersagen können.  Neue biotechnologische  und bioinformatische 
Techniken sowie die zunehmende Menge verfügbarer experimenteller Daten sollte in naher 
Zukunft umfassendere genregulatorische Netzwerkmodelle ermöglichen und somit  helfen, 
(individuelle) molekulare therapeutische Effekte genauer zu erforschen.
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Appendix
 1 Validation of the microarray data by real-time PCR
The analysis  of  the microarray data  revealed  121 genes with significant  expression changes  in 
response to intramuscular IFN-β-1a therapy (supplemental table). Of these, 12 were selected to be 
remeasured by real-time PCR. Six of the genes were down-regulated and six were up-regulated in 
the microarray data set. Apart from that, 3 additional genes were analyzed by real-time PCR: MX1, 
B2M and IFIT1. The mRNA and protein levels of MX1 [1,2] and B2M [3,4] are known markers of 
the biological activity of IFN-β. Their maximum increase in expression is reached within 12-36 
hours of drug administration. However, this increase is not sustained for a full week (see discussion 
in the main text). MX1 encodes a protein with antiviral activities, while B2M is a component of 
major  histocompatibility  complex  (MHC)  class  I  molecules.  IFIT1  was  included  as  a  further 
prominent  IFN-β-inducible  gene  [5].  Besides,  the  GAPDH  gene  expression  was  used  as  a 
housekeeping control. We analyzed the samples obtained before and one week after start of IFN-β-
1a i.m. therapy for a subset of 14 patients (Pat01-04, Pat07-08, Pat15-21 and Pat24).
Real-time  PCR  measurements  were  performed  with  TaqMan  assay  reagents  according  to  the 
manufacturer's instructions on a 7900HT Sequence Detection System (Applied Biosystems, Foster 
City,  CA,  USA).  The  predesigned  primers  and  TaqMan  probes  were  purchased  from Applied 
Biosystems (table S1). Total RNA (1 μg) from each sample was reverse transcribed to cDNA using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). 
The real-time PCR reactions were performed in triplicates and the sample pair of each patient was 
always processed in a single batch to minimize variability. Fluorescence was screened during each 
denaturation/extension  cycle.  The  cycle  at  which  the  fluorescence  from  a  sample  crosses  the 
threshold for detection above background (Ct value) was computed automatically using the SDS 2.3 
software (Applied Biosystems, Foster City, CA, USA).
Ct values are inversely proportional to the log of the initial mRNA copy number. Therefore, we 
preprocessed the data in a way to obtain expression levels that are in a linear relationship with the 
microarray data. First, we calculated the median Ct value of each triplicate (to reject outliers) and 
normalized the data of each sample to the median Ct value of GAPDH mRNA in the same sample 
as follows: ΔCtgene = Ctgene - CtGAPDH. Second, we transformed the data using the equation 2-ΔCt, and 
scaled the result by a factor of 1000 for convenience. The preprocessed transcript levels were then 
utilized to compute paired t-tests comparing each gene's expression at one week into therapy versus 
baseline. We repeated this analysis on the microarray data using only the 14 MS patients whose 
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expression  was  studied  via  real-time  PCR.  Moreover,  Pearson  correlation  coefficients  r were 
calculated  for  each  gene  to  assess  whether  the  data  generated  by  both  techniques  correlate. 
Expression  differences  and correlations  with  P-values  below 0.05  were  considered  statistically 
significant.
Overall, real-time PCR confirmed the results from the array experiments (table S2). The mRNA 
levels obtained by the two methods correlated significantly for all genes. Moreover, the real-time 
PCR data validated the expression differences observed during first week of IFN-β treatment for all 
selected genes. Ten genes were remeasured that were identified as up- or down-regulated after one 
week in the full microarray data by use of the MAID filtering procedure. Real-time PCR confirmed 
the significance of these expression changes.  The data  of two genes,  Fc receptor  FCER1A and 
lipoxygenase ALOX12, are shown in figure S1. The results presented here demonstrate that the 
microarray experiments were performed and analyzed adequately.
Table S1: Genes examined by real-time PCR
Real-time  PCR  was  performed  for  a  total  of  16  genes,  including  GAPDH  as  a 
normalization control. The rightmost column provides the IDs of the TaqMan assays used.
Official Symbol GeneCards ID Entrez Gene ID TaqMan Assay ID
FCER1A GC01P157526 2205 Hs00758600_m1
TNFSF10 GC03M173706 8743 Hs00234356_m1
CSF1R GC05M149413 1436 Hs00911250_m1
CDKN1C GC11M002861 1028 Hs00175938_m1
OAS1 GC12P111807 4938 Hs00973637_m1
AQP9 GC15P056217 366 Hs00175573_m1
ALOX12 GC17P006840 239 Hs00167524_m1
GNAZ GC22P021728 2781 Hs00157731_m1
ESAM GC11M124128 90952 Hs00332781_m1
MS4A7 GC11P059902 58475 Hs00960227_m1
CTSW GC11P065405 1521 Hs00175160_m1
FGFBP2 GC04M015571 83888 Hs00230605_m1
MX1 GC21P041720 4599 Hs00182073_m1
IFIT1 GC10P091142 3434 Hs01675197_m1
B2M GC15P042790 567 Hs00984230_m1
GAPDH GC12P006514 2597 Hs99999905_m1
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Table S2: Comparison of the measurements by real-time PCR and Affymetrix microarrays
We examined 12 genes with significant expression changes during first month of IFN-β-
1a i.m. therapy according to the array data (upper part) and 3 additional genes (lower part) 
by  real-time  PCR  analysis.  On  the  basis  of  the  real-time  PCR  and  corresponding 
microarray  data  of  a  subgroup  of  14  patients  each  gene  was  retested  for  differential 
expression between week one and baseline.  Cells in the columns "Regulation week 1" 
visualize whether a gene was found significantly up- or down-regulated or not. The two 
rightmost columns provide Pearson correlation coefficients r and the respective P-values 
for evaluating whether the real-time PCR data resemble the array data.
↓ Down-regulated
↑ Up-regulated
No significant expression change
   P-value < 0.05






































































































FCER1A ↓ 27 15 <0.001 ↓ 1227 738 <0.001 ↓ 0.90 <0.001
TNFSF10 ↓ 304 139 0.007 ↓ 3637 2665 0.012 ↓ 0.53 0.004
CSF1R ↓ ↓ 251 107 0.008 ↓ 4707 2752 <0.001 ↓ 0.54 0.003
CDKN1C ↓ ↓ 106 47 0.005 ↓ 855 385 <0.001 ↓ 0.74 <0.001
OAS1 ↓ 237 219 0.527 1156 791 0.005 ↓ -0.09 0.632
AQP9 ↑ 70 108 0.042 ↑ 1690 2475 0.027 ↑ 0.89 <0.001
ALOX12 ↑ 96 122 0.022 ↑ 737 1207 0.002 ↑ 0.78 <0.001
GNAZ ↑ 187 234 0.332 873 1282 0.007 ↑ 0.65 <0.001
ESAM ↑ 151 188 0.456 356 739 0.004 ↑ 0.40 0.037
MS4A7 ↓ ↓ 92 39 0.002 ↓ 2808 1422 <0.001 ↓ 0.53 0.004
CTSW ↑ 58 69 0.124 2687 3094 0.040 ↑ 0.69 <0.001
FGFBP2 ↑ 80 112 0.015 ↑ 5993 7071 0.132 0.84 <0.001
MX1 206 151 0.366 2178 1561 0.219 0.97 <0.001
IFIT1 5 3 0.448 667 464 0.199 0.68 <0.001











(real-time PCR vs 
Affymetrix)
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Figure  S1:  Gene  expression  levels  obtained  by  real-time  PCR  (x-axis)  and  DNA 
microarrays (y-axis) for two selected genes. FCER1A (left) was found significantly down-
regulated, and ALOX12 (right) was found significantly up-regulated consistently in both 
measurements. There are two data points for each patient, displaying the expression before 
first and second IFN-β injection, respectively. The data pairs are drawn in a different color 
for each patient and are linked by an arrow (always pointing to the one week sample).  
Despite a good correlation of the two types of data, the interindividual differences at the 
transcript level become evident.
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 2 Performance evaluation of the TILAR algorithm
An objective assessment  of the global  performance of a GRN inference method is  challenging, 
because there is no "gold-standard" network whose detailed interactions are perfectly known (or at 
least known with high confidence) [6]. All we have today is a rather fragmentary and only partially 
correct perception of the (regulatory) interactions between genes. In our original paper on TILAR, 
time-course Affymetrix  microarray data  of 19 rheumatoid arthritis  patients  were used for GRN 
reconstruction.  We then evaluated TILAR's performance by comparing the inferred network (or 
rather the path of models from an empty to a fully connected network) with gene interactions that 
were automatically extracted from the literature by text-mining [7]. Such text-mining information is 
expected  to  be  incomplete  and contain  errors,  and thus  might  be  better  referred  to  as  "bronze 
standard". As a result TILAR outperformed the other algorithms tested and best inference quality 
was achieved with the adaptive TILAR approach. The latter utilizes gene expression data and TFBS 
predictions, and furthermore incorporates prior knowledge on gene-TF interactions by introducing 
additional weights δ on the parameters in the model. The lower the weights δj for the parameters βj 
that represent known or suspected gene-TF interactions, the more these interactions are preferred to 
be in the final  model  (default  is  δj=1.0 for no gene-TF interaction  preference).  Here,  the same 
evaluation procedure was applied, but in comparison to the original publication a different data set 
(the microarray data of the 24 MS patients) is used for reverse engineering the regulation structure 
of a different set of genes.
First, we selected genes that are most frequently co-mentioned in the context of MS in PubMed. A 
respective list of genes was obtained from the Autoimmune Disease Database (version 1.2 as of 
October 22, 2009), which is a literature-based database that provides gene-disease associations of 
all autoimmune diseases [8]. Out of the top 50 genes cataloged for "multiple sclerosis", 42 genes 
were  measured  in  the  Affymetrix  data  set  (table  S3).  We  then  applied  the  software 
PathwayArchitect 2.0.1 to obtain literature-derived gene-gene interactions between them. As most 
of the 42 genes are well studied, many gene regulatory relationships were found, so that a reliable 
GRN  inference  assessment  is  possible.  In  total,  we  retrieved  303  (undirected)  gene-gene 
interactions of type "expression" or "regulation" as labeled by PathwayArchitect. TILAR constrains 
genes to regulate other genes via one or more TFs. Gene-gene interactions are thus only implicitly 
defined in the inferred network by gene-TF and TF-gene interactions. Therefore, the knowledge 
used to assess the method is different from the knowledge integrated during the modeling. Apart 
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Table S3: List of the 50 most frequently mentioned genes in the context of MS
The column "#PMIDs" shows (in  descending order)  the  number  of  PubMed abstracts 
where  the  gene  occurs  in  the  context  of  MS.  These  numbers  were  derived  from the 
Autoimmune Disease Database. A subset of 42 genes was contained in the microarray data 
and used to evaluate the performance of the TILAR network inference approach. For each 
measured gene the corresponding "GeneCards ID" is given as well as mean and standard 
deviation (SD) over the 72 samples in the data set.
Official Symbol #PMIDs GeneCards ID Entrez Gene ID Official Full Name Mean SD
MBP 1181 GC18M072819 4155 myelin basic protein 576 156.02
TNF 820 GC06P031652 7124 tumor necrosis factor (TNF superfamily, member 2) 412 120.44
IFNG 813 GC12M066834 3458 interferon, gamma 237 67.67
IFNB1 806 GC09M021067 3456 interferon, beta 1, fibroblast 15 8.64
IL10 360 GC01M205007 3586 interleukin 10 85 43.15
IL4 303 GC05P132037 3565 interleukin 4 24 16.86
MOG 291 GC06P029732 4340 myelin oligodendrocyte glycoprotein 48 20.72
TRAT1 281 GC03P110026 50852 T cell receptor associated transmembrane adaptor 1 666 219.86
IL2 268 GC04M123652 3558 interleukin 2 22 16.05
IL6 212 GC07P022732 3569 interleukin 6 (interferon, beta 2) 100 29.61
TGFB1 164 GC19M046528 7040 transforming growth factor, beta 1 1441 373.28
IL1B 143 GC02M113303 3553 interleukin 1, beta 617 155.16
ICAM1 142 GC19P010247 3383 intercellular adhesion molecule 1 494 92.41
CD4 136 GC12P006769 920 CD4 molecule 683 144.07
IFNA1 128                                              
HLA-DRB1 123                                              
NOS2A 113                                              
GFAP 101 GC17M040338 2670 glial fibrillary acidic protein 50 35.92
MMP9 93 GC20P044070 4318 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase) 1164 870.68
CD8A 85 GC02M086865 925 CD8a molecule 2248 823.61
VCAM1 84 GC01P100897 7412 vascular cell adhesion molecule 1 94 44.20
CCL5 83 GC17M031222 6352 chemokine (C-C motif) ligand 5 8054 2168.19
HLA-B 81                                              
HLA-DQB1 72 GC06M032735 3119 major histocompatibility complex, class II, DQ beta 1 867 237.92
CCL2 68 GC17P029606 6347 chemokine (C-C motif) ligand 2 76 298.61
MICB 67                                              
APOE 64 GC19P050100 348 apolipoprotein E 18 10.81
MAG 64 GC19P040474 4099 myelin associated glycoprotein 17 15.83
CCR5 63                                              
PLP1 61 GC0XP102837 5354 proteolipid protein 1 48 32.07
NFKB1 60 GC04P103641 4790 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 1921 281.71
CD86 59 GC03P123256 942 CD86 molecule 837 163.03
CTLA4 59 GC02P204440 1493 cytotoxic T-lymphocyte-associated protein 4 163 56.79
CCL3 57                                              
PER1 57 GC17M007984 5187 period homolog 1 (Drosophila) 422 147.35
BTNL2 55 GC06M032470 56244 butyrophilin-like 2 (MHC class II associated) 24 9.51
ITGA4 55 GC02P182029 3676 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 1077 350.58
CXCR3 53 GC0XM070752 2833 chemokine (C-X-C motif) receptor 3 173 67.53
POMC 53 GC02M025295 5443 proopiomelanocortin 29 12.89
ALB 52 GC04P074509 213 albumin 47 22.84
IL2RA 50 GC10M006093 3559 interleukin 2 receptor, alpha 205 57.80
CD40 49 GC20P044181 958 CD40 molecule, TNF receptor superfamily member 5 369 53.13
FAS 48 GC10P090741 355 Fas (TNF receptor superfamily, member 6) 644 142.17
LTA 48                                              
OMG 48 GC17M026645 4974 oligodendrocyte myelin glycoprotein 173 61.32
CD28 47 GC02P204279 940 CD28 molecule 287 75.25
CNP 47 GC17P037372 1267 2',3'-cyclic nucleotide 3' phosphodiesterase 823 211.84
IL5 46 GC05M131905 3567 interleukin 5 (colony-stimulating factor, eosinophil) 35 23.81
PROM1 46 GC04M015578 8842 prominin 1 51 29.13
FASLG 45 GC01P170894 356 Fas ligand (TNF superfamily, member 6) 410 104.41
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from that, the gene-gene interactions provided by PathwayArchitect also allow to benchmark other 
inference techniques which do not employ other information in addition to gene expression data.
For constructing a GRN of the 42 genes with TILAR, we analyzed their regulatory regions and 
found DNA-binding sites of 8 TF entities (table S4) overrepresented at the significance level α=0.1. 
These TFs are connected to 28 out of the 42 genes by means of 56 TF-gene interactions. We then 
applied TILAR to fit a linear model to the expression data while including only a subset of these 
predicted TF-gene interactions. The precise model parameters (representing gene-TF interactions) 
were estimated by least  angle regression (LARS). LARS builds up estimates for the parameters 
(regression coefficients) in successive steps, each step adding one covariate to the model, so that 
gradually all parameters are set non-zero. In simple terms, LARS is a fast and less greedy version of 
traditional forward selection methods. LARS defines in each step the presence of more and more 
gene-TF interactions and thus (indirectly) the presence of more and more gene-gene interactions. In 
this way, LARS specifies network models with different degrees of network connectivity.
Next, we tested whether the inferred edges between genes do exist in the literature-derived network 
of  303  gene-gene  interactions.  For  this  purpose,  we  calculated  the  evaluation  metrics  recall, 
precision and false positive rate for different network connectivities (i.e. in case of LARS for each 
regression  step).  Two  common  visualizations  for  assessing  how  well  an  inferred  network 
approximates  the  "gold  standard" network  are:  1)  a  plot  of  the  recall  versus  the  precision 
performance of a method (RPC) and 2) the receiver operating characteristic (ROC) curve, where the 
false positive rate is plotted against the recall. The "area under the curve" (AU) of both, RPC and 
ROC,  are  standard  performance  measures  and  have  also  been  applied  to  evaluate  network 
predictions  within  the  DREAM (Dialogue  for  Reverse  Engineering  Assessments  and Methods) 
project [6]. We computed these AU values by the integral of the curve that results from a linear 
interpolation between the points in the RPC and ROC plot, respectively. In case of the AU(RPC), 
this yields only an approximation, as here a linear interpolation is not correct [6]. Though, we used 
the hyperbolic and more accurate functional form at the end of the recall-precision trajectory in 
order to adequately account for incomplete network reconstructions, that is, if the GRN inference 
method does not include some edges at all. To assess the statistical significance of a particular AU 
value, we computed the AU(ROC) and the AU(RPC) for 1000 random GRN predictions (RAND). 
The RAND algorithm randomly assigns interactions between genes until a fully connected network 
results. We then calculated the probability (P-value) that an AU value obtained by RAND will be 
higher than the AU value of TILAR (or another method). The P-values were computed by 1 minus 
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the cumulative probability, evaluated at the AU value of the respective inference method, of the 
normal distribution having the mean and standard deviation of the RAND AU values. The accuracy 
of those empirical  P-values is limited due to the rather small number of RAND iterations and the 
fact that a normal distribution only approximates the AU value distribution in the interval [0,1], but 
for presented benchmarking analysis this should suffice.
In  addition  to  the  assessment  of  inference  qualities  of  TILAR and  adaptive  TILAR,  we  also 
compared the results of 5 other GRN inference methods: Lasso [9], CLR [10], ARACNE [11], 
GeneNet [12], and qp-graph [13]. The Lasso (least absolute shrinkage and selection operator) is 
implemented by LARS and, in this case, aims to find a sparse solution that expresses each gene's 
expression as a linear function of the expression of other genes. In comparison, TILAR includes 
predicted TF-gene interactions by the design of the system of linear equations and describes gene-
gene interactions indirectly through connections between TFs and genes. Hence, the only difference 
between the Lasso approach and TILAR is, in fact,  the additional constraint in TILAR that the 
regulatory effect of a gene via a particular TF is the same for each target gene of this TF. CLR and 
ARACNE use  mutual  information  to  describe  gene  regulatory  relationships,  and  GeneNet  and 
qp-graph  compute  a  partial  correlation  network.  These  algorithms  build  (undirected)  gene 
association  networks  (or  rather  networks  with  different  sparsity  dependent  on  the  cut-off  for 
inferred  edge weights)  and have  been implemented  using  the  R packages  minet,  GeneNet  and 
Table S4: TFBS overrepresented in the regulatory regions of the selected genes
There  were  8  consolidated  TFs  whose  DNA-binding sites  occurred  more  often  in  the 
regulatory region of the 42 genes than expected by chance (P-value<0.1).
TF Symbol Transfac Accession Official Full Name P-value Expected Count Count
TBP M00216, M00252, M00471 TATA box binding protein 0.001 2.72 9
RUNX1 M00271 runt-related transcription factor 1 0.005 2.70 8
M00302 0.005 1.13 5
MEF2A myocyte enhancer factor 2A 0.011 3.12 8
SOX5, SOX9, SRY M00042, M00160, M00410 0.050 3.41 7
IRF1, IRF2 M00062, M00063 interferon regulatory factor 1 and 2 0.063 2.16 5
NFKB1, NFKB2, REL, RELA 0.067 5.99 10
HNF1A M00132, M00206 HNF1 homeobox A 0.068 1.55 4
Σ = 56
NFATC1, NFATC2, NFATC3, 
NFATC4
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1-4
M00006, M00231, M00232, 
M00233, M00026
SRY (sex determining region Y)-box 5 and 9, sex 
determining region Y
M00051, M00052, M00053, 
M00054, M00194, M00208
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells family members
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qpgraph. The entire set of Lasso solutions was computed by the R package lars. All methods were 
run  with  default  settings  and  applied  on  the  same  gene  expression  data  set.  The  data  were 
standardized, i.e. the expression levels were transformed for each of the 42 selected genes so that 
they have mean 0 and variance  1.  The adaptive  variant  of  TILAR was used to  integrate  prior 
knowledge on gene-TF interactions. A gene-TF interaction describes a gene as a putative regulator 
of a TF's activity.  For instance,  a gene may encode proteins that regulate the mRNA level of a 
particular TF or post-translationally modify the TF, affect its cellular localization, compete for its 
DNA-binding sites or participate in its upstream signaling pathways. In consequence, as gene-TF 
edges have no straightforward physical interpretation, their nature is rather phenomenological and 
accurate knowledge on gene-TF edges is difficult to obtain. Here, we used PathwayArchitect 2.0.1 
to  retrieve  potential  (literature-derived)  influences  of  genes  on  TFs  of  type  "expression", 
"regulation" or "protein modification". In this way, we found 34 (directed) interactions between the 
42 genes  and 8 TF entities.  We then applied  the  adaptive  TILAR method  with  three  different 
weights for the coefficients of preferred edges (δj=0.45, δj=0.30 and δj=0.05). Apart from that, we 
implemented  another  random algorithm (gene-TF-RAND)  which,  similar  to  TILAR,  constructs 
regulatory networks of TF-gene and gene-TF interactions. Gene-TF-RAND does not consider the 
microarray gene expression data, but includes all the 56 predicted TF-gene interactions. The method 
represents a "use TFBS only" inference strategy as gene-TF edges are just randomly added to the 
network. As for TILAR, gene-TF interactions were not allowed when gene and TF were already 
connected by a TF-gene interaction, and gene-gene interactions result implicitly. The AU values of 
gene-TF-RAND were calculated by the mean of 1000 repeated runs.
Figure S2 shows the RPC and ROC curves that resulted by evaluating the global performance of the 
different  inference  algorithms  using  the  303  (regulatory)  gene-gene  interactions  from 
PathwayArchitect.  It  is  easy  to  see  that  TILAR  and  adaptive  TILAR  outperformed  all  other 
modeling algorithms. The maximum precision of TILAR is 0.615 and of adaptive TILAR 0.793. In 
comparison, the precision of all the other methods reaches maximum 0.472 (qp-graph). AU values 
and the respective  P-values that indicate whether the algorithm's AU values are higher than for 
RAND are given in table S5. The table shows that the interactions inferred by TILAR match the 
interactions derived from literature significantly more than random, whereas this was not the case 
for CLR, ARACNE, GeneNet, Lasso and qp-graph. Hence, the overall performance of the methods, 
which do not integrate different types of biological information, is poor. One reason for this is that  
(despite mathematical differences) they all infer interactions solely based on gene co-expression. As 
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was discussed by Zampieri et al. for E. coli and yeast, such co-expression patterns tend to unveil 
stable functional categories (e.g. co-participation in a protein complex, genomic co-localization or 
similar  biological  function) rather than transient or condition-specific  interaction structures (e.g. 
TF-DNA binding) [14]. Moreover, when trying to infer the regulator from a group of co-expressed 
genes, there is a risk to arbitrarily select one of these genes. The constraints realized by TILAR 
incorporate  TFBS  (and  literature)  information  and  thus  aid  in  detecting  true  regulatory  gene 
interactions more reliably.  Interestingly,  gene-TF-RAND also showed relatively high AU values. 
This suggests that TILAR performs well because of both the quality of TFBS predictions and data-
fitting using LARS. Additional knowledge on potential gene-TF interactions was integrated by the 
adaptive  TILAR.  Dependent  on  the  parameters  δj that  express  the  confidence  in  this  prior 
knowledge the inference quality increased considerably.  However,  a lower  δj than 0.05 did not 
improve the result much.
     ROC plot      recall-precision plot
Figure S2: ROC and recall-precision curves of different GRN modeling strategies. The 
better a method performs, the closer its ROC and RPC curve will be to the upper-right and 
upper-left  corner,  respectively.  TILAR outperformed CLR, ARACNE, GeneNet,  Lasso 
and qp-graph in inferring the regulatory relationships between the 42 selected genes. If 
adequate prior knowledge on gene-TF interactions is available,  the adaptive variant of 
TILAR can be used to further increase the inference quality.
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To summarize, we reconfirmed that we can utilize information on TF-gene interactions (predicted 
by TFBS overrepresentation analysis) and gene-TF interactions (derived from the literature by text-
mining) to construct GRN models that describe regulatory interactions between genes (and TFs) 
with  superior  accuracy.  The  benchmarking  analysis  generated  results  comparable  to  our  study 
where  we  first  introduced  TILAR  [7].  In  the  original  publication  on  TILAR  we  discuss  the 
algorithm's performance in more detail and point out remaining issues, e.g. the fact that databases 
containing TFBS sequence motifs are still by far not complete. We showed that it is important to 
include additional  biological  information into the reverse engineering of GRNs. Eventually,  the 
integration of heterogeneous data and prior biological knowledge is increasingly relevant  in the 
whole field of computational biology.
Table S5: Benchmark result for TILAR and other GRN inference algorithms
The rating  of  the methods  is  based on the  area under  the RPC and ROC curves.  An 
AU(ROC) very close to 0.5 is no better than random. For the adaptive variant of TILAR 
(the first 3 rows of the table) δj is set lower than 1.0. P-values for the adaptive TILAR with 
δj=0.05  were  below  the  computational  accuracy  of  R  (2.22  E-16).  The  table  clearly 
demonstrates that the integration of various types of data is much more suited to model 
gene regulation.
Network Inference Method AU(ROC) AU(ROC) P-value AU(RPC) AU(RPC) P-value
0.68 <2.22 E-16 0.57 <2.22 E-16
TILAR δj=0.30 0.63 3.78 E-11 0.50 <2.22 E-16
TILAR δj=0.45 0.59 2.07 E-06 0.45 3.60 E-09
TILAR δj=1.00 0.56 0.001 0.38 0.064
gene-TF-RAND 0.55 0.010 0.38 0.046
Lasso 0.53 0.095 0.38 0.085
qp-graph 0.50 0.414 0.36 0.363
GeneNet 0.50 0.491 0.35 0.487
CLR 0.48 0.779 0.34 0.782
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